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Abstract 
PI3K are a family of lipid kinase enzymes that are involved in a broad spectrum of 
cellular, physiological and pathological processes.  Notably, PI3K dysfunction is 
associated with cancer, inflammation and metabolism.   
The PI3K family consists of three classes, Class I, Class II and Class III, which are 
defined according to their structure, function and lipid specificity.  Class I is further 
subdivided into Class IA, which consists of p110, p110 and p110, and Class IB, 
which consists of p110.  Both p110 and p110 are ubiquitously expressed. 
Conversely, p110and p110 have a restricted tissue distribution, limited mainly 
to leukocytes, where they are highly enriched.  
In this work, we have focused on understanding the role of p110 in macrophages 
and specifically, on gaining insight into its role in genome-wide transcriptional 
regulation.  Our results suggest that the contribution of p110δ activity to 
transcriptional regulation in growing primary macrophages is very limited.  
Genetic or pharmacological inactivation of p110δ resulted in differential regulation 
of less than twenty-five unique genes.  Interestingly, at the level of genome-wide 
transcription, we have observed a significant difference between the effects of 
pharmacological and genetic inactivation.  Indeed, none of the genes identified 
were differentially regulated as a result of both pharmacological and genetic 
inactivation of p110δ.  We discovered that the majority of the genes differentially 
regulated in p110δ KI macrophages are located within close proximity to the 
Pik3cd gene.  We propose that the differential regulation of these genes represents 
an artefact of the genetic engineering strategy employed to generate the p110δ KI 
mice.  We have confirmed that genetic inactivation of p110δ results in reduced 
expression of Rab6b, a gene which is not linked to Pik3cd.  We have confirmed that 
this does translate into a reduced level of rab6b protein in p110δ KI macrophages. 
 
Parts of this thesis have been published elsewhere: 
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages 
Evangelia A. Papakonstanti, Olivier Zwaenepoel, Antonio Bilancio, Emily Burns, 
Gemma E. Nock, Benjamin Houseman, Kevan Shokat, Anne J. Ridley and Bart 
Vanhaesebroeck, TJournal of Cell Science [1]  
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CHAPTER 1 
1. INTRODUCTION 
1.1. The PI3K family of enzymes 
Phosphoinositide-3-kinases (PI3Ks) are a family of enzymes that play an important 
role in cellular signalling via their activation-dependent production of modified 
phosphatidylinositol (PtdIns).  PI3K enzymes are subdivided into three classes 
according to their structure, lipid substrate specificity and regulation [Figure 1.1] 
[2-3].  The unifying feature of Class I, Class II and Class III PI3Ks is their highly 
homologous catalytic kinase domains, which consist of a kinase domain linked to a 
helical PIK (PI-Kinase homology) domain.  This kinase domain interacts with 
Adenosine-triphosphate (ATP) and transfers a phosphate from ATP to 
Phosphatidylinositol 4,5-bisphosphate (PIP2) generating Phosphatidylinositol 4,5-
trisphosphate (PIP3).  All PI3K isoforms contain a PIK domain located next to the 
highly homologous kinase domain.  In addition to these highly conserved regions, a 
number of auxiliary domains exist, which vary across the PI3K classes [Figure 1.1].  
For example, Ras binding domains (RBD) are a common feature of the Class I and 
Class II isoforms, but are not present in Class III PI3K [Figure 1.1].  The presence of 
these variable domains is likely to contribute to differential functionality and 
regulation of the different Classes of PI3K enzymes.  
 
Figure 1.1. Classification, domain structure and in vivo substrate preferences of PI3K 
enzymes. PI3K enzymes are divided into three classes based on their structure, lipid specificity and 
the regulatory units which they associate [4]. 
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1.1.1. Class I PI3K 
The Class I PI3K isoforms, p110α, p110β, p110δ and p110γ, exist as heterodimers 
consisting of a catalytic p110 subunit constitutively associated with one of several 
regulatory subunits [5] that are described below.  The in vivo phosphoinositide 
substrate preferred by Class I PI3K isoforms is PtdIns (4,5)P2 (PIP2), which is 
catalytically converted to PtdIns (3,4,5)3 (PIP3) [Figure 1.1]. 
1.1.1.1. Class IA and Class IB subdivision 
Class I PI3Ks are further divided into Class IA, which consists of three isoforms, 
p110α, p110β and p110δ, and Class IB, which encompasses only p110γ [Figure 1.1 
& 1.2] [6].  Class IA isoforms all signal downstream of Receptor Tyrosine Kinases 
(RKTs) and associate with p85-type regulatory subunits.  The solitary Class IB 
isoform, p110γ, is dissimilar to the Class IA isoforms in that it signals downstream 
of G protein-coupled receptors (GPCRs) and associates with unrelated p101 or 
p84/87 regulatory units [7-9].   Recent data has somewhat blurred this division 
within Class I as p110β has been found to be capable of signalling downstream of 
GPCRs as well as RTKs [10-11].  Nevertheless, the structural difference between 
Class IA and Class IB PI3K heterodimers, with regard to their regulatory subunits, 
provides some rationale for maintaining the division. 
 
Figure 1.2. The classification of Class IA and Class IB PI3K isoforms.  Class IA isoforms couple 
to a p85-type regulatory subunit, whereas Class IB p110γ catalytic subunits couple to either p101 
or p87 regulatory subunits. Class IA isoforms signal downstream of RTKs and associate with p85-
type regulatory subunits, whilst p110γ signals downstream of GPCRs. p110β has been found to 
signal downstream of GPCRs as well as RTKs. 
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1.1.1.2. Class IA PI3K isoforms 
1.1.1.2.1. Class IA PI3K catalytic subunits 
Whilst p110α and p110β are ubiquitously expressed in mammalian tissue [10, 12] 
p110 has a more restricted expression pattern.  Significant expression of p110 is 
observed predominantly in leukocytes [13-14]  and to a lesser extent in neurons 
[15], melanocytes and breast cells [16].  
1.1.1.2.2. Class IA PI3K regulatory subunits 
The p110 subunits of Class IA isoforms associate with one of a number of related, 
structurally similar ‘p85-type’ regulatory subunits encoded by three genes.  PIK3RI 
encodes subunits p85α, p55α and p50α by alternative promoter usage, whilst 
PIK3R2 and PIK3R3 encode p85 and p55 respectively.  These Class IA regulatory 
subunits contain two (SH2) domains interspersed by an inter-SH2 domain through 
which the p110 subunits bind [2].  All of the p110 subunits are equally capable of 
binding to each of the p85-type regulatory subunits. 
Within the PI3K enzyme, the regulatory subunit is necessary to maintain the 
structural stability of the p110 subunit and furthermore, to enforce a reversible 
steric inhibition upon catalytic activity in the absence of upstream stimuli [17-18].  
This intra-dimer regulation appears to be bi-directional; the p110 subunits possess 
protein kinase activity that enables them to cross-phosphorylate their associated 
p85 regulatory subunit in the case of p110α, rendering the PI3K enzyme inactive.   
In this respect, p110δ and p110β differ from p110α in that they auto-
phosphorylate themselves rather than its associated regulatory subunits [13, 19].  
The effect of this auto-phosphorylation appears to be the same; the PI3K enzyme is 
rendered inactive.    
1.2. Cellular signalling by Class IA PI3K isoforms 
1.2.1. Activation of Class IA PI3K isoforms 
Stimulation of PI3K activity occurs in response to activation of upstream 
transmembrane receptors that recognise and bind specific extracellular ligands. 
Receptor Tyrosine Kinases (RTKs) are a key class of receptor that initiate 
intracellular signalling, partially via the activation of PI3K enzymes.  Upon ligand 
engagement, activated dimeric RTK receptor complexes are formed by monomer 
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oligomerisation [Figure 1.3].  This ligand-induced proximity between receptor 
monomers triggers cross-phosphorylation of the dimers on their intracellular 
domains [Figure 1.3 B].  These phosphorylated residues are recognised by the p85-
type regulatory subunits via their SH2-domains [Figure 1.3 C][20].  Thus, the 
regulatory subunits act as adaptor proteins recruiting associated p110 subunits to 
active receptor complexes in a stimulus-dependent manner [Figure 1.3 C].  The 
documented inability of p110γ to respond to RTK signalling is validated by the 
absence of SH2-binding domains in the Class IB regulatory subunits p101 and 
p84/87 [8]. 
Mechanistically, activation of PI3K upon recruitment to an activated RTK occurs in 
two ways.  First, the conformational changes induced within the PI3K enzyme 
upon RTK-docking relieve the steric-inhibition imposed by the regulatory unit and 
secondly, the recruitment brings the enzyme into close proximity with its lipid 
substrate [Figure 1.3 C] [18].   PI3K production of PIP3 from PIP2 embodies the 
classic model of almost instantaneous signal amplification, which is reliant upon 
the rapid generation of a second messenger (PIP3) from an existing precursor 
(PIP2).   Upon cellular stimulation, PIP3 levels increase [Figure 1.3 C] and this 
localised concentration of PIP3 initiates the next phase of PI3K signalling [Figure 
1.3 D].  
 
Figure 1.3. PI3K heterodimer recruitment to the membrane.  Recruitment occurs via 
interaction with stimuli-induced phosphorylation sites on the intracellular domains of activated 
RTKs. Activated PI3K rapidly converts PIP2 to PIP3, which then recruits and regulates activity of 
Pleckstrin Homology (PH)-domain containing effectors.   
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1.2.2. Signalling downstream of Class IA PI3K activation 
PIP3 potentiates and diversifies the PI3K-RTK signal via interactions with a range 
of effector proteins [Figure 1.3 D] [21].  The selective capacity of these PIP3-
responsive proteins to interact with phosphoinositide species via their intrinsic 
PIP3-binding Pleckstrin Homology (PH) domains facilitates their regulation by one 
of several mechanisms.  Most apparently, the interactions of these proteins with 
PIP3 results in their relocalisation into membrane proximal foci [Figure 1.3 D].  
This spatial regulation often creates enhanced proximity between a protein and its 
substrates, regulators and or complexes with which it interacts [22].  Additionally, 
in some cases, the PIP3-PH-domain interaction itself can induce conformational 
changes that alter the activity of the proteins. 
1.2.3. Temporal regulation of PI3K signalling 
The swift generation of second messengers, such as PIP3, from existing precursors 
fulfils the necessity to rapidly transmit a signal in response to RTK activation.  It is 
equally imperative that negative regulation acts to restrict and terminate this 
signal with comparable rapidity.  Indeed, prompt generation and subsequent 
degeneration of second messengers enables tight temporal and signal-dependent 
control to be maintained over processes such as migration, metabolism and 
perhaps most importantly proliferation.  Therefore, just as PIP2 is rapidly catalysed 
to PIP3, this PIP3 must be rapidly catabolised upon signal termination [Figure 1.4].  
Phosphatase and tensin homology (PTEN) is the main ubiquitous lipid 
phosphatase that limits PIP3 levels.  PTEN reduces PIP3 levels by 
dephosphorylating the 3’ position of its inositol ring returning it to its original 
PtdIns (4,5)P2 form [23].  The high frequency of with which mutations that 
inactivate PTEN have been detected in a range of human solid tumours highlights 
the necessity of negative regulation of PI3K signalling. 
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Figure 1.4. Enzymatic conversion of PIP2 to PIP3 by PI3K activity and dephosphorylation to 
PIP2 (PtdIns 4,5)P2 by PTEN. 
 
Other lipid phosphatases that also regulate PI3K signalling include SH2-domain-
containing inositol 5-phosphatase (SHIP-2) that is mainly restricted to 
haematopoietic cells [24] and SH2-domain-containing inositol 5-phosphatase 1 
(SHIP-1), which is more widely expressed [25].  Unlike PTEN the SHIP 
phosphatases dephosphorylate the 5’ position of the PIP3 inositol ring and as a 
result they generate an alternative product PtdIns (3,4)P2 [24].  Thus it is 
important to note that the SHIP phosphatase activities are not identical to PTEN by 
virtue of the different PtIns product that they produce which has its own distinct 
associations and effects.   The implications of the alternative products generated by 
PTEN and the SHIP phosphatases are still being investigated [26]. 
1.2.4. Akt  
Akt (also known as Protein Kinase B [PKB]) is the most well characterised effector 
of PI3K signalling.  Upon PI3K activation, Akt is rapidly redistributed from the 
cytoplasm to the plasma membrane via its high affinity interaction with PIP3.  
Consequent activation of Akt occurs in a sequential manner, and is dependent first, 
upon the conformational changes induced upon binding PIP3 and secondly, upon 
its co-localisation with two regulators. 
The two independent regulators required to maximally activate Akt are 3-
phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin 
complex 2 (mTORC2) [27].  Phosphorylation of Akt residue Threonine 308 (T308) 
by PDK1 appears to be the first step in Akt activation following PIP3 binding and 
associated conformational changes [28].  Maximal activation of Akt requires an 
 22 
additional phosphorylation event on Akt residue serine 473 (S473) and this is 
catalysed by mTORC2.  The phosphorylation of S473 appears to require T308 
phosphorylation as a prerequisite.  Phosphorylation of Akt on S473 is considered 
indicative of complete activation of Akt [29].  Consequently, activated Akt is often 
referred to in the literature as phospho-Akt (p-Akt).  
Akt is a serine/threonine protein kinase that recognises and phosphorylates 
substrates with a consensus Arg-X-Arg-X-X-Ser/Thr-φ sequence (X denotes any 
amino acid and φ a bulky hydrophobic residue).  Activation of Akt has pleiotropic 
effects that can be summarised broadly as resulting in the promotion of a pro-
survival, growth and proliferative phenotypes [30-32].  The mechanisms and 
downstream effectors through which Akt contributes to growth and survival are 
complex and far from completely elucidated.  It is known that, Akt orchestrates 
changes to cellular composition and activity by targeting a broad range of effector 
proteins, which themselves have diverse downstream interactions [Figure 1.5].  
 
 
Figure 1.5. Signalling Cascade initiated downstream of PI3K-Akt activation.  Akt 
phosphorylates a broad range of downstream effector proteins including several kinases resulting 
in phosphorylation cascades. The effects of Akt activation included alterations in protein synthesis, 
proliferation and metabolism.  There is significant overlap and cross talk amongst the pathways 
that regulate these processes. This facilitates a coordinated response to the initial upstream 
extracellular signal that is acting in part via activation of PI3K-Akt signalling.  [Pathway image 
reproduced courtesy of Cell Signalling Technology, Inc. (www.cellsignal.com)] 
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The balance between cell stasis and proliferation and fundamentally between 
apoptosis and survival are tightly regulated.  In the absence of survival signals the 
cells default response is stasis and ultimately programmed cell death (apoptosis).   
Akt appears to regulate many of its targets by means of multiple complementary 
mechanisms.  If we consider the way in which Akt actively contribute towards a 
shift from cell stasis into a pro-proliferation state this phenomenon is very 
apparent.  First, Akt alongside other regulators must actively promote progress 
through the cell cycle to facilitate proliferation.  In order to do this Akt must also 
relieve the default cellular stasis that occurs in the absence of sufficient growth 
stimuli.  One means by which Akt suppresses cell stasis is by targeting p27kip1 and 
p21cip1.  Akt limits the activity of both these proteins, which themselves act to block 
cell-cycle progression, first, by direct phosphorylation of these targets but also 
indirectly by suppressing the transcription of p27kip by the Forkhead related family 
type 0 (FOXO) transcription factors.  Thus, Akt relieves cell-cycle blockade by 
inactivating p27kip1 and by concurrently reducing its de novo production through 
negative regulation of the FOXO family of transcription factors.  We can observe a 
similar pattern of two-pronged regulation of Akt targets in terms of the 
contribution of Akt to the induction of growth and proliferation.  Cyclin D, cyclin E 
and c-myc are required for cell-cycle progression and are marked for proteosomal 
degradation by Glycogen Synthase Kinase-3 (GSK-3) in the absence of growth and 
survival signals.  Direct phosphorylation of GSK-3 by Akt inhibits its activity and 
thus promotes the stability of these pro-proliferation proteins [33].   Concurrently, 
Akt indirectly enhances translation of cyclin D and c-myc mRNAs by activating 
mTORC1, a pivotal regulator of protein synthesis and growth.  Specifically, Akt 
inactivates tuberous sclerosis complex 2 (TSC-2) the complex that functions to 
repress the activity of mTORC1 in the absence of suitable upstream growth and 
survival signals.  The activation of mTORC1 downstream of Akt activity has 
multiple effects beyond stimulating cap-dependent translation, which contribute to 
the proliferation and growth phenotype.  In particular, the role of mTORC1 in the 
regulation of cellular metabolism has received a great deal of interest in relation to 
metabolic disorders and also in relation to cancer [reviewed in [34].  The mTORC1 
pathway is just one of several pathways with which the PI3K-Akt pathway 
interacts.  Indeed, cellular signalling pathways actually highly interconnected 
networks with many shared effectors, regulators and numerous feedback loops.  
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Thus, the effects and mechanisms of regulation through which Akt promotes 
growth, proliferation and survival are both complex and wide-ranging.  The effects 
of inhibiting the “PI3K-Akt pathway” are often investigated in isolation, but should 
always be considered in the context of interconnected pathways.  Complementary 
mechanisms and pathways synergise to facilitate rapid and dramatic changes in 
the location, concentration and activity of key effector proteins/complexes.  
Regulation occurs at all levels, including protein stability and post-translational 
modification, as well as translational and transcriptional regulation. 
1.2.5. Regulation of transcription downstream of PI3K-Akt pathway 
The effect of PI3K-Akt activity upon transcriptional regulation is of particular 
relevance to this thesis.  The modulation of the activity of number of transcription 
factors occurs downstream of PI3K-Akt activation.   
As mentioned above, Akt suppresses the transcription of p27kip via its inhibitory 
actions towards the FOXO family transcription factors.  Akt contributes to their 
signal-dependent regulation by directly phosphorylating them.  Indeed, Akt is an 
important negative regulator of FOXO transcription factors and all but one 
members of the FOXO family contain three Akt consensus sites.  The 
phosphorylation of FOXO proteins by Akt is thought to suppress their function 
primarily by the generation of docking sites for 14-3-3 proteins.  Once tethered to 
14-3-3 proteins the FOXO transcription factors are unable to shuttle into the 
nucleus or to bind DNA [35].  FOXO proteins are one of many p-Akt targets that are 
recognised by the 14-3-3 proteins.  The possibility that the phosphorylation 
directly affects FOXOs capacity to bind DNA independent of 14-3-3 has not been 
ruled out.  
Alongside the repression of pro-apoptotic genes, Akt has been shown to regulate 
positively the expression of the crucial pro-survival protein, BCL-2 [36].  By 
directly phosphorylating and activating the transcription factor cAMP-responsive 
element (CREB)-binding-protein (CPB/p300) Akt stimulates the expression of B 
Cell Lymphoma (BCL)-2 [36].  Activation of PI3K-Akt has been associated with 
enhanced activity of a Nuclear Factor-κ B (NF-κB), a fundamental regulator of pro-
survival and inflammatory gene expression.  Like the FOXO transcription factors, 
NF-κB is constitutively expressed but perpetually degraded or tethered in an 
inactive state in the cytosol.  NF-κB is held inactive via its sequestration in the 
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cytoplasm by inhibitory complexes known as IκBs.  The canonical pathway 
through which NF-κB is activated involves its release from the Inhibitor of κB 
(IκBs) cytoplasmic tethers.  Specifically, activated IκB-kinases (IKKs) 
phosphorylates IκB, which results in the liberation of NF-κB from these tethers, 
allowing it to shuttle into the nucleus and to influence transcription [37] [38].  In 
addition, the capacity of NF-κB to bind to DNA, which is stimulated by 
transactivators such as CPB/p300, has also been shown to be regulated in part by 
direct phosphorylation of NF-κB [39].  The mechanisms through which PI3K-Akt 
activity modulates NF-κB-dependent transcription are controversial.  An early 
publication relating to the mechanism through which PI3K-Akt promotes NF-κB-
mediated transcription downstream of tumour necrosis factor (TNF)-α pointed to 
a direct phosphorylation of IKK by Akt, which resulted in NF-κB release [Figure 
1.6][40].  This finding was strongly refuted by the Karin group  who proposed an 
alternative mechanism of enhanced NF-κB-mediated transcription observed 
downstream of PI3K-Akt activity involving the regulation of a later stage of NF-κB-
mediated transcription [41].  Subsequently, Sizemore et al. showed that Akt 
activity downstream of IL-1β may be involved in the induction of the stimulatory 
phosphorylation of the RelA/p65 NF-κB dimer [Figure 1.6][42].   Supporting this 
role for PI3K-Akt activity in the stimulation of NF-κB phosphorylation Madrid et al. 
also found PI3K-Akt activity contributed to the induction of NF-κB 
phosphorylation [Figure 1.6].  Interestingly, this paper found evidence that this 
was dependent on the activation of the Mitogen-activated protein kinase (MAPK) 
p38 downstream of Akt.   Thus, this brought together the previous observations 
that PI3K-Akt activation contributed to the promotion of NF-κB-mediated activity 
[42-43] and that independent of nuclear translocation p38 activity also affects NF-
κB activity [44]. 
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Figure 1.6. Schematic illustration of PI3K signalling regulating transcription. Activation of Akt 
positively regulates NF-κB transcriptional activation.  The mechanism through which this occurs is 
controversial, shown here are two possible mechanisms; firstly the activation of IKK by Akt 
resulting in the release of NF-κB from cytoplasmic IκB tethers or secondly by direct 
phosphorylation of NF-κB, which enhances its transcriptional activities.  Activation Akt suppresses 
FOXO-driven transcription: phosphorylation of FOXO proteins induces associated with 14-3-3 
proteins which prevent them entering the nucleus.  Activation of Akt results in activation of CREB 
and transcription of BCL-2.  
 
In mast cells, Akt activity was found to modulate not only NF-κB but also AP-1 and 
Nuclear Factor of Activated T cells (NF-AT)-driven transcription in response to 
immunological stimulus.  Overexpression of wild-type Akt was found to enhance 
the transcription of IL-10 and TNF-α, two inflammatory cytokines that are co-
ordinately regulated by these transcription factors.  In the case of NF-AT, it is the 
inactivation of GSK-3 by Akt, which appears to facilitate its activation by releasing 
it from inhibitory cytosolic interactions.  Phosphorylation of GSK-3 is also 
predicted to facilitate the transcription of pro-proliferative AP-1-driven genes 
recognised by the cJun-fos complex.  This is because GSK-3 negatively regulates 
cJUN by preventing it from forming a transcriptionally active complex with fos.  
Thus, it seems that the regulation of cellular phenotype by Akt potentially involves 
modulation at multiple levels including translation and transcription.  GSK-3 
appears to represent a common node in the regulation of transcription and 
translation downstream of Akt.   
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1.2.5.1. The PI3K-Akt transcriptome? 
The majority of studies regarding regulation of transcription by PI3K-Akt have 
applied a reductionist approach, focusing on either individual transcription 
factors/families downstream of PI3K, or on individual genes regulated by PI3K.  
What are lacking in the literature are studies in which the effects of PI3K-Akt 
activity on genome-wide expression are determined.  This unbiased systems 
biology approach has the potential to assist in better characterising and 
understanding the complex and multifaceted effects of PI3K-Akt signalling. 
A limited number of studies have been published that identify a gene expression 
signature that is indicative of aberrant PI3K-Akt activation in malignant disease.  
The identified gene signatures have potential predictive value in determining the 
patients that are likely to be responsive to PI3K-Akt targeting strategies [45].  Yet, 
in terms of extracting the biological effects of PI3K-Akt activity on the 
transcriptome these disease-state based studies are less useful.  The results are 
complicated by the presence of numerous other variable gene alterations and 
cancer associated dysfunctions. 
To the best of our knowledge, at the time that we started this project, there were 
no publications regarding the genome-wide impact of PI3K inactivation on 
transcription.  This is in spite of the availability of numerous mouse models and 
pan/selective-PI3K inhibitors.  One group did investigate the modulation of gene 
expression in response to chronic Akt activation in heart tissue [46].  Akt activation 
was previously associated with a reduction in cardiomyocyte death and an 
increase in cardiac hypertrophy, which is in line with the well characterised pro-
survival and growth activities of Akt.   Based on this finding, the authors set out to 
identify genes downstream of Akt activation, which contribute to increased 
cardiomyocyte survival and growth.  A comparison was made between genome-
wide expression of WT heart tissue and heart tissue derived from transgenic mice 
expressing a cardiac-specific constitutively active Akt (myr-Akt) [46]. Only forty 
genes were found to be significantly deregulated by the constitutive expression of 
Akt, with roughly equivalent numbers increased versus decreased [46].  The 
authors validated ten of the genes identified using quantitative-PCR (qPCR) and 
found that all of them displayed a similar pattern but the data for only seven of 
them were statistically significant.  Insulin growth factor-binding protein 5 was 
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identified as highly upregulated by both chronic and acute activation of Akt [46].  
This upregulation was predicted to contribute to the pro-survival effect of Akt 
activation in cardiomyocytes.  The results of this study, in particular the minimal 
number of genes affected provides some indication that the role of PI3K-Akt in the 
modulation of gene expression might be quite restricted, at least in this cell type.  
On the other hand, it is possible, had the study investigated the effects of loss of 
Akt, that many more Akt-regulated genes would be identified.   
The Raes group later investigated the involvement of PI3K in LPS-induced 
transcriptional regulation, in particular focusing on comparing the effects of PI3K 
and NF-κB inhibition [47].   This was of particular relevance because PI3K is 
upstream of NF-κB activation but the LPS-induced MyD88 signalling pathway also 
independently activates NF-κB.  The authors analysed the expression of 233 well-
characterised inflammatory genes in LPS-stimulated RAW 264.7 macrophages 
using a biased inflammatory-focused microarray.  Their data, as predicted, 
revealed a significant overlap between the genes affected by pan-PI3K inhibition 
and NF-κB inhibition [47].  The data also identified several genes that were 
regulated by PI3K and not NF-κB and vice versa [47].  These findings suggest that 
the PI3K pathway contributes to LPS-induced gene regulation via its cross-talk 
with the NF-κB pathway but also indicates that both PI3K and NF-κB act 
independently as well.  
During the course of this project, additional studies were published regarding the 
impact of PI3K inactivation on the transcriptome.  The first was a second study by 
the Raes group that followed up the findings of Mendes et al. [47-48].  In order to 
delineate the separate contributions of PI3K and mTORC1, the effects of PI3K 
inhibition, NF-κB inhibition and this time also inhibition of mTORC1 were 
investigated.  With regards to the effects of NF-κB inhibition, the authors identified 
a cluster of LPS-induced genes that were not affected by either PI3K or mTORC1 
inhibition but were differentially expressed in the presence of an NF-κB-inhibitor 
[48].  This was consistent with the findings of their earlier study and provides 
further evidence that PI3K regulation of transcription in response to LPS is not 
solely coordinated via regulation of NF-κB.  Interestingly, the results also revealed 
that PI3K and mTORC1 inhibition have different and in some cases opposing 
effects on LPS-induced gene regulation.  For example, one set of genes observed to 
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be affected by PI3K inactivation were differentially affected by the pan PI3K 
inhibitor Wortmannin compared to the effects of LY294002.  The genuine PI3K-
dependent effect on these genes is likely to be represented by the effect of 
Wortmannin, which enhances the LPS-stimulated induction of these genes.  It is 
probable that the observed repression of this set of genes by LY294002 is likely to 
as a result of the dual inhibition of PI3K and mTORC1 occurring in response to the 
high dose of LY294002 used (25 μM).  Indeed, treatment with the mTORC1 
inhibitor Rapamycin, similarly repressed the expression of these genes.  Despite 
the fact that both NF-κB and mTORC1 are downstream targets of PI3K, PI3K 
inhibition did not affect the same set of genes as inhibiting either NF-κB or 
mTORC1 [48].  Not only were the effects overlapping yet far from identical, but in 
fact, the results of this study revealed that mTORC1 inhibition can actually have the 
inverse effect to PI3K inhibition [48].  These data, which reveal the disparate 
effects of pan-PI3K, mTORC1 and NF-κB inhibition, highlight the fact that cell 
signalling “pathways” are really components within complex networks. 
The first publication regarding the genome-wide impact of pan-PI3K inhibition on 
expression was published in 2010 [49].  Previous data had indicated that PI3K 
inactivation negatively impacted upon the growth of tibiae in mice.  The authors 
therefore set out to identify genes that are affected by PI3K activity, which are 
involved in chondrocyte differentiation a key process in bone development.  
Treatment of primary mouse chondrocytes with LY294002 resulted in 
transcriptional changes that the authors describe as modest [49].  Indeed, the 
majority of genes were deregulated by less than 1.4-fold.  In total 5035 probe sets 
were identified as differentially regulated in the presence of LY294002, but this list 
was generated without the application of filters statistical significance, which 
would no doubt reduce the list considerably.  Only 416 probe sets were 
upregulated by more than twofold and only 596 probe sets were downregulated 
by more than two fold [49].  These probe sets are likely to include duplicate probes 
interrogating the same gene and a number of false positives, thus the number of 
actual genes modulated by LY294002 is likely to be significantly lower.   Based on 
the data and the analysis published one can assume that pan-PI3K inhibition 
modestly interferes with the transcriptional regulation of less than 1012 genes in 
these cells.  The author cross-analysed these results with those obtained from 
analysis of differential gene expression in various regions of a micro-dissected 
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bone growth plate.  In doing so, they identified biologically relevant genes that are 
regulated by PI3K in chondrocytes and differentially expressed in a specific region 
of the growth plate. 
Towards the end of our project, the Okkenhaug group published the first paper 
detailing the effects of genetic inactivation of p110δ on the transcriptome, using 
the p110δ KI mouse model, in which p110δ has been inactivated (see next 
section)[50].  Using genome-wide microarray expression analysis the 
transcriptome of p110δ KI T regulatory cells (Tregs) was compared to that of wild-
type Tregs.  The authors aimed to identify deregulation of gene expression that 
might be responsible or contributing to the defective development, differentiation 
and suppressive function of Tregs derived from p110δ KI mice.  In total, 125 probe 
sets were found to be deregulated by twofold or more in the p110δ KI Tregs (p ≤ 
0.01)[50].  This represents less than 0.3% of the transcripts interrogated by the 
microarray used.  Within the 125 were twenty seven genes that belong to a 
previously published Treg gene signature, but none of the classic well-
characterised Treg-associated genes were identified [50].  The authors validated 
around half of the genes identified as differentially regulated using qPCR.  Only 
seven of these genes were confirmed as being twofold or more deregulated in 
p110δ KI Tregs, whilst the majority of the others validated, showed a similar 
pattern but failed to meet the statistical criteria.   It is possible that some of these 
unconfirmed genes identified in the gene array are genuinely modulated by PI3K 
activity but that this modulation is subtle as was mainly observed for genes 
affected by pan-PI3K inhibition in chondrocytes.  
In summary, both at the start of this project and at the time of writing, surprisingly 
little data was available regarding the genome-wide impact of PI3K activity on 
transcription.  The data so far, determined using overexpression of Akt, pan-PI3K 
inhibition and genetic inactivation of a specific PI3K isoform, all points to a 
relatively minor impact of PI3K activity on the transcriptome.   As PI3K inhibitors 
are now entering clinical trials, fully appreciating their impact not just on 
signalling and translation but also on transcription seems all the more important.  
It will be interesting to see in the future if the effects of inhibition of different Class 
IA PI3K isoforms are similar or disparate and furthermore, whether some of the 
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functional diversity between the isoforms can be explained at the level of 
transcriptional regulation. 
1.3. Investigating the physiological and pathological 
implications of PI3K activity 
The extensive effects of PI3K-Akt activity on cellular processes naturally translate 
into numerous physiological effects.  Indeed, PI3K-Akt signalling has been 
identified as a key regulator in a diverse and extensive range of physiological 
processes, including angiogenesis, metabolism and immunity [32, 51].  Moreover, 
the PI3K-Akt pathway has been implicated in the aetiology or progression of a vast 
array of pathological conditions. Cancer was perhaps the first human condition in 
which dysfunctional PI3K was found to play a key role.  Indeed, mutations in 
PIK3CA the gene encoding p110α, and also in the PTEN gene are in fact, some of the 
most common somatic mutations in solid tumours [31, 52-57].   
Investigation into the physiological and pathological processes in which PI3K 
partakes has been greatly aided by the use of mouse models generated using a 
variety of gene-targeting strategies.  Details regarding the generation of these 
models and highlights from the wealth of information obtained from these models 
are discussed below, alongside a summary of available pharmaceutical tools. 
1.3.1. Tools and models for investigating PI3K functions 
1.3.1.1. Pharmacological tools available to disrupt PI3K function 
1.3.1.1.1. Pan-PI3K inhibitors 
Much of the initial and indeed continuing investigations into PI3K function have 
utilised inhibitors that are broadly effective against multiple PI3K isoforms.  The 
two commonly used pan-PI3K inhibitors are LY294002 [58] and Wortmannin [59], 
both of which inhibit all Class I PI3K isoforms.  Obviously, when using pan-PI3K 
inhibitors, it is not possible to distinguish which of the individual isoforms are 
responsible for any phenotypic changes observed in their presence.  It is also 
important to recognise that LY294002 has been found to inhibit a number of non-
PI3K targets including mTORC1, DNA-dependent protein kinase and casein kinase-
2 [60-61].  Further complicating the interpretation of the effects of pan-PI3K 
inhibitors is the differential inhibitory effects of LY294002 and Wortmannin across 
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the PI3K family.  Wortmannin has an IC50 of around 5 nM across the PI3K family 
with a similar inhibitory effect on Class I, II and III PI3K enzymes, but a ten-folder 
lower inhibitory effect on the PI3K-C2α enzyme.  LY294002 is less potent than 
Wortmannin but is much more soluble and has an IC50 of around 1 µM across the 
Class I and III PI3K enzymes but has a negligible effect on Class II PI3K enzymes.  
Despite their off-target effects the use of pan-PI3K inhibitors has provided valuable 
insights into the processes in which PI3K enzymes as a family are integral.  Pan-
PI3K inhibitors also provide useful controls when used alongside isoform-selective 
inhibitors. 
 
1.3.1.1.2. Isoform-selective PI3K inhibitors 
There is now a broad selection of small molecule isoform-selective inhibitors, 
which have varying selectivity for one or a sub-group of the PI3K isoforms.  All 
currently available PI3K inhibitors are reversible competitive inhibitors, which 
inhibit Class I PI3K lipid activity by interacting with and thereby occluding access 
to the ATP-binding pocket of PI3K catalytic subunits.  IC87114, which selectively 
targets p110δ, was the first of these PI3K isoform-selective drugs to be used in 
published work [62], and is still used today to probe for p110δ functions in vitro 
and in vivo in animal models [63-64]. 
Recent advances have been made regarding the development of isoform-selective 
inhibitors.  These advances were driven by the observation of a conformational 
change adopted by p110δ and p110γ but rarely adopted by p110α or p110β [65].    
Specifically, based on these findings a number of inhibitors that are highly selective 
for both p110δ and p110γ (p110δ/γ) as compared to the other PI3K Class I 
isoforms, have been developed [66]. 
 
1.3.1.2. Genetic strategies for disrupting PI3K activity 
A number of genetic models for PI3K inactivation have been generated in order to 
fully appreciate and delineate the range of cellular, physiological and pathological 
roles of PI3K enzymes.  Initial strategies involved targeting the regulatory subunits 
in an attempt to assess the effects of pan-Class I PI3K inactivation.  More recently 
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research has moved towards the investigation of more targeted isoform-specific 
disruption. 
 
1.3.1.2.1. Targeting of the regulatory subunit 
Two groups developed mouse lines in which the p85 regulatory units were 
targeted, with the aim of investigating the effects of abrogating Class IA PI3K 
activity in vivo [67-68]. Both of these mouse lines were found to have defective B 
cell development and one of the lines failed to survive in normal environments as a 
result of this.   No defects in T cell defects were reported by either group, which at 
the time implied that PI3K activity is essential for B cell but not T cell development 
and function. Paradoxically, when non-immunological responses were assessed in 
the regulatory subunit knockout (KO) mice, insulin-responsive signalling was 
found to be enhanced [57].  Further analysis of cells derived from these regulatory 
subunit knockout mice revealed serious problems with the deletion strategies, 
which may well be responsible for this phenotype.   First, the expression of 
untargeted regulatory subunits was enhanced (increased expression of p85β in the 
pan-p85α KO model, for example) and secondly the expression of the Class IA 
catalytic subunits was decreased.    
 
1.3.1.2.2. Targeting of the catalytic subunits 
Initially, isoform-specific mouse models for each Class IA isoform were generated 
using the traditional deletion strategy.  Analysis of cells derived from these mice 
revealed that this strategy, as with the regulatory subunit KO models, causes off-
target effects.  The expression of untargeted p110 isoforms is affected and 
furthermore, a notable disruption to the expression of the regulatory subunits was 
observed [69].  The compensatory changes that occur in response to deletion of the 
regulatory or catalytic subunit highlights the complexity of targeting a multiple 
isoform family, in particular, one that functions in a heterodimeric form.  The 
mechanism by which these compensatory effects occur remains unknown.  As a 
result of these compensation mechanisms, the gene deletion/KO models have now 
largely been superseded by an improved targeting strategy.  
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This novel knock-in (KI) strategy results in the expression of an inactive, lipid 
kinase-dead form of the p110 of interest.   Abrogation of lipid kinase activity is 
achieved by the engineering of a point mutation into the gene, which alters the 
conserved DFG motif to AFG.  This results in the translation of the protein with a 
single amino acid substitution at a functionally important residue located in the 
mouth of the ATP-binding pocket.  The expression of untargeted p110 subunits is 
unaffected in all KI mice analysed, as is the expression of the regulatory subunits 
[70].  Analysis and comparison of the phenotypes of the p110 KI lines to the p110 
null lines revealed that certain phenotypes observed in the PI3K KO mouse lines 
were not due to the loss of lipid kinase activity.  For example, the p110γ KO mice 
had a prominent cardiac phenotype which was absent in the p110γ KI mice [71] 
and was due to loss of a scaffolding function performed by p110γ in a cyclic-AMP 
regulatory complex [70]. 
In summary, the KI model abrogates the need to delete the entire catalytic subunit 
gene and thus does not induce compensatory changes in the expression of the 
untargeted regulatory or catalytic subunits.  The model is a more representative of 
pharmacological inhibition as the targeted isoform is still translated, present in the 
cell and able to interact normally with regulatory subunits and other proteins, but 
is simply catalytically inactivate.  The phenotypic effects of genetically inactivating 
the lipid kinase activity of p110α, p110β and p110γ are summarised below, 
alongside a more detailed analysis of the effects of loss of p110δ lipid kinase 
activity. 
1.3.1.2.3. Additional models for studying PI3K function 
Indeed, a wide range of mutant mouse lines have been generated to study the 
effects of both loss and gain of PI3K activity in vivo.  These include conditionally 
inactivated models that utilise targeted DNA cleavage strategy to delete a 
particular PI3K gene [72].  This can be used to remove a particular isoform at a 
certain stage of development or in a certain cell type/cell lineage only.   The effects 
of increased uncontrolled PI3K activity have been studied in Pten-inactivated mice, 
and in mice where Pik3ca, the gene encoding p110α, is mutated so that it encodes a 
constitutive active form of p110α. A homozygous mutation activating or 
inactivating Pik3ca or Pten respectively, are both embryonic lethal in vivo [12, 73-
74].  The lethality observed in these mutant mouse lines, in which PI3K activity is 
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rendered independent of upstream signalling, emphasises the importance of 
tightly controlled and signal responsive-PI3K signalling.    
 
1.3.2. Non-redundant cell-specific functions of Class IA PI3K isoforms 
Recent research has focused on distinguishing between the individual functions of 
the PI3K isoforms, with the ultimate aim of discerning how selective inhibition 
could be clinically useful.  The interest in isoform-specific functions has been 
enhanced by the expectation that isoforms-specific inhibitors may have improved 
toxicity profiles compared to pan-PI3K inhibitors.  
A solid body of evidence now indicates that there are functions performed solely or 
predominantly by a particular isoform in a certain cell type or downstream of a 
specific stimulus [1, 75-79].  Vanhaesebroeck et al. published one of the earlier 
examples of this functional division [80].  The authors used microinjection of 
isoform-selective antibodies to illustrate that in BAC1.2F5 macrophages, the 
various cellular responses to Colony Stimulating Factor (CSF-1) were regulated by 
different isoforms.  Chemotaxis induced by CSF-1 was found to be dependent on 
p110δ and p110β activity, whereas proliferation induced by CSF-1 was strongly 
dependent on p110α activity [Figure 1.7] [80].  These data indicate that the 
differential functionality can occur downstream of a single stimulus in a particular 
cell type.  Subsequent investigations into the non-redundant roles of Class IA PI3K 
isoforms in primary bone marrow-derived macrophages revealed that p110δ 
regulates CSF-1-driven chemotaxis as it does in BAC1.2F5 macrophages, but that in 
primary macrophages p110δ is also necessary for a normal proliferative response 
to occur [1].  This finding revealed that the contributions of the Class IA PI3K 
isoforms are influenced by cell state, i.e. primary versus immortalised. 
 
Figure 1.7 Schematic representing the role of Class IA PI3K isoforms in CSF-1-induced 
responses in BAC1.2F5 macrophages.  Blockade of p110α resulted in inhibition of CSF-1-induced 
proliferation, whilst blockade of p110δ and to a lesser extent p110β resulted in inhibition of CSF-1 
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induced chemotaxis and associated cytoskeletal changes. [Altered with permission from Prof. 
Vanhaesebroeck] 
 
1.4. Cellular and physiological roles of Class IA PI3Ks  
1.4.1. Cellular and physiological roles of p110α  
Both p110α KO and p110α KI (p110αD933A/D933A) mutations are embryonic lethal 
[12, 32].  Staining of p110α KO embryos at a stage prior to lethality exposed a 
severe proliferation defect.  This effect of p110α inactivation on proliferation was 
confirmed by the incapacity of explanted murine embryonic fibroblasts (MEFs) to 
proliferate ex vivo [12].  Subsequent cellular studies using p110α-specific 
antibodies and RNA interference (RNAi) have revealed that p110α has a crucial 
role in cell cycle progression, which may represent the mechanism underlying the 
proliferative defects of p110α KO cells [78].   
Substantial angiogenic abnormalities were detected in the p110α KI embryos, 
including failure to form and expand a normal vascular network [51].  Graupera et 
al. subsequently created an endothelial-specific model for genetic inactivation of 
p110α, and in doing so established that the observed p110α-dependent angiogenic 
abnormalities were sufficient to cause embryonic lethality.  Heterozygous p110αP 
KI mice were found to be viable, but tissues from the adult mice have defects in 
angiogenic responses.  This indicates that the role of p110α in angiogenesis is not 
limited to developmental embryonic angiogenesis, and might therefore be relevant 
to tumour-induced angiogenesis [51].   
Further investigation of the heterozygous p110αP KI mice revealed a major role for 
p110α in metabolic regulation; significant metabolic deregulation was observed in 
both the mice and cells derived from them [32].  Foukas et al. attributed this to 
disruption of a positive role performed by p110α in signalling downstream of 
several metabolic regulators, including insulin and leptin [32].   
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1.4.2. Cellular and physiological roles of p110β 
Investigation into the effects of p110β loss of function were initially precluded by 
the early embryonic lethality of the p110β KO mutant mice and the failure of MEFs 
derived from p110β KO embryos to proliferate in culture [81].  Subsequently, a 
mutant p110β mouse model was developed which encoded a deletion in the 
catalytic domain of the p110β gene (p110βΔ21,22/Δ21,22) [10]. Two p110β KI mouse 
lines have since been generated and in both cases a partial lethality has been 
observed [[82], Dr Guillermet-Guibert, The Centre for Cell Signalling, unpublished 
data].   MEFs and bone marrow-derived macrophages extracted from p110β KI 
mice are able to proliferate [Guillermet-Guibert, Centre for Cell Signalling, 
unpublished data].  Together these data suggest that the kinase activity of p110β is 
in fact not essential for proliferation but p110β certainly appears to contribute in 
some way, perhaps by assisting p110α in driving the cell to enter S phase, as 
shown by Marques et al. [78].  
Physiologically, p110β plays an important role in haemostasis and in particular in 
thrombus formation.   Activation and aggregation of platelets in response to sheer-
stress appears to require p110β activity.  In the absence of p110β activity, platelet 
aggregation is reduced in vitro and this translates to a reduction of thrombus 
formation in vivo [83].  Mechanistically, the absence of p110β activity seems to 
abrogate the capacity of integrin αIIβ β3 complexes to form the stable adhesion 
contacts that facilitate platelet aggregation. 
 
1.4.3. Cellular and physiological roles of p110δ 
p110δ KI (p110δ D910A/D910A) mice have been generated and they are not only 
viable, and fertile but also have no gross anatomical or behavioural defects [84].  
As stated earlier, p110δ has a very limited tissue distribution and is highly 
enriched in leukocytes and, as a result, the genetic inactivation of p110δ primarily 
impacts upon the function of immune cells.  In the section below, I have 
summarised the effects of p110δ inactivation on some of the immune cell types. I 
have introduced macrophage function and immunity in greater detail in a 
subsequent section. 
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1.4.3.1. The role of p110δ in macrophage biology 
The effects of p110δ inhibition on macrophage function are of particular relevance 
to my project.  As with most immune cells, an ability to migrate and specifically, to 
move in a directional manner (chemotax) towards a stimulus, is essential for 
macrophage function.  As described above, Vanhaesebroeck et al. showed that 
p110δ regulates chemotaxis downstream of CSF-1 in BAC1.2F5 macrophages [80].  
Subsequent in depth analysis of the role of p110δ in macrophage 
migratory/chemotaxis has revealed that p110δ inactivation in primary 
macrophages results in a reduction of actin polymerisation, membrane ruffling and 
cell spreading [79].  The underlying molecular mechanism of these cytoskeletal 
and motility defects was found to be caused by deregulation of two key regulators: 
RhoA and Rac1.  Rac1 and RhoA are both small guanidine tri-phosphate (GTP)-ases 
that cycle from an inactive guanidine di-phosphate (GDP)-bound state to an active 
GTP-bound state with the help of regulatory molecules, which either stimulate the 
proteins’ own intrinsic GTP hydrolysis activity or enhance GTP binding.  Rac1 
activity was found to decreased upon p110δ inactivation, and conversely RhoA 
activity is increased in both basal and CSF-1-stimulated macrophages in the 
absence of p110δ activity.  This increased RhoA-GTP activity was found to be the 
crux of the migratory problem in these macrophages [79].   
In primary macrophages, p110δ has been found to play a far more extensive role 
downstream of CSF-1 than it does in immortalised BAC1.2F5 macrophages.  
Indeed, in primary macrophages, p110δ is the major isoform responsible for CSF-
1-induced p-Akt induction and its inhibition represses CSF-1 induced proliferation 
as well as chemotaxis [1, 79].  p110δ activity has been shown to be necessary for 
normal proliferation of many other immune cells including B cells, T cells.  It 
should be noted that, unlike the B cell defects in the p110δ KI mice, macrophages 
derived from these mice differentiate into phenotypically normal macrophages in 
vivo and ex vivo [79].  Thus, these data indicate that although p110δ plays a 
significant role in regulation of macrophage proliferation, its activity is not 
necessary for macrophage development and differentiation.  
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1.4.3.2. The role of p110δ in mast cell biology 
Mast cells, which reside in situ in tissues, play a central role in allergic response.  
Mast cell detect allergens through the Immunoglobin E (IgE) molecules on their 
surface and upon repeat exposure, allergen binding to surface-IgE initiates a 
signalling cascade.  This cascade induces the release of mast cell granular contents, 
which includes histamine amongst other inflammatory mediators.  Ali et al. found 
that mast cells derived from p110δ KI mice are partially unable to degranulate and 
release inflammatory mediators in response to allergic stimulus [75].  This cellular 
defect translates into attenuated allergic responses in vivo in p110δ KI mice [75].   
 
1.4.3.3. The role of p110δ in T and B cell biology 
Signalling downstream of the T cell Receptor (TcR) was observed to be affected in 
p110δ KI mice.  This causes a reduction in T cell proliferation in response to anti-
CD3 stimulation [84] but despite this T cells retain their capacity to differentiate 
into the main mature T cell subtype, effector T cells. 
When the p110δ KI mice were first generated the initial publication focused on 
both ex vivo and in vivo evidence of serious defects in B cell Receptor (BcR) as well 
as TcR signalling [68, 84].  B cells defects in the p110δ KI mice are wide ranging 
and include a vastly diminished ability to produce antigen-specific antibodies in 
response to immunological challenge [84].  The production of antibodies in 
response to immunological challenge requires the formation of micro-anatomical 
structures in known as germinal centres (GCs) in secondary lymphoid organs.  In 
these GCs, B cells undergo division, antibody class switching, somatic 
hypermutation and ultimately differentiation into either memory B cells or plasma 
B cells.  The plasma B cells that differentiate in the GCs are responsible for the 
production of antigen-specific antibodies.  Histological analysis of lymphoid tissue 
revealed that the inability of p110δ KI mice to produce antigen-specific antibodies 
was associated with a complete absence of GCs.  The GC reaction involves also 
involves antigen-presenting cells (APCs) and specialist type of T cells known as 
follicular T helper (TFH) cells, which support the differentiation of B cells.  A recent 
publication has revealed that it is the absence of p110δ activity in T cells rather 
than B cells, which is responsible for the lack of GC formation and associated low 
antibody titres in p110δ KI mice [85].  Rolf et al. showed that selective deletion of 
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p110δ in B cells did not result in the same blockade of GC formation or antibody 
production as observed in the p110δ KI mice [85]. Yet, selective deletion of p110δ 
in T cells did result in these GC-related phenotypes mimic [85].  Specifically, the 
inability of p110δ KO T cells to expand and differentiate into a normal TFH cell 
population was found to be the limiting factor preventing GC formation [85].   
Tregs are another important T cell population that are reduced in p110δ KI mice.  
Tregs as their name suggests, perform an important regulatory function; they 
maintain peripheral tolerance by limiting both the activity and expansion of 
effector T cells.  Tregs extracted from these mice have been found to have reduced 
suppressive capacities and do not produce the anti-inflammatory cytokine IL-10 ex 
vivo [86].    
In summary, inactivation of p110δ has a significant impact on the adaptive 
immune cell population.  This includes abnormal B cells differentiation and 
severely disrupted function resulting in poor humoral responses.  This B cell 
dysfunction appears to be primarily a T cell-intrinsic effect rather than a direct 
result of the loss of p110δ activity in the B cells themselves.  T cells derived from 
p110δ KI mice have distortions in their subpopulations, which affects the spectrum 
of T cell activity and also p110δ KI Effector T cells have attenuated TcR signalling. 
 
1.4.4. Cellular and physiological roles of p110γ 
Like the p110δ KI mice, the p110γ null mice are viable, fertile and display with no 
gross anatomical or behavioural defects [71, 84].   Similarly, as observed in the 
p110δ KO and p110δ KI mice, p110γ KO mice have a range of immunological 
defects that are apparent in vitro and in vivo [71].  A p110γ KI mouse line has also 
been generated, which closely replicate the p110γ KO mice phenotypes, with the 
exception that the cardiac phenotype observed in the p110γ KI mice that was 
absent.  This was attributed to disruption of a p110γ scaffolding function in the 
p110γ null mice [87]. 
Analysis of leukocytes derived from p110γ null mice revealed a number of defects, 
which can mostly be traced back to lack of p110γ signalling downstream of GPCR 
agonists.  This concurs with the hypothesis that p110γ couples primarily to GPCRs.  
In particular, the in vitro migratory responses to GPCR-linked chemo-attractants 
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such as complement component C5a were defective in both macrophages and 
neutrophils [71].  This migratory defect has been shown to translate into reduced 
neutrophil migration to a site of viral infection in vivo p110γ null mice [71].  Other 
GPCR-dependent immunological responses were found to be affected by loss of 
p110γ activity, including GPCR-stimulated oxidative burst in neutrophil [71].  
Unlike p110δ KI mice, p110γ null mice appear to have no defects in B cell 
developmental or functionality [71]. 
Some groups have presented evidence for a role of p110γ in T cells; effector T cells 
were found to migrate inefficiently and this was attributed to downstream 
dysfunction in migratory responses caused by loss of p110γ activity [88].  More 
recent data suggest that the defects in T cell function in p110γ null could actually 
be attributed to an impairment of TcR signalling.  Although the TcR is an RTK and 
p110γ is known to function downstream of GPCRs, p110γ was nevertheless found 
to be activated in response to TcR engagement [89].  Loss of p110γ activity 
reduced the capacity of T cells to interact with APCs by forming immunological 
synapses, a crucial step in the activation of T cells by APCs [89].  In summary, 
p110γ activity appears to be necessary for GPCR-ligand-driven migration and 
activation of both innate and adaptive immune cells.  Furthermore, loss of p110γ 
attenuates the capacity of these cells to perform their normal functions in infected 
tissues such as cytotoxic killing of pathogens.  
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1.5. Macrophages in the immune system 
1.5.1. The components of the immune system and stages of immune 
response 
The mammalian immune system consists of a diverse range of functionally distinct 
cell types [Figure 1.8].  The complete immune response is a complex and 
coordinated tri-phasic response. 
 
Figure 1.8. Illustration of the haematological cell lineage.  Haematopoietic cells derive from 
pluripotent stem cells in the bone marrow and then differentiate into a range of cells either 
belonging to the lymphoid or the myeloid lineage.  Each cell has a specialised function.  
Macrophages are differentiated from monocytes and belong to the myeloid lineage. [Image 
reproduced with permission from Wikimedia Commons, original illustration by A. Rad.] 
 
1.5.1.1. Macrophages and the innate immune response 
Rapid detection of a pathogenic threat and subsequent activation of innate 
immune cells, including macrophages and neutrophils is the first stage of any 
immune response.  The innate immune cells are the first line of defence, utilising 
search and destroy tactics to clear pathogen.  Further to this, the innate immune 
cells must call to arms the adaptive immune cells that are capable of providing 
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more pathogen-specific immunity.  Macrophages reside in situ in most solid tissues 
and are primarily derived from circulating monocytes [Figure 1.8] [90].  
Macrophages perform their search and destroy duties first, by employing highly 
sensitive detection mechanisms and secondly, by engulfing pathogenic material 
using a specialised endocytostic process known as phagocytosis.  
 
1.5.2. Initiation of the adaptive immune response 
Activated macrophages induce adaptive immunity by releasing a wide range of 
inflammatory mediators including cytokines and chemokines [91].  The cocktail of 
inflammatory mediators released recruits adaptive immune cells to the site of 
infection and also contribute to the process of adaptive cell activation.  The 
combined pathogen-specific cytotoxic and antibody/humoral functions performed 
by T and B cells are necessary to clear a tissue of pathogens and cells infected with 
them.  To direct the adaptive immune cells to initiate the appropriate programme 
the macrophages must present fragments of the pathogen to the incoming cells.  To 
do this they first engulf pathogens or pathogen fragments using a specialised 
endocytosis process known as phagocytosis.  This material is processed internally 
and displayed on the surface of the macrophages in complex with Major 
Histocompatibility Complex Class II (MHC Class II).  The MHC II-antigen complex 
engages with antigen recognition receptors such as the TcR on adaptive immune 
cells and stimulates the formation of immunological synapses [92].  This 
interaction between APCs and T cells is affected by loss of p110γ inactivation [89].  
In the case of T cells, interaction of naive T cell MHC-antigen receptors with MHC-
antigen complexes induces proliferation and differentiation of the cells into 
effector T cells or helper T cells.   The effector T cells are then able to identify host 
cells infected by the pathogen and destroy them by cytotoxic mechanisms.  
Meanwhile, primed B cells that have been previously exposed to a particular 
pathogen proliferate and in the presence of TFH cell stimulation differentiate into 
plasma B cells.  The reduced numbers of TFH cells in the p110δ KI mice was found 
to be responsible for the drastically reduced production of pathogen-specific 
antibodies in these mice.     
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1.5.3. Recognition of lipopolysaccharide and other pathogens by 
macrophages 
Macrophages are able to achieve an exquisite sensitivity to the presence of a wide 
range of pathogens [93].  This is achieved by expressing an array of highly selective 
pattern recognition receptors (PRRs) that recognise specific molecular patterns in 
pathogenic material, known as pathogen-associated molecular patterns (PAMPs). 
Lipopolysaccharide (LPS), the major component of gram-negative bacteria cell 
walls, is of particular clinical significance because to its capacity to induce life-
threatening endotoxic shock syndrome (also known as Septic Shock).  Following 
recognition by macrophages LPS induces an immune response as described above.  
The production of a cocktail of macrophage-derived inflammatory mediators is 
thought to be a major element in the development of endotoxic shock syndrome.  
Several of these mediators, including TNFα, stimulate local vasodilation in order to 
facilitate entry of leukocytes into the infected tissue [94-96].  If systemic 
vasodilation occurs due to excess soluble vasodilators in to the blood stream a 
rapid drop in blood pressure.  This can cause insufficient tissue perfusion and 
hypoxia and ultimately can result in multi-organ failure and death [97]. 
 
1.5.3.1. Recognition of LPS by macrophages 
Recognition of LPS and initiation of intracellular signalling requires the formation 
of multi-protein complexes.  LPS itself forms a complex with LPS binding protein 
(LPB) in the plasma [Figure 1.9].  This LPS-LBP complex is presented to Toll-Like-
Receptor 4 (TLR4) by the membrane-anchored protein CD14. [Figure 1.9] [93, 98-
100].  This CD14-TLR4 complex also requires another extracellular accessory 
protein MD-2 [Figure 1.9] in order to respond appropriately to LPS-LBP.  Deletion 
of TLR4, MD-2 or CD14 in mice results in hypo-responsiveness to LPS and 
concomitant resistance to endotoxic shock [98, 100-103]. 
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Figure 1.9. LPS is recognised by macrophages via a PRR complex in association with an 
accessory protein.  LPS in complex with plasma LBP binds to the macrophage surface complex 
consisting of TLR4-CD14 in association with the accessory protein MD2.  The TLR4 component of 
this complex is then activated.  
 
1.5.3.2. LPS-induced signalling downstream of TLR4-CD14-MD-2 complex 
LPS signalling is initiated via adaptor proteins that interact with the intracellular 
Toll/IL-1 Receptor (TIR) domain of TLR4 [Figure 1.10].  The details of the exact 
components, pathways and mechanisms contributing to LPS-induced signalling are 
not yet fully elucidated.  It is clear that LPS activates a number of canonical 
signalling pathways including the MAPK, NF-κB and the PI3K-Akt pathways.  The 
classical LPS-signalling pathway activated directly downstream of TLR4 is the 
myeloid differentiation primary response gene 88 (MyD88)-dependent pathway.  
MyD88 is recruited to activated TLR4 receptors and acts as an adaptor recruiting 
kinases, which then initiates downstream signalling.  Deletion of MyD88 is 
sufficient to abrogate LPS-induced signalling and cytokine production [104].  IL-1 
Receptor-associated kinase 4 (IRAK4) is the main kinase recruited to TLR4 by 
MyD88 [105].  IRAK4 facilitates the formation of a downstream effector complete 
composed of kinase TNF-Receptor-Associated Factor 6 (TRAF6) and IRAK1.  The 
TRAF6-IRAK1 complex then propagates the signal via phosphorylation of 
downstream proteins [Figure 1.10][105].   
 
 
 
 46 
 
 
 
Figure 1.10. Illustration of the activation of NF-κB-dependent transcription by LPS via the 
MyD88-dependent pathway.  LPS recognition results in recruitment of the adaptor protein 
MyD88 to the TLR4 TIR domain and initiates a cascade of signalling via several kinases. 
Downstream kinase activity results in the release of NF-κB from its inhibitory partner IκB. Release 
of NF-κB reveals its NLS and allows it to enter the nucleus and upregulate expression of pro-
inflammatory genes.  
 
1.5.3.3. LPS induces a shift in the macrophage transcriptome 
LPS has profound effect upon the transcriptome of macrophages and this 
transcriptional regulation appears to play a central role in the induction of the 
activated inflammatory phenotype.  LPS alters the expression of thousands of 
genes including the induction of a wide range of inflammatory mediators such 
chemokines and cytokines.   
One of the most well characterised transcription factors regulated by LPS 
signalling is NF-κB.  As described earlier, Akt activity promotes the activation of 
NF-κB but downstream of LPS independent pathways also potently induce NF-κB.  
The presence of inactive NF-κB tethered in the cytosol, allows LPS and other 
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immunological stimuli to rapidly initiate transcriptional changes by inducing the 
liberation and activation of NF-κB.  The MyD88 pathway rapidly initiates activation 
of NF-κB downstream of TLR4-LPS engagement. Specifically, IRAK1 activity 
induces the activation of NF-κB-driven transcription indirectly by the activation of 
IKKs.  As described above, activated IKK phosphorylates IκB and this results in the 
release NF-κB [37] [38].  This activation of NF-κB results in the upregulation of 
early NF-κB-driven pro-inflammatory genes, which contribute to LPS-driven 
macrophage functions.  Further to this, a second delayed wave of transcriptional 
change is initiated via the de novo expression of NF-κB-regulated transcription 
factors or their regulators.  This deferred response allows the cells to modulate 
macrophage phenotype to suit the stage of the infection and plays a role in the 
induction of tolerance.   
A second pathway downstream of TLR4 activation, the so-called “MyD88-
independent” pathway, has been identified and its components are necessary for 
optimal induction of inflammatory genes, including those encoding cytokines 
[106].  The components and mechanisms of action of the MyD88-independent 
pathway are poorly characterised.  Two adaptor proteins, TIR domain-containing 
adaptor inducing IFN-β (TRIF) and TRIF-related adaptor molecules (TRAM), are 
known to bind the TLR TIR domain.  In the absence of MyD88 activity, these 
components have been found to facilitate LPS-induced activation of NF-κB and also 
induce the activity of the MAPK pathway (p38 activation) in dendritic cells [104, 
106].  How this pathway functions in concert with MyD88 signalling is not yet fully 
characterised. 
1.5.3.4.   Regulation of LPS responses by PI3K 
PI3K dependent phosphorylation of Akt at S473 and T308 occurs rapidly in 
response to LPS-stimulation [107-108].  The mechanism by which PI3K activity 
and downstream Akt activation are coupled to LPS stimulation is currently unclear.  
We know that PI3K p85 regulatory subunits can be recruited to another member 
of the TLR family, TLR2 upon activation and that this recruitment was sufficient to 
activation PI3K activity [109].  This recruitment was suppressed by site-directed-
mutagenesis of specific tyrosine residues on TLR2 indicating direct recruitment 
and its aberration had functional significance [109].  Whether direct recruitment of 
PI3K to the TLR4 complex occurs in response to LPS remains an open question.   
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PI3K has been reported to interact with MyD88 upon LPS stimulation, which 
suggests that PI3K may be recruited to the TLR4 complex rather than directly to 
TLR4 [110].   It is also possible that PI3K is activated by LPS in an autocrine 
manner by ligands secreted by LPS-stimulated macrophage or alternatively by an 
intracellular effector of LPS.   Indeed, it is not inconceivable that multiple 
mechanisms contribute to the activation of PI3K in response to LPS. 
There is a significant body of evidence that indicates PI3K activity plays a role in 
LPS-induced responses [107-108, 111-112].  Early data and indeed much of the 
current data attributes a negative regulatory role to PI3K activity downstream of 
LPS [107, 111-112].  Contrary to evidence discussed above indicating a positive 
regulatory role for PI3K-Akt upstream of NF-κB [42, 113], the inhibition of PI3K in 
monocytic cells has been shown to increase NF-κB activity [107].  Importantly, an 
increased production of pro-inflammatory cytokines was concomitantly observed, 
alongside enhanced NF-κB activity upon PI3K inhibition [107].  Indeed, PI3K-
dependent suppression of TNFα induction has been observed in vivo in p85α KO 
mice.  The p85α KO mice have higher TNFα serum levels than their wild-type 
counterparts when challenged with LPS.  On the other hand, contradictory studies 
have shown a profound reduction in the secretion of TNFα from p110δ KI 
leukocytes including macrophages [114-115].  In macrophages, this was attributed 
to a defect in the secretion of TNFα, whilst its production remained unaffected 
[114-115].  It remains possible that another PI3K Class IA isoforms negatively 
regulates the transcription or translation of TNFα in these cells, which could 
account for the increased production upon pan-PI3K inhibition.  Alternatively, the 
increased TNFα secretion observed in p85 KO mice could be as a result of a 
compensatory mechanism and perhaps should not be taken at face value.   
Data is increasingly pointing to the differential regulation of cytokine production 
or secretion downstream of PI3K-Akt upon LPS-stimulation.  mTORC1 and GSK-3 
are two central nodes downstream of PI3K-Akt that both appear to play significant 
role in differential regulation of cytokine/chemokine production.  GSK-3, which is 
inactivated by Akt activity as described above, negatively regulates the production 
of the important immuno-modulator cytokine IL-10, whilst also positively 
regulating the production of a number of potent pro-inflammatory cytokines 
including TNFα, IL-12 [116].  Thus, Akt activation results in a suppression of TNFα, 
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IL-12 whilst enhancing the production of IL-10 through GSK-3 inactivation [Figure 
1.11][116].  In contrast, Akt activates mTORC1 activity downstream of PI3K by 
inactivating TSC1/TSC2 and mTORC1 has the polar opposite effect on the 
production of these same cytokines [Figure 1.11].   
 
 
Figure 1.11. Schematic of the differential effect of PI3K activity on cytokine production 
mediated modulation of GSK-3 and mTORC1 activity.  Inactivation of GSK-3 and activation of 
mTORC1 results in enhanced production of immune-modulatory IL-10 and suppression of pro-
inflammatory mediators including IL-12, Il-6 and TNFα.   
 
Thus, by the inhibition of GSK-3 and the activation of mTORC1, PI3K-Akt signalling 
suppresses the production of several pro-inflammatory cytokines, whilst 
simultaneously enhancing the production of the key immune-regulatory cytokine 
IL-10 [Figure 1.11].  The potential in vivo immune-regulatory effects of IL-10 have 
been demonstrated in vivo by the improved symptoms of patients with Crohn’s 
disease who were treated with bacteria encoding a recombinant IL-10 [117].  
Furthermore, IL-10 has been shown to suppress NF-κB activity, which might in 
part explain why the inhibition of PI3K-Akt in monocytic cells resulted in enhanced 
production of some cytokines whilst also enhancing NF-κB transcriptional activity 
[107].  
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There is also evidence to suggest that PI3K may function in the later stages of LPS 
responses.   After an initial exposure to LPS, the immune system responds less 
vigorously to a second LPS exposure.  This so-called endotoxin tolerance that 
blunts the immune systems activation in response to LPS is thought to be safety 
mechanism that prevents an unnecessarily and potentially damaging maximal 
response being initiated [96, 118].  In RAW 264.7 macrophages, inhibition of PI3K 
was found to increase TNFα and Nitric Oxide production in response to a second 
exposure to LPS.  These data suggest that tolerance was not properly induced or 
was overcome in the absence of PI3K activity.  The potential importance of PI3K-
Akt in the induction of tolerance was also apparent in Akt null mice, which had 
hyper-inflammatory phenotypes and concurrently failed to develop endotoxin 
tolerance.  Thus, evidence points to a role for PI3K in LPS responses both in the 
initial stages and in longer-term responses such as the induction of tolerance 
[119].  
Together, these data suggest that PI3K-Akt activity primarily functions to 
negatively regulate the induction of LPS-induced responses.  There is conflicting 
data that suggests that certain LPS-induced inflammatory responses require PI3K 
activity in macrophages.  Despite this, the primary role of PI3K appears to be the 
induction of mediators that suppress or limit the activation of LPS-responses.  It is 
not unheard of for the same effector to activate signalling whilst also downstream 
initiating negative regulators of the same signalling and indeed this represents a 
capacity to module rather than simply switch on or off responses.  It therefore 
seems plausible that PI3K may act to modulate responses by maintaining some 
degree of homeostasis, rather than simply by repressing inflammation.  
 
1.5.4. The importance of a balanced immune response 
It is vital that when the immune system responds to infections the response is both 
balanced and appropriate; otherwise it can do considerably more harm than the 
pathogen itself.  The loss of peripheral tolerance and resulting misdirected 
immunity can be extremely harmful [120].  The importance of a balanced and 
appropriate immune response and the role p110δ plays in achieving this balance is 
apparent in the p110δ KI mice.  These mice develop inflammatory bowel disease 
(IBD) in the form of inflammatory colitis, which ultimately causes rectal prolapse 
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in a certain proportion of the female mice.  The colitis has been attributed to an 
inappropriate immune response to commensal enteric bacteria [84, 121].  This 
phenotype suggests that the observed negative regulation of bacterial responses 
by PI3K does indeed translate into a deregulation in vivo.  The data implies that 
p110δ may play a negative regulatory role in suppressing responses to commensal 
bacteria in the gut.  Indeed, p110δ maps to the human IBD sensitivity locus [122], 
although it must be noted that to date, there is no direct evidence that inactivation 
of p110δ in humans results in IBD.  The inappropriate inflammatory reaction to 
commensal bacteria has been partly attributed to the reduced population of Treg 
cells in these mice.  In support of this, in adoptive transfer experiments Treg cells 
derived from p110δ KI mice were unable to protect against experimental colitis 
induced in WT mice [86].  A more recent publication has provided evidence that 
the loss of p110δ in macrophages also contributes to the IBD in the p110δ KI mice 
[123].  Thus PI3K and specifically p110δ does appear to contribute to the 
regulation of the immune responses to bacteria in innate and adaptive immune 
cells.  
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1.6. Therapeutic potential of PI3K inhibition 
Whilst considering the phenotypes observed in the various PI3K mouse models, it 
is apparent that inhibition of the PI3K Class I enzymes represents an opportunity 
to modulate a range of physiological and pathological processes.  Indeed, at the 
time of writing, there were at least eighteen clinical trials underway using a wide 
range of PI3K inhibitors [124]. 
1.6.1. Therapeutic potential of targeting p110α 
The high prevalence of PIK3CA and PTEN mutations in human solid tumours has 
revealed that PI3K and specifically p110α are targets worthy of attention in 
pharmaceutical/translational research [125].  A large proportion of the clinical 
trials currently underway are testing the efficacy of PI3K inhibition in the 
treatment of human solid tumours.   Initially, it was thought that p110α-selective 
inhibitors could represent a “magic bullet” in the treatment of human 
malignancies.  This was not purely based on the frequency of the PIK3CA 
mutations, but also on supporting data that indicated p110α plays a pivotal role 
not just in proliferation, metabolism and angiogenesis [32, 51, 53, 125].  Recent 
data has suggested that inhibition of p110α and even pan-Class I PI3K inhibition 
may not be sufficient to kill cancer in the majority of cases [126-127].  Instead, if 
we wish to utilise PI3K-targetted inhibitors to improve clinical outcome in 
oncology, it may be necessary to combine them with conventional chemotherapies 
or inhibitors of other deregulated pathways. 
 
1.6.2. Therapeutic potential of targeting p110β 
The role of p110β in the regulation of platelet formation makes it an interesting 
potential anti-thrombosis target.  Thrombosis, often occurring as the result of the 
rupture of atherosclerotic lesions, is a major health concern as it can lead to heart 
attacks and strokes.  Current anti-thrombotic therapies interfere with the capacity 
of platelets to aggregate and thus reduce thrombus formation but also interfere 
with normal haemostasis.  As a result, standard therapies prolong bleeding and can 
result in serious bleeding complications.  Inhibition of p110β holds particular 
promise as a therapeutic strategy because it appears to specifically affect sheer 
stress-induced activation of platelets and thus does not have a detrimental impact 
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upon bleeding times [83, 128].  This potential capacity to reduce sheer-stress 
induced thrombus formation in at-risk patients without prolonged bleeding time 
would be a major step forward in the field of prophylactic treatment for heart 
attack and strokes. 
A potentially important discovery regarding p110β function in tumours has 
recently been made [129-130].  As described above, the PI3K pathway is 
commonly deregulated in cancer, predominantly by activation of p110α or by 
inactivation of PTEN [125, 131-132].  Wee et al. found that whilst tumours 
harbouring PIK3CA mutations were responsive to inactivation of p110α those 
harbouring PTEN mutations were not [130].  The authors found that whilst 
inactivation of p110α and also p110δ had little impact on proliferation of PTEN 
null cell lines, downregulation of p110β reduced PI3K activity and concordantly 
reduced cell growth [130].  These finding highlights the importance of 
understanding the isoform specific roles of the PI3K family members if we are to 
target them successfully for maximum therapeutic benefit. 
 
1.6.3. Therapeutic potential of targeting p110δ 
As this project focuses on p110δ, I have concentrated on detailing a number of 
representative conditions in which p110δ-selective inhibition may address unmet 
medical needs. 
 
1.6.3.1. Treatment of immune disorders and inflammatory conditions  
There is a vast array of chronic human conditions in which inappropriate activity 
of the immune system maintains an unnecessary and damaging inflammatory 
state.  Consequently, selective inhibition of p110δ and also p110γ represents an 
exciting opportunity to treat such conditions by disrupting a number of immune 
functions that drive inflammation. 
 
1.6.3.2. The leukocyte PI3K isoforms p110γ and p110δ  
The therapeutic potential of dual inhibition of p110γ and p110δ has received much 
attention as they are both enriched in leukocytes and particularly, because their 
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inactivation in vivo results in different but complementary immunological 
phenotypes.  It is hypothesized that, by inhibiting both isoforms, it may be possible 
to more completely disrupt the dysfunctions associated with chronic inflammatory 
or autoimmunity conditions.  On the other hand, when the individual 
immunological dysfunctions resulting from either p110δ or p110γ are considered, 
it seems predictable that dual inhibition could also result in an unacceptable 
degree of immune-compromise [71, 84, 133-134].   Indeed, a p110γ null-p110δ KI 
mouse line was generated and the mice were very sickly with severely 
compromised immune systems that prevented it surviving in a normal 
environment [134]. 
Research over the past decade has identified an ever-increasing list of conditions 
in which inflammation is at least a contributing factor to the pathogenesis, such as 
cancer, neuro-degeneration and cystic fibrosis.  Thus, the breadth of possible 
therapeutic applications for p110δ/γ-selective inhibitors is potentially 
considerably broader than one might initially anticipate. 
Below I have focused on the potential clinical benefits of p110δ-selective inhibitors 
in two classic immune disorders: Asthma and Rheumatoid Arthritis.  Subsequently, 
I provide a summary of the data regarding the use of p110δ-selective inhibitors in 
the treatment of haematological malignancies.  
 
1.6.3.3. Allergic disorders and chronic inflammation 
Allergic disorders are increasingly prevalent in the western world and remain a 
cause of significant morbidity.  As described previously, Ali et al. first delineated a 
cellular mechanism by which p110δ KI mice had significantly attenuated allergic 
responses [75].  The mast cells of these mice fail to degranulate efficiently in 
response to allergen-IgE stimulation, significantly attenuating the release of a 
range of inflammatory mediators as well as smooth muscle constrictors.  The 
authors subsequently showed that p110δ but not p110γ is required for maximal 
IgE-dependent hypersensitive responses to an allergen in vivo [135].  Following 
these publications, the area of p110δ and allergy has received considerable 
interest from the public domain http://news.bbc.co.uk/1/hi/health/7247600.stm 
and the pharmaceutical/translation research community.  It has been observed 
that p110δ inactivation also reduces macrophage infiltration to the lungs in 
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murine asthma models (and other chronic respiratory inflammatory conditions) 
[63].  Indeed, the ability to reduce inflammatory infiltration of the lung tissue, 
attenuate mast cell degranulation and consequently, to decrease inflammatory 
mediators, together indicates p110δ-selective inhibitors could be utilised as potent 
anti-asthma drugs.  
 
1.6.3.4. Rheumatoid Arthritis 
As with severe asthma, chronic inflammatory disorders such as Rheumatoid 
Arthritis (RA) are characterised by a milieu of inflammatory cells that have 
infiltrated the diseased tissue.  These inflammatory cells continue to drive active 
inflammation in absence of pathogenic stimuli and this chronic inflammation 
causes swelling, pain, functional impairment and eventually results in physical 
damage to the joint structures.  The pathology of RA involves a major auto-immune 
humoral response; primed B cells produce auto-antibodies that drive cytotoxic T 
cell action, which erodes the joint.  As described above, both the differentiation and 
activation of B cells is impaired in p110δ KI mice, as the capacity of T cells to 
activate in response to TcR ligation. Furthermore, Randis et al. found that 
inactivation of p110δ substantially reduced neutrophil infiltration and importantly 
reduced joint erosion in a mouse model of serum-induced arthritis [136].  This 
reduction was found to be comparable to the reduction observed when p110γ was 
inhibited. Importantly, the reduction in joint swelling and destruction was greatly 
enhanced by combined inactivation of both isoforms [136].  Thus, targeting p110δ 
activity alone or in combination with p110γ-selective inhibitors may represent a 
novel method for interfering with both the infiltration of immune cells and 
humeral element of the pathogenesis of RA. 
 
1.6.3.5. Haematological malignancies 
PIK3CA is rarely mutated in haematological malignancies and therefore, p110α-
selective inhibitors are unlikely to address the aberrant proliferation inherent to 
these conditions [137-138].  Similarly, mutations in PIK3CD have not been 
identified in haematological malignancies.  Despite the absence of mutations, PI3K-
Akt signalling has been found to be constitutively active in a large proportion of 
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haematological malignancies [138-140].  Importantly, this constitutive activation 
of Akt correlates with poor survival of patients with acute myeloid leukaemia 
(AML) [140].   
The expression of p110δ is consistently high in AML blasts, whilst the expression 
of the other Class I PI3K isoforms varies widely between patients [64].  Consistent 
with this, in the majority of leukaemia subtypes, p110δ appears to be the key, if not 
sole isoform upstream of constitutively active Akt.  The dominance of p110δ 
upstream of constitutively active Akt is demonstrated by the fact that both 
constitutive and FLT-3-stimulated p-Akt in primary AML blast cells was equally 
repressed by treatment with a pan-PI3K inhibitor or a p110δ-selective inhibitor 
[64].  Crucially, the observed suppression of p-Akt levels correlated with an almost 
complete blockade of proliferation, whilst the treatment of normal haematological 
progenitors did not affect their proliferation [64].   
Pharmaceutical companies have been quick to pursue the potential of p110δ 
inhibition in the treatment of leukaemia.  The capacity to repress aberrant growth 
of haematological malignancies by targeting an enzyme that is not expressed in the 
majority of tissues is particularly desirable because this should translate to lower 
toxicity in vivo.  Gilead, who bought out Calistoga, are currently undertaking 
clinical trials to test the efficacy of a novel p110δ-selective inhibitor, CAL-101, in 
the treatment refractory leukaemia.  Preclinical in vitro work revealed that CAL-
101 efficiently blocked proliferation of primary chronic lymphocytic leukaemia 
(CLL) cells and also induced apoptosis in these cells [141].  In addition, Lannutti et 
al. found that treating T-acute lymphoblastic leukaemia (ALL) and B-ALL cells with 
CAL-101 in vitro resulted in decreased proliferation and a reduction in 
phosphorylation of Akt and its downstream targets [142].   
The initial results from the CAL-101 trial have been extremely promising; 
especially with regards to the CLL patient group [143-144].  The therapeutic 
benefit of CAL-101 was expected to be due to suppression of survival and growth 
signalling in the leukaemic cells.  Interestingly, the clinical activity of CAL-101 is 
not in keeping with the predicted mode of action.  Specifically, patients display 
rapid lymph node shrinkage and concomitant but transient lymphocytosis, 
alongside a notable reduction of circulating CCL-3, CCL-4 and CXCL13 [143].  In 
vitro investigation of these observations revealed a reduced migratory and 
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chemotactic capacity of CLL cells in the presence of CAL-101 and confirmed that 
the secretion of chemokines was reduced [143].  Thus, it appears that CAL-101 has 
a dual mechanism of action against CLL.  First, as expected, CAL-101 suppresses 
survival signals in the CLL cells.  Secondly, it interferes with the stromal cell 
interaction that facilitates leukaemic cell accumulation in the lymph nodes and 
suppresses the secretion of inflammatory mediators.  In line with this additional 
anti-inflammatory effect, the clinical trial coordinators have reported that the best 
responders to CAL-101 treatment are those patients whose disease has the most 
inflammatory characteristics [144].  Whether or not CAL-101 and other similar 
agents will need to be combined with cytotoxic drugs to achieve long-term 
remission is yet to be clarified, but certainly, the capacity to induce rapid 
lymphocytosis could represent an opportunity to enhance the efficacy of 
traditional therapies. 
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1.7. PROJECT AIMS AND OBJECTIVES 
The fundamental objective of this project was to better understand the role that 
p110δ plays in macrophage biology.  Initially, we focused on comparing the role of 
p110δ to that of the other PI3K Class IA isoforms in macrophage signalling.  
Following this, we have focused on addressing the unanswered question, to what 
degree does p110δ activity contribute to the regulation of macrophage 
transcription?  At the time we started, this study there were no publications 
describing the effects of inactivating p110δ on the transcriptome of macrophages, 
or any other cell.  We therefore set out to determine the effects of p110δ 
inactivation on the macrophage transcriptome, and whilst doing so hoped to 
identify potential biomarkers of p110δ inactivation.  The initiation of several 
clinical trials testing p110δ-selective inhibitors has made this task all the more 
relevant.  Additionally, we wanted to observe whether genetic and 
pharmacological inactivation of p110δ have similar effects on gene expression. 
 
1. To compare the roles of the Class IA isoforms in macrophage signalling 
2. To investigate the effects of inactivation of p110δ on the macrophage 
transcriptome 
3. To compare the effects of genetic and pharmacological inactivation of p110δ on 
the transcriptome of macrophages 
4. To identify potential biomarkers of p110δ inactivation 
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CHAPTER 2 
2. MATERIALS AND METHODS 
2.1. Mice 
Maintenance of mouse colonies: Mouse colonies were maintained in accordance 
with Home Office Guidelines with the help of a qualified Animal Technician.  
p110δD910A/D910A mice are viable fertile and have no gross anatomical or behavioral 
defects and have been described previously in Okkenhaug et al. [84].  The 
p110δD910A/D910A mice (p110δ KI) are usually bred using heterozygous crosses as 
the female homozygous mice frequently suffer from anal prolapses as a result of 
severe colitis [86, 123]. The mice used in the Affymetrix experiment and in the 
subsequent TaqMan® validation were obtained from a separate colony from 
Cambridge, which was maintained as a homozygous line.  WT controls were 
obtained from a WT colony bred in house, which itself was original derived from a 
commercial breeder.  
2.1.1. Genotyping of mice  
2.1.1.1. Sample digestion 
An ear clipping or tail snip were digested by incubation in 100 μl NaOH at 100˚C 
for 10 min, followed by 10 min incubation at Room Temperature (RT).  The 
reaction was stopped by the addition of 16.6 μl of Tris-HCl pH 8.8 and the samples 
were vortexed and stored at -20˚C. 
2.1.1.2. UPolymerase chain reaction (PCR) 
PCR master mix as detailed in Table 2.1 was prepared for n+2 samples and was 
aliquoted into autoclaved PCR tubes containing 5 μl of digested DNA.  
Amplification of target templates was achieved using the cycling conditions 
detailed below. 
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Table 2.1. PCR master mix reagents and cycling conditions. a. Constituents of PCR master mix. 
b. PCR cycling conditions. 
2.1.1.3. Primers 
Forward primer used at a final concentration of 0.2 M: D148 
(AGGGAACCGCCGTATGAC)  
Reverse primer used at a final concentration of 0.2 M: D146 
(AATGCTTTCGTCCCACGTCC) 
 
Expected fragment size 
Genotype Abbreviation Base pairs (bp) 
Wild type WT 426 
Heterozygous Het 426 and 554 
p110δD910A/D910A  p110δ KI 554 
       Table 2.2. Expected fragment sizes from genotyping PCR. 
 
 
 
 
 
 
PCR Master Mix 1n (μl) 
DNA 2 
10X PRIMER MIX 5 
10X PCR BUFFER 5 
dNTP 5 
PCR H2O 32.75 
50XTaq 
polymerase 
0.25 
Step Amplification conditions       Time 
1 94°C  3 min 
2 94°C  30 sec 
3 65°C 30 sec 
4 72°C 30 sec 
5 Return to 2  
and repeat x 39 
6 72°C 7 min 
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2.2. Reagents, solutions and buffers 
Reagents 
Buffers and reagents 
Tris 
buffered 
saline (TBS) 
20 mM Tris HCl pH 7.5, 137 mM NaCl in ddH2O 
TBS-Tween 
(TBS-T) 
0.1% (v/v) TWEEN 20 in TBS 
Tris EDTA 
(TE) buffer 
10 mM Tris HCl pH 7.5, 1 mM ethylenediamine tetra-acetic acid (EDTA) 
Cell lysis 
buffer  
(to obtain 
protein) 
50 mM Tris-HCl pH 7.4, 100 mM NaCl, 50 mM NaF, 5 mM EDTA,  
2 mM ethylene glycol tetra acetic acid (EGTA), 40 mM β-glycerophosphate, 10 
mM sodium pyrophosphate, 1% (v/v) Triton X-100  
Running 
buffer 
0.25 M Tris-HCl, 0.192 M glycine, 0.1% (w/v) SDS, pH 8.3 
Transfer 
buffer 
48 mM Tris-HCl pH 8.5, 0.39 M glycine, 0.1% (w/v) SDS, 20% (v/v) ethanol 
Stripping 
buffer 
5% (w/v) Trichloracetic acid (TCA) dissolved in ddH20 
Enhanced chemiluminescence (ECL) solution 
Mix equal volumes of solution A and solution B 
Solution A 20 mM Tris-HCl pH 8.5, 0.02% (v/v)H202 
Solution B 20 mM Tris-HCl pH 8.6, 13.2 mg coumaric acid, 0.868 mg luminal 
Table 2.3. Reagents and buffers. 
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2.2.1. Inhibitors 
Powdered inhibitors were solubilised in Dimethyl sulfoxide (DMSO) to a standard 
concentration of 10 mM.  The diluted inhibitors were stored at -20°C in small 
aliquots (5-10 µl/tube) aliquots to avoid repeat freeze-thaw cycles of inhibitors.   
For use the inhibitors were diluted by 1 in 100 in medium to generate a 
concentration of 10 µM and were subsequently diluted further in medium to a final 
concentration as required for experiments.  As a negative control the equivalent 
volume of DMSO was diluted 1 in 100 and subsequently diluted further as per the 
inhibitor used. 
Inhibitor Target Source Cat. No. Solvent 
PW12 
(“Paul Workman-12”) 
p110α Prof. K Shokat 
(PIramed 
compound) 
N/A DMSO 
TGX155 p110β Collaborator N/A DMSO 
IC87114 p110δ Calbiochem 528118 DMSO 
LY294002 pan-
PI3K 
Calbiochem 440202 DMSO 
Wortmannin pan-
PI3K 
Calbiochem 681676 DMSO 
  Table 2.4.  Small molecule inhibitors. 
 
 IC50s (µM) of PI3K inhibitors on Class I PI3K p110 isoforms 
Inhibitor  p110α p110β p110δ p110γ 
PW12 0.015 0.83 0.73 0.97 
TGX155 >20 0.03 0.34 >20 
IC87114 > 200 16 0.13 61 
LY294002 9.3 2.9 6.0 >20 
Wortmannin 0.57 2.33 0.40 0.089 
Table 2.5 IC50s of PI3K inhibitors on Class I PI3K p110 isoforms. 
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IC87114 IC50 (µM) 
Class IA PI3K isoform IC50 (µM) 
p110α  >200 
p110β 16 
p110δ 0.13 
p110 61 
Table 2.6. IC50 for p110δ-selective inhibitor IC87114.   IC87114 was the first isoform-selective 
small molecule inhibitor to be used in published research [62]. 
2.2.2. Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.7. Antibodies. 
Antigen Manufacturer Cat. Number 
Primary antibodies for immunoblotting 
p110δ Santa Cruz sc-7176 
Phospho-Akt (S473) Cell Signalling Technology 4060 
Phospho-p-38 
(T180/Y182) 
Cell Signalling Technology 9215 
Akt Cell Signalling Technology 9272 
Rab6b (KT79) Abcam ab95374 
Rab6a Abcam ab55660 
GAPDH Abcam ab8245 
Vinculin Sigma V9131 
β-actin Sigma A5441 
Primary antibodies for Fluorescence Activated Cell Sorting 
F4/80-PE eBiosciences 12480182 
IA/IE-PE BD Biosciences 557000 
PE-IgG2a, κ, isotype 
control 
BD Biosciences 553930 
FITC-IgG2a, κ, isotype 
control 
BD Biosciences 11432181 
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Primary antibodies were diluted in 3% (w/v) Bovine Serum Albumin (BSA)-TBS-T 
to the appropriate dilution (usually 1 in 1000).  Aliquots were stored at -20°C and 
were re-used up to four times, depending on their potency. 
2.3 Cell culture 
2.3.1 Macrophage cell lines 
Cell 
Line 
Medium Growth Supplements Starvation conditions Source of cells 
BAC1.
2F5 
[145] 
DMEM 10% serum* (v/v) 2 mM L-
glutamine,  
0.15 mM L-asparagine,  
50 nM 2-mercaptoethanol, 
antibiotics & 
10 ng/ml Colony Stimulating 
Factor-1 (CSF-1) 
Remove CSF-1 for 12-48 
h  
Frozen vials 
(passage 5) 
Division of Cell 
and Molecular 
Biophysics 
Kings College 
London 
 
J774.
2 
[146] 
RPMI 10% (v/v) serum, 1 mM 
sodium pyruvate,  
1X non-essential amino acids,  
50 nM 2-mercaptoethanol & 
antibiotics. 
Reduce serum from 10% 
to 5% (v/v) in complete 
medium for 12-24 h  
Frozen vials 
(passage 5) 
Division of Cell 
and Molecular 
Biophysics 
Kings College 
London 
 
IC-21 
[147] 
RPMI As per J774.2 Reduce serum from 10% 
to 5% (v/v) in complete 
medium for 12-24 h 
Frozen vials 
(passage 5) 
Division of Cell 
and Molecular 
Biophysics 
Kings College 
London 
 
RAW 
264.7 
[148] 
DMEM As per J774.2 Reduce serum from 10% 
(v/v) to 0.1-5% (v/v) in 
complete medium for 12-
24 h 
Frozen vials 
(passage 5) 
Division of Cell 
and Molecular 
Biophysics 
Kings College 
London 
Table 2.8. Macrophage cell lines, culture medium and starvation conditions. Serum refers to 
heat-inactivated foetal bovine serum (FBS) which was been tested in vitro to ensure macrophages 
generated in its presence were endotoxin-responsive. 
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2.3.1.1 Maintenance of cell lines 
Cells were maintained in a humified incubator containing 5% CO2 at 37°C in the 
medium detailed in Table 2.8.  The cells were passaged in accordance with 
standard sterile conditions every two to three days. 
 
2.3.1.2 Passage procedure 
Cells were washed with pre-warmed calcium- and magnesium-free Phosphate 
Buffered Solution (PBS) and were subsequently detached by incubation in 5 ml of 
Versene per 75 cm2 flask at 37°C for 5-10 min.  Versene contains EDTA which 
disrupts cellular adhesions by sequestering calcium ions.  The detached cells were 
then resuspended and diluted in the appropriate pre-warmed medium and seeded 
into fresh tissue culture-treated flasks. 
 
2.3.2 Isolation and differentiation of primary macrophages 
Macrophages can be derived from mice in two main ways. First, differentiated 
tissue macrophages can be purified from the spleen or after thyoglycolate 
stimulation, from the peritoneum. Alternatively, precursor cells can be extracted 
from the marrow in mouse leg bones and differentiated ex vivo in the presence of 
recombinant Colony Stimulating Factor-1 (CSF-1) or CSF-1-containing L cell 
conditioned medium (LCCM).  We chose to extract bone marrow precursor cells 
and differentiate them ex vivo because this generates much higher yields of 
macrophages per mouse.  
 
2.3.2.1 Macrophage growth medium 
RPMI 1640, 10% (v/v) heat-inactivated low endotoxin FBS, 1 mM sodium 
pyruvate, 1x non-essential amino acids, 0.029 mM 2-mercaptoethanol. The above 
was supplemented with either 20 ng/ml recombinant CSF-1 or 10% (v/v) LCCM. 
 
 
 
 66 
2.3.2.2 Isolation of precursor cells 
Bone marrow precursor cells were extracted from femur and fibula bones from the 
hind legs of mice following cervical dislocation and dissection.  The detached legs 
were dipped in ethanol and cleared of soft tissue before cutting the bones at both 
ends.  Subsequently, the marrow was flushed out of the bones with pre-warmed 
medium using a 25G needle attached to a syringe.  The exudates were 
homogenized and spun at 5000 x g for 5 min at RT.  After resuspension the cells 
were counted and seeded at a concentration of 1x106 cells per ml in macrophage 
growth medium containing either 20 ng/ml of CSF-1 or 10% (v/v) LCCM on 10 cm2 
Petri dishes.  
 
2.3.2.3 Original macrophage differentiation protocol 
This protocol was used to generate macrophages used in experiments detailed in 
Chapter 3.  After three days culture, non-adherent cells were collected and re-
seeded at 3-5x105 cells/ml on 10 cmP2 P etri dishes and were allowed to 
differentiate in complete medium containing 20 ng/ml CSF-1 for a further four 
days before use [Figure 2.1].  Primary macrophages were detached for passage 
using the same method described above for the macrophage cell lines.  The cells 
were re-plated on fresh Petri dishes in complete medium containing 20 ng/ml CSF-
1 and allowed to grow and differentiate for a further four days at which pointed 
they were harvested for use in experiments [Figure 2.1]. 
 
Figure 2.1.  Timeline of primary macrophage extraction and differentiation.  Precursor cells 
were split on day 3 and differentiated macrophages were harvested on day 7.  
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2.3.2.4 Modified macrophage differentiation protocol 
All primary macrophages used in Chapter 5 and 6 (all microarray analysis and 
associated experiments) were generated using a modified protocol.  This was due 
to a problem with the original protocol. 
The precursor cells were plated as described above, except the concentration of 
CSF-1 was increased from 20 ng/ml to 30 ng/ml.  One day after isolation the cells 
were fed 5 ml of fresh complete medium supplemented with 30 ng/ml of CSF-1.  
After a further three days of culture the medium was removed from plates and 
fresh medium supplemented with 20 ng/ml of CSF-1 was added.  The removed 
medium was spun down to collect the non-adherent cell population, which was 
then re-plated in fresh medium supplemented with 20 ng/ml CSF-1 [Figure 2.2].  If 
the original dishes were 80 to 100% confluent on this third day some of the 
adherent cells were removed along with the non-adherent population by gently 
pipetting medium over the mono-layer of cells using a p1000 pipette.  The 
following day (day 4) and on the sixth day after isolation all dishes were fed with 5 
ml of medium supplemented with 20 ng/ml of CSF-1 [Figure 2.2].  Seven days after 
isolation the cells were harvested for use in experiments using the standard 
splitting procedure described above [Figure 2.2]. 
 
Figure 2.2.  Modified primary macrophage differentiation protocol.  Precursor cells were fed 
on day 1 after isolation, split on day 3 and fed again on day 4 and day 6.  Differentiated 
macrophages were harvested on day 7. 
 
2.3.2.5 ULCCM production  
LCCM was obtained by culturing fibrosarcoma L-cells, which secrete CSF-1.  The 
cells were cultured in large flasks and were sealed using parafilm to induce 
hypoxic conditions after they had reached approximately 70% confluency.  The 
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medium was removed after approximately two weeks and was tested to confirm 
its capacity to support the generation of primary macrophages from bone marrow 
precursor cells at 10% (v/v) of complete medium.   
 
2.3.3 Cell stimulation 
2.3.3.1 Stimulation with CSF-1 
After starvation by depletion or reduction of either FBS or CSF-1 (as described in 
Table 2.7) cells were stimulated with 30 ng/ml of CSF-1 for 10 min at 37°C.  
Stimulation was stopped by placing the plates on ice, removing of the medium and 
washing the cells with ice-cold PBS.  The cell lysates were then prepared as 
described below. 
 
2.3.3.2 Stimulation with Lipopolysaccharide (LPS)  
Cells were stimulated with 1 µg/ml LPS for 30 min at 37°C in complete medium 
containing 10% FBS.  Stimulation was stopped by placing the plates on ice, 
removing of the medium and washing the cells with ice-cold PBS.  The cell lysates 
were then prepared as described below. 
 
2.4 Protein analysis and detection 
2.4.1 Western blot analysis  
2.4.1.1 Cell lysis and sample preparation 
Cells were lysed with lysis buffer supplemented with a protease inhibitor cocktail 
(Sigma, P2714) and two phosphatase inhibitor cocktails (Sigma, P2850 & P0044).  
The wells were scraped and their contents transferred into Eppendorf tubes for 
incubation on ice for 30 min with intermittent vortexing.  Cellular debris was 
separated and removed from the samples by centrifugation 8000 x g for 10 min at 
4°C.  Supernatants were transferred to ice-cold Eppendorf tubes and protein 
concentrations were measured using the Bio-Rad protein assay Bradford reagent 
to measure the absorbance at 595 nm.  Finally, sample concentrations were 
equalized by the addition of appropriate volumes of lysis buffer prior to addition of 
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5X sample buffer containing Dithiothreitol (DTT).  The samples were denatured by 
boiled at 95°C for 5 min prior to use or storage at -80°C. 
 
2.4.1.2 Sodium Dodecyl Sulphate-polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.9. SDS-PAGE small gel components. 
 
Gel preparation: Small gels were hand poured using the BioRad system.  Briefly, 
resolving gel mix was prepared as described in Table 2.9, poured into the mould 
and allowed to set.  Subsequently the stacking gel mix was poured onto of the set 
resolving gel with a ten or fifteen tooth comb in place. 
 
 
 
 
 
 Resolving  Stacking  
Ingredient 8% 15%  
1.5 M Tris-HCl pH 8.8 3.75 ml 3.75 ml -------- 
1 M Tris-HCl pH 6.8 ---------  0.625 ml 
H20 6.95 ml 4.25 ml 3.4 ml 
30% Acrylamide 
Solution 
4.0 ml 7 ml 0.85 ml 
10% SDS 0.15 ml 0.15 ml 0.05 ml 
10% APS  
(ammonium 
persulfate) 
0.15 ml 0.15 ml 0.05 ml 
TEMED 
(tetramethylethylened
iamine) 
0.01 ml 0.015 ml 0.005 ml 
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2.4.1.3 Loading and separation of protein samples 
The gels were placed in an electrophoretic tank containing running buffer, the 
combs were removed and the denatured samples were loaded alongside a protein 
molecular weight marker.  The proteins were subsequently separated by SDS-
PAGE for 90 min at 100 Volts (V).   Following separation, the proteins were 
transferred to an ethanol-activated polyvinylidene fluoride (PVDF) membrane 
(ImmobilonTM-P, Millipore) by electroblotting at 100 V for 1 h at 4°C. 
 
2.4.1.4 Antibody incubation and protein detection 
Following transfer, PVDF membranes were blocked in 5% Milk powder TBS-
Tween (TBS-T) for 20 min to reduce non-specific binding of antibodies to the 
membrane.  Membranes were subsequently washed and incubated overnight at 
4°C in the appropriate antibody diluted in 3% BSA-TBS-T.  Excess antibody was 
washed off the membrane using TBS-T prior to addition and incubation for 1 h at 
RT with horseradish peroxidase-conjugated secondary antibodies diluted in 5% 
Milk-TBS-T. 
 
2.4.1.5 Visualisation of bands 
 Membranes were washed with TBS-T and subsequently incubated for 2-3 min in a 
home-made ECL solution.  Finally, exposure of medical X-ray film to the 
membranes was performed using a standard film cassette in a dark room facility.  
The exposed films were chemically developed and fixed.  Densities of bands were 
quantified using either ImageJ software or a densitometer (GS-800 Calibrated 
Densitometer, Biorad).  Densitometry provides quantification of the density of 
bands but density of bands does not actually correlate in a linear manner with 
HRP-signal.  Thus, caution should be applied when analyzing results and 
comparisons across multiple experiments is not advisable.  The results can be 
considered as semi-quantitative. 
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2.4.1.6 Stripping membranes 
Membranes were washed thoroughly with ddH20 prior to incubation in 5% (w/v) 
TCA stripping buffer for 20 min at RT.  The membranes were washed and re-
blocked before storage or further probing. 
 
2.4.2 Semi-quantitative analysis of PI3K activation using p-Akt to Akt ratios 
Direct measurement of changes in the PI species that are generated by active PI3K 
enzymes requires the use of either radioactivity activity assays or imaging using 
PIP3 specific fluorescent probes, both of which are technically challenging and time 
consuming.  In in vitro research the level of p-Akt or the ratio of p-Akt over Akt, as 
detected by antibodies and quantified using a densitometer is commonly used as a 
proxy read-out for PI3K activity [149].  
 
2.5 Fluorescence activation cell sorting (FACS) 
2.5.1 Preparation and staining of cells 
 Cells were scraped into 200 μl ice cold 1% BSA-PBS and collected in chilled 15ml 
tubes with 1 ml of 1% (w/v) BSA-PBS prior to spinning at 5000 x g for 5 min at 
4°C.  Following an additional wash step, the cells were incubated on ice for 30 min 
and subsequently resuspended in 450 μl 1% (w/v) BSA-PBS.  The samples were 
divided into polystyrene round-bottom tubes and incubated with 1 μl of the two 
appropriate antibodies for 1 h at RT in the dark.  The stained cells were washed to 
remove unbound antibody as described above and resuspended prior to analysis. 
 
2.5.2 Analysis of stained cell by FACS 
Analysis of staining and data acquisition was performed using a FACS machine 
(DAKO Cyan ADP FACS).  Viable cells were gated according to their forward scatter 
and side scatter profiles.  Data was analysed using FlowJo software (TreeStar). 
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2.6 Extraction of cellular RNA and quality control 
2.6.1 Cell lysis 
Cells were washed with ice-cold PBS and lysed in RLT Plus buffer (Qiagen, 74104)   
containing 10 μl of Beta-Mercaptoethanol (β-MCE)/1 ml.  The inclusion of β-MCE 
in the RLT Plus buffer improved the consistency with which RNA of high quality 
was obtained.  Plates were snap-frozen and stored at -80°C.  
 
2.6.2 RNA extraction 
Thawed lysates were homogenized using QIAshredder columns in accordance with 
the manufacturer’s instructions (Qiagen, 79656).  Total cellular RNA was 
subsequently isolated using the RNeasy Plus Mini Kit (Qiagen, 74104) in 
accordance with the manufacturer’s instructions.  Purified RNA was eluted in the 
maximum recommended volume of 50 μl RNase-free H20.  
N.B. The RNeasy Plus Mini Kit was used as it includes columns that eliminate 
genomic DNA from RNA samples, which the RNeasy Mini Kits do not include. 
 
2.6.3 RNA quantification and purity assessment 
Total RNA was analysed using a NanoDrop® ND-100 Spectrophotometer to 
determine concentration and to assess purity.  The NanoDrop calculates 
concentration by measuring the absorbance of a sample at 260 nm; absorbance 
correlates with concentration in a linear manner (Beer-Lambert law).  RNA 
absorbs strongly at 260 nm, whereas contaminants such as phenol and ethanol 
absorb around 280 nm. The ratio of absorbance at 260 nm over 280 nm can 
therefore be used to determine purity; a ratio of 2.0 or above is indicative of a pure 
RNA sample.  Other contaminates such as proteins and EDTA strongly absorb at 
230 nm and therefore the A260/230 nm ratio can also be used to monitor RNA 
sample purity. 
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2.7 Quantitative real-time PCR (qPCR) 
Real-time qPCR is a two-step method used to quantify the expression of a gene of 
interest by measuring PCR amplification of a target sequence within a sample. 
First, the RNA is reverse transcribed to generate cDNA and the cDNA sequence of 
interest is subsequently amplified by PCR using sequence-specific primers.  This 
sequence-specific amplification is measured in real time (after each cycle) 
throughout the PCR.   Measurement of amplification is performed using one of two 
main methods. 
 
1. The SYBR Green method utilises a fluorescent dye that intercalates in a non-
specific manner into newly synthesized DNA.  The fluorescence emitted is 
positively correlated with the amount of amplified DNA and therefore, with 
the concentration of the target sequence in the sample. 
 
2. The TaqMan method utilises gene-specific probes covalently linked to a 
fluorescent reporter dye at the 5’-end and a fluorescence quencher at the 3’-
end measure target-specific amplification.  These probes anneal within the 
region amplified by the gene-specific primers.  During amplification the 
probe is cleaved by the 5’-nuclease activity of the advancing polymerase 
resulting in the separation of the reporter from the quencher resulting in 
emission of fluorescence.  The fluorescence detected in this method is 
directly correlated with the concentration of the target DNA sequence 
[Figure 2.3]. 
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Figure 2.3. TaqMan® gene-specific probes.  The advancing polymerase displaces the reporter 
from the 5’-end of the bound probe resulting in its separation from the quencher and concomitant 
emission of fluorescent signal. Image reproduced with permission from Applied Biosystems. 
[www.appliedbiosystems.com]. 
 
2.7.1 Reverse transcription 
Reverse transcription was performed using the TaqMan® Reverse Transcription 
Reagents Kit (Applied Biosystems, N8080234) in accordance with the 
manufacturer’s instructions.  Briefly, 1-5 µg of RNA was reverse transcribed using 
Multiscribe Reverse Transcriptase at 2.5 U/µl, in the presence of random-hexamer 
primers at 2.5 µM, mixed dNTPs at 0.5 mM, MgCl2 at 5.5 mM plus 5 µl 10X PCR 
buffer and sufficient H20 to make the mix up to 50 µl per reaction.  The reaction 
was then performed in a thermal cycler [Table 2.9].  The cDNA generated was 
either processed or stored at -80C. 
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Reverse transcription thermal settings 
Temperature Time  
25C 10 min  
37C 60 min  
95C 5 min  
4C -------- 
Table 2.10. RT-PCR thermal cycling conditions. 
 
2.7.2.  qPCR 
We utilised the TaqMan method to measure the relative expression of genes of 
interest in control samples compared to samples derived from treated or mutant 
cells.  Inventoried TaqMan Gene Expression Assays (part number, 433182) 
containing gene-specific primers and probe sets that had been pre-designed and 
validated by Applied Biosystems were used in accordance with manufacturer’s 
instructions qPCR method.  In addition to assays for the genes of interest, assays 
for endogenous controls such as beta-actin or 18S were included in every 
experiment to allow for normalisation across samples.  Briefly, a master mix was 
made for each assay as described in Table 2.10, and aliquoted into appropriate 
wells of a 384-well plate before  the addition of 2 µl of cDNA produced by Reverse 
Transcription.    
 
qPCR master mix                                        1n 
Universal Master Mix (4364338)  5 μl 
ddH20    
  
 2.5 μl 
Taqman primers/probe 20X  0.5 μl 
Table 2.11. qPCR master mix. 
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Each reaction was performed in triplicate.  In order to account for contamination 
and non-specific amplification a negative control of additional replicates 
containing no added cDNA (RT negative) were included for each assay.  40 cycles 
of amplification was performed using an Applied Biosystems Prism 7900HT 
Sequence Detection System using the cycling conditions detailed in Table 2.11. 
 
Step Time Temp. Ramp rate Notes 
PCR activation  15 min 95°C 20°C/s Activates hot start polymerase 
2-step cycling     
Denaturation 0 s 95°C 20°C/s  
Annealing & extension 60 s  20°C/s Fluorescence data collection 
Number of cycles 33-55   Dependent on amount of template 
DNA 
Table 2.12. qPCR cycling conditions. 
 
Amplicon TaqMan Assay ID 
Housekeeping genes 
18S rRNA Hs99999901_m1 
GAPDH Mm99999915_g1 
β-actin Mm00607939_s1 
TBP Mm00446971_m1 
Targets  
Clstn1 Mm00502631_m1  
Efcab1 Mm00523825_m1  
Efhd2 Mm00482568_m1  
Fblim1 Mm00505298_m1  
Fst Mm00514982_m1  
Htatsf1 Mm00459252_m1  
Kif1b Mm00801813_m1  
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Mthfr Mm00487784_m1  
Nin Mm01265284_m1  
Pdpn Mm00494716_m1  
Plod1 Mm01255760_m1  
Rab6b Mm00620651_m1  
Rex Mm03029904_g1  
Ube4b Mm00502528_m1  
Ubiad1 Mm00503616_m1  
Table 2.13. TaqMan Inventoried gene expression assays 
 
2.7.3 Data extraction and analysis 
Obtaining raw data:  Before obtaining values from amplification plot two 
parameters must be set; the base line and the threshold.  Both are set 
automatically by the Sequence Detection Software (SDS) Relative Quantification 
(RQ) Manager, but should be checked manually to ensure correct positioning.   
 
Baseline: Background fluorescent signal accounts for the majority of the signal 
detected during early thermal cycles prior to substantial amplification.    The 
baseline threshold must be set across a range exceeding this level of background 
fluorescence; the SDS RQ Manager software automatically sets the baseline from 
cycles 3-15.  If the baseline is set appropriately the initial amplification will occur 
one or more cycles after the end of this base line (i.e. after 16 cycles if the 
automatic baseline is left in place).  If the target is particularly abundant, as is 
usually the case for housekeeping genes such as 18S rRNA, the initial amplification 
will occur earlier than cycle 15.  The baseline must then be manually adjusted to 1-
2 cycles prior to the initiation of amplification. 
 
Cycle threshold (Ct) value: The final value obtained for each replicate is the cycle 
threshold (Ct) value.  The Ct is the cycle of the PCR reaction at which the detected 
fluorescence crosses the threshold [Figure 2.4].  Transcripts of low abundance 
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have larger the Ct values as the number of cycles taken to reach the fluorescence 
threshold is greater.   
 
Threshold: In order to obtain an accurate Ct value the appropriate threshold must 
be set.  The threshold must be above the initial linear region and below the plateau 
region, i.e. within exponential linear region.   The threshold is automatically set at 
10 standard deviations above the baseline and this should be within the region of 
exponential amplification in all plots [Figure 2.4].   The position of the threshold is 
best assessed in the log view of an amplification plot in which the region of 
exponential amplification appears linear.  Identifying where the replicates are the 
least variable within this linear region assists in the identification of the optimal 
position for the threshold.  To assess the precision of the replicates the x-axis of the 
amplification plot can be widened. 
 
Figure 2.4.  qPCR amplification plot features. Baseline automatically set from 3-15 cycles and the 
threshold is automatically set 10 standard deviations above the end of the baseline. CT value is read 
off the graph from the intercept of the amplification line through the threshold.  
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2.7.3.1  Relative quantification of gene expression 
The Comparative Ct method allows the user to determine relative expression of a 
gene of interest in two or more conditions and subsequently to calculate folds 
change from these values.  This method abrogates the need to generate a standard 
curve of transcript copy number, but as a result cannot be used for absolute 
quantification.  This method relies upon the fact that the amplification efficiencies 
of the target amplification and the endogenous control amplification are 
equivalent.  100% amplification efficiency denotes a doubling of PCR 
product/amplicon at every PCR cycle, i.e. exponential amplification.  All TaqMan 
Gene Expression assays have been validated by the manufacturer and are reported 
to have an average efficiency of 100% (-/+ 10%). 
Having obtained a Ct value for each well the delta Ct (ΔCt) equation can be used 
to calculate fold change relative to the control sample, known as the calibrator.  In 
this project WT unstimulated was set as the calibrator sample.  First, the Ct value is 
normalized to the housekeeping control to account for any sample to sample 
variation to generate the ΔCt value.  The ΔCt value can then be normalized to the 
ΔCt of the calibrator sample, producing the ΔΔCt value which is negative.  Finally, 
the ΔΔCt value can be converted into a fold change using the formula (treatment 
over calibrator) 2-ΔΔCt.    
 
Calculations for comparative Ct method 
1. Ct target gene - Ct endogenous control = ΔCt 
2. ΔCt sample - ΔCt calibrator = ΔΔCt 
3. Apply the formula: 2-ΔΔCt = fold change relative to calibrator sample 
 
2.7.4 Semi-high throughput qPCR 
2.7.4.1 TaqMan Array Microfluidic cards 
Applied Biosystems offer TaqMan assays in a semi-high throughput format 
containing multiple TaqMan assays.  These TaqMan Array Microfluidic cards are a 
form of low density arrays (LDAs) contained within microfluidic 384 well-cards.  
The arrays are available either as custom cards in which the included assays are 
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selected by the customer or alternatively as pre-designed gene-signature cards.  
The array cards allow for standardized relative quantification of the expression of 
a selection of genes across multiple unique samples in a semi-high throughput 
format.   
 
2.7.4.2  LDA formats 
TaqMan Array Microfluidic cards are available in ten different formats which allow 
the user to determine relative expression of between eleven and 380 genes 
depending on the number of samples analysed per card, the number of replicates 
per reaction and the number of endogenous control assays included.  We choose to 
use format 32 (part number, 4346799) which can include up to 31 unique assays 
alongside at least one mandatory endogenous control assay with three replicates 
per assay.  This format allows the relative quantification of all thirty unique assays 
and one control to determined in four unique samples per array card.  We included 
four endogenous controls.    
 
2.7.4.3  LDA method 
The custom-made array cards were used in accordance with the manufacturer’s 
instructions.  Briefly, total RNA was reverse transcribed as described above except 
that a High Capacity RT Kit (Applied Biosystems, 4368813) was used instead of the 
standard RT kit.   
The cDNA was then mixed with TaqMan PCR Master Mix and RNase-free water as 
described in Table 2.13; twice the volume of this master mix was made for each 
sample as each sample was loaded into two reservoirs.  The volume of master mix 
made was increased to ensure there was enough to load 100 µl/reservoir.  The 
manufacturer recommends that between 30 and 1000 ng of total RNA should be 
included per sample/reservoir, we used 250 ng/reservoir. 
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Component Vol (µl)/reservoir Vol (µl)/sample 
cDNA sample + Rnase free H20 50 120 
TaqMan universal PCR Master Mix 50 120 
Total 100 140 
Table 2.14. Components of qPCR mix for analysis in TaqMan Array Cards. 
 
100 µl of each sample mix was pipetted into two of the eight loading reservoirs at 
the top of the cards.  The cards were spun and sealed using the array card sealer.  
The arrays were then run on an Applied Biosystems Prism 7900HT Sequence 
Detection System with a TaqMan Array Card file pre-loaded. 
 
Manufacturer’s video demonstrating loading and processing of TaqMan arrays: 
http://www2.appliedbiosystems.com/lib/multimedia/taqman_tlda/tlda_1.cfm 
 
2.7.4.4  LDA data analysis 
Analysis of TaqMan array card data is identical to analysis of individual TaqMan 
assays. The data for all cards from one experiment must be loaded into the SDS RQ 
Manager software together to allow baselines and thresholds to be set consistently 
across all cards for each assay. 
Manufacturer’s video demonstrating analysis of TaqMan array data:  
http://media.invitrogen.com.edgesuite.net/ab/videos/TMArrayCard_iw_360.swf 
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2.8 Genome-wide expression analysis 
Genome-wide expression analysis allows the user to rapidly identify the effects of a 
certain permutation such as an inhibitor or mutation, on global transcriptional 
regulation.  The expression of every gene can be determined and compared in a 
control and treatment sample.  There are now a number of microarray platforms 
available which enable rapid analysis of the entire transcriptome in multiple 
samples.   
In the case of two-colour arrays, the control and treatment samples are processed 
so that the final samples are labeled with two different fluorophores.  The 
differently labeled samples are then mixed and hybridized to a single microarray.  
This method can be used to identify genes that are either up- or down-regulated in 
the treatment sample compared to the control sample can be determined.   
Alternatively, one-colour arrays are available that allow the user to obtain an 
expression value for each gene/transcript in the microarray in multiple 
independent samples, which are each hybridized to a separate array.  This allows 
for the comparison of expression of a gene of interest across many samples and 
even across multiple experiments if batch effects are taken into account.  A 
comparison of the expression of different genes within a sample cannot be made 
because factors such as hybridization efficiency of probes-target sequences effect 
the final expression value.  Both of these approaches have allowed scientists to 
identify lists of individual genes affected by particular treatments, mutations or 
disease states and have also provided a more global perspective on the effects. 
 
2.8.1. RNA integrity 
RNA is highly susceptible to degradation because ribonucleases (Rnases) are 
ubiquitous in the environment and can easily contaminate a sample.  Significant 
degradation of RNA can affect whole-genome expression analysis.  Therefore, in 
addition to the assessment of purity of samples RNA integrity must also be checked 
to confirm quality.  
The abundance of two ribosomal RNA (rRNA) species, 18S and 28S, is used as a 
marker to assess the integrity of RNA.  The abundance of these rRNA species in a 
sample can be measured by running RNA samples labeled with an intercalating 
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fluorescent dye on an electrophoretic gel.   28S and 18S rRNA exist in equal 
concentrations in cells, but twice as much fluorescent dye intercalates into 28S 
rRNA than into 18S resulting in a 28S band with double the fluorescent intensity of 
the 18S band.  Furthermore, 28S rRNA is degraded before the 18S rRNA in samples 
exposed to ribonucleases and thus, a ratio significantly less than two indicates 
degradation of RNA species has occurred within the sample.  Significant shifts in 
the ratio of 28S to 18S are normally observed alongside smearing on the gel due to 
the presence of fragmented RNA.  
 
2.8.1.1 Agilent Bioanalyser 
RNA quality can now be determined with improved accuracy using technology 
developed by Agilent.  The Agilent Bioanalyzer applies the standard 
electrophoretic technique in a chip format with software that utilises an algorithm 
to assess RNA integrity.  The algorithm takes into account the 18S to 28S rRNA 
ratio alongside additional factors that are also predictive of RNA quality [150].  The 
software generates an electropherogram on which the two distinct peaks, which 
correspond to the 18S and 28S rRNA can be seen alongside the 25 nucleotide 
marker [Figure 2.5]. 
 
Figure 2.5. Agilent Electropherogram. Agilent Bioanalyzer produces an electropherogram on 
which the fluorescence signal from labelled 28S and 18S rRNA species is plotted alongside a 25 
nucleotide marker. The x-axis (25-4000) represents nucleotides (nt).  18S rRNA at around 1400 nt 
and 28S rRNA at around 4000nt.  Based on the area under the peaks for the 18S and 28S rRNA a 
ratio of 2.0 is calculated, and no smaller fragments are apparent indicating no degradation products 
were present in this sample. To the right the gel image of the sample; the upper band is the 28S 
rRNA, the lower is the 18S rRNA and the green band represents the marker which can also be seen 
as a small peak.  
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An RNA Integrity Number (RIN) is assigned to each sample; the RIN scale ranges 
from ten to one and in some cases highly degraded samples are not assigned a RIN.  
A RIN of ten indicates an optimal intact sample to a RIN, whereas a RIN below eight 
is indicative of moderate degradation and RIN below 7 is indicative of highly 
degraded RNA [Figure 2.6] [150].     
 
Figure 2.6. RNA integrity number. Aligent Bioanalyzer assigns a RIN to each sample analysed 
based on a number of parameters including the 18S to 28S ratio and the presence of small RNA 
fragments that represent degradation products. 
 
Ideally samples to be analysed by microarray should have a RIN of 8 or more and 
the RIN across a sample set should also be relatively consistent within an 
experiment.   
 
2.8.1.1.1 Agilent method 
 RNA samples were analysed to determine integrity using an Agilent Bioanalyser in 
accordance with the manufacturer’s instructions. Briefly, 1 µl of each sample was 
loaded into the wells of the RNA 6000 Nanochip pre-loaded with a sieving polymer 
and fluorescent dye.  A 25 nucleotide marker and a ladder of RNA fragments were 
also loaded.  The chip was vortexed using an IKA vortex mixer (Model MS2-S8/S9) 
at 2400 rpm and then analysed using the Agilent Bioanalyzer.  All samples used in 
our microarray studies were assigned a RIN of between 9.8 and 10, with 18S to 28S 
ratios of between 1.8 and 2.0. 
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2.8.2. Affymetrix genome-wide expression analysis 
Affymetrix is a world-leader in the field of whole-genome expression analysis as 
the most frequently used microarray platform in published work.  Affymetrix 
microarrays are in the form of GeneChips® that encompass one-colour 
oligonucleotide arrays.  In oligonucleotide arrays the probes (complementary 
sequences that hydridise to labeled target sequences) are synthesized in clusters in 
situ on a glass surface using the photolithographical method.  
 
Figure 2.7.  Schematic of the hybridisation of a labeled target sequence from the sample to a 
probe.  Labeled RNA samples are added to chip and allowed to hybridise with complementary fixed 
probes.  [Image reproduced with permission from Affymetrix Image Library]. 
 
Highly complementary labeled target sequences will form multiple non-covalent 
bonds with the corresponding probe and will thus remain hybridized after washes 
remove those partially complementary sequences. 
 
2.8.2.1. The Affymetrix Mouse Genome GeneChip®  430 2.0 Array 
The Affymetrix Mouse Genome GeneChip® 430 2.0 Array that we used in this study 
provides complete coverage of the mouse genome with over 39,000 transcripts 
interrogated by over 45,002 probe sets.  The clusters of probes synthesised on a 
GeneChip® are made up of probe sets, which each consist of eleven probes that 
together are designed to interrogate a particular sequence.  Each probe is twenty-
five base pairs long and is complementary to a different segment of the 3’ region of 
a given sequence.  Each probe set includes a number of mismatch probes that 
enable a value for non-specific binding to the transcript of interest to be 
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determined.   The expression value for each probe set is the mean value of all the 
probes within that set normalised to the non-specific binding detected.  The probe 
sets allow multiple independent measures to be obtained for a single gene or 
transcript, which increases the accuracy and reproducibility of the final probe set 
expression value.  Furthermore, some genes/transcripts are represented by 
multiple probe sets, which target different sequence regions and the presence of 
these redundant multiple probe sets spotted at different locations increases the 
reliability of the data obtained.  Multiple probe sets can in some cases assist in the 
identification of regulatory events affecting part but not all of the sequence being 
interrogated. 
 
2.8.2.2. GeneChip® 3’ IVT Expression Kit 
2.8.2.2.1. RNA Amplification, Fragmentation and Labelling 
 The total RNA was processed using the GeneChip® 3’ In Vitro Transcription (IVT) 
Expression Kit in accordance with manufacturer’s instructions.  The GeneChip® 3’ 
IVT Expression Kit utilizes poly-A directed primers to produce fragmented 
amplified RNA (aRNA) [Figure 2.8; steps 1-5]. 
Briefly, first-strand and second-strand cDNA were synthesised from total RNA 
[Figure 2.8; steps 1-3].  Subsequently in vitro transcription was performed using 
biotinylated Ribonucleotide Analogs [Figure 2.8: step 4].  The biotinylated aRNA 
generated was purified and quantified using the NanoDrop® ND-100 
Spectrophotometer [Figure 2.8: step 5].  The RNA 6000 Nano Kit with an Agilent 
2100 Bioanalyser were employed to confirm the size of aRNA samples were 
between 250-5500 nucleotides long. 
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Figure 2.8. A summary of the protocol for the GeneChip® 3’ In vitro transcription (IVT) 
expression kit. First and Second Strand cDNA are synthesised from total RNA for each sample, and 
subsequently in vitro transcription is performed using biotinylated ribonucleotide Analogs to 
generate aRNA.  aRNA is purified from the mixture and subsequently measured and fragmented 
prior to hydridisation to a GeneChip® Mouse Genome 430 2.0 Array chips. [Image from the 
Affymetrix GeneChip® 3’IVT Express Kit User Manual, reproduced with permission from the 
Affymetrix GeneChip® 3’ IVT Express Kit User Manual, part 901228 [www.affymetrix.com]. 
 
The biotinylated amplified RNA (aRNA) was then fragmented [Figure 2.8: step 6].  
A hybridization cocktail was then made including the fragmented labeled aRNA 
and a number of hybridization controls as described in Table 2.15.  This was then 
injected into the GeneChip® Mouse Genome 430 2.0 arrays and left to hybridise on 
a rotor in a hybridization oven at 45°C for 16 h [Figure 2.8: step 7]. 
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Component Volume/array  Final dilution 
Fragmented and labeled aRNA 12.5 µg (33.3 µl) 0.05 µg/L 
Control Olignonucleotide B2 4.2 µl 50 pM 
20X Hybridization Controls 
(bioB, bioC, bioD, cre) 
12.5 µl 1.5, 5, 25, 100 pM respectively 
2X Hybridisation Mix 125 µl 1X 
DMSO 25 µl 10% 
Nuclease free water 50 µl ------ 
Total volume 250 µl ------ 
Table 2.15.  Hybridisation cocktail components. 
 
After 16 h incubation with the labeled fragmented aRNA the chips were washed 
and stained according to the IVT kit protocol in a GeneChip® Fluidics Station 450 
(according to the manufacturer’s Fluidics protocol FS450_0001).  Washed chips 
were subsequently scanned in the Affymetrix GeneChip® Scanner 3000. 
 
2.8.2.3. Analysis of Affymetrix data 
Analysis of expression data is described in further detail in Chapter 4.  Briefly, the 
data for all chips was extracted and normalized using the GeneChip-Robust 
Multiarray Averaging (GC-RMA) algorithm.  The data was reduced by filtering to 
include only the top 10,000 most variable probe sets.   
Genome-wide expression analysis produces expansive data sets and thus, 
mathematical models must be employed to drastically reduce the dimensionality 
of the data in order to obtain useful information. 
We employed Principal Component Analysis (PCA) to reduce the data in order to 
obtain information on clustering and to identify outliers.  Subsequently, the data 
was analysed to identify affected genes and pathways or processes that were 
enriched with those genes identified.   
Differentially regulation was determined by calculating the ratio of the average 
expression data of each probe set in the IC87114 samples compared to in the 
DMSO samples.  This ratio was converted into a log fold change using a log to the 
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base 2 conversion.  The statistical significance of fold changes was calculated and 
the p values were subsequently adjusted hypotheses using the Benjamini-
Hochberg (B-H) Correction formula [151].  The B-H correction controls for the 
false discovery rate thus reducing the number of false positives likely to occur 
within a dataset.  This correction is required as a result of the multiple hypotheses 
testing that is intrinsic to microarray data analysis and which inflates Type I 
statistical errors.   
 
2.8.2.3.1. Network and gene ontology enrichment analysis 
 Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems®) was used to test 
for an enrichment of genes associated with a particular gene ontology or network 
within our data sets.  The software automatically excludes duplicate probe sets 
from analysis and also only excludes those probe sets mapped to a particular gene 
or function in analysis.  Top pathways and gene ontologies are identified and the 
statistical significance of the enrichment is provided by the software as a score.  A 
score of 20 indicates the relevance of the network to the gene list has a statistical 
significance of p = 10-20. 
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CHAPTER 3 
 
3. INVESTIGATING THE FUNCTIONS OF CLASS IA PI3K 
ISOFORMS IN MACROPHAGES 
 
3.1.  Introduction 
Previous investigations into the contributions of the individual Class IA PI3K 
isoforms in immortalised BAC1.2F5 macrophages revealed that the isoforms 
perform distinct roles downstream of CSF-1 stimulation.  Specifically, in these cells 
inhibition of p110δ activity blocks CSF-1-induced cytoskeletal rearrangements and 
chemotaxis, whilst blockade of p110α activity has no effect on these processes but 
instead significantly reduces proliferation and p-Akt generation [80].   Based on 
these data it appears that in BAC1.2F5 macrophages, p110δ is required to drive 
CSF-1-induced actin cytoskeleton rearrangements and chemotaxis whilst p110α 
alone regulates proliferation [80].  These findings showed that the Class IA PI3K 
isoforms can fulfil distinct roles downstream of a single stimulus.  Furthermore, 
these data revealed that the uninhibited PI3K isoforms do not compensate for the 
loss of activity of an inhibited isoform in these cells downstream of CSF-1, at least 
not upon acute inhibition in the conditions tested. 
In order to establish whether the observed non-redundancy of Class IA PI3K 
isoform function is a common feature of macrophage-like cells, Dr Papakonstanti a 
former postdoctoral fellow in the laboratory, compared their contributions 
downstream of CSF-1 in primary macrophages.  The data indicated that all 
observed responses to CSF-1 including induction of p-Akt, proliferation and 
chemotaxis are repressed by inhibition of p110δ but not by the inhibition of p110α 
or p110β [p-Akt data are shown in Figure 3.1, data regarding proliferation and 
chemotaxis are not shown].  First, these data confirmed that the functions of the 
isoforms are also non-redundant in primary macrophages as they are in BAC1.2F5 
macrophages.  Secondly, these data revealed a significant disparity between the 
isoform contributions in primary macrophages compared to BAC1.2F5 
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immortalised macrophages.  Specifically, primary macrophages are much more 
dependent on p110δ activity than BAC1.2F5 macrophages.  The observed 
dominance of p110δ in primary macrophages is consistent with its reported 
dominance in primary mast cells and primary lymphocytes [75, 84, 152].   
 
 
Figure 3.1. CSF-1-induced p-Akt in primary macrophages is significantly reduced by 
inhibition of p110δ, and is not significantly affected by inhibition of either p110α or p110β.   
Dr Papakonstanti starved the macrophages of CSF-1 overnight prior to 1 h pre-treatment with the 
indicated inhibitors: PW12 (0.5 µM), TGX155 (0.5 µM), IC87114 (5 µM).  Subsequently the 
macrophages were stimulated by the addition of CSF-1 (33 ng/ml) and the p-Akt to Akt ratios were 
then measured using western blotting [1].  Graph presents data for the mean ± s.e.m. of two 
experiments performed in duplicate (*p <0.05; **p <0.01; ***p <0.001). 
 
It is of interest to note that inhibition of p110δ in primary macrophages does not 
result in the complete repression of CSF-1-induced p-Akt and in fact the reduction 
represents approximately 50% of the uninhibited CSF-1-induced p-Akt level 
[Figure 3.1].  Nevertheless, inhibition of the other isoforms had no significant 
impact on CSF-1-induced p-Akt. 
 
3.2. Investigating a correlation between immortalised state and 
loss of p110 delta dependency in macrophages 
We reasoned that the observed dominance of p110α in the induction of CSF-1-
induced p-Akt in BAC1.2F5 macrophages, whilst p110δ was primarily responsible 
for this in primary macrophages, might be related to the immortalised state of the 
former cells.  We therefore set out to clarify whether the shift to dominance of 
p110α is common to macrophage cell lines and thus is correlated with the 
immortalised state.   To do this we compared the involvement of the Class IA PI3K 
isoforms in the generation of CSF-1-induced p-Akt in additional macrophage cell 
lines.  We acknowledge that it could also have been informative to determine the 
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involvement of p110γ in CSF-1-induced p-Akt.  This was not done primarily as this 
work was performed within the constraints of a body of work that had already 
been performed by Dr Papakonstanti.  In addition, p110γ is thought to only act 
downstream of GPCRs rather than RTKs such as CSF-1 unlike p110α and p110δ 
which are recruited and activated by RTKs and p110β that can couple to GPCRs 
and also to RTKs. 
Before embarking on this task, we confirmed the previous unpublished data that 
identified p110α as the principal isoform responsible for CSF-1-induced p-Akt in 
BAC1.2F5 macrophages [Figure 3.2].   
 
 
Figure 3.2.  BAC1.2F5 macrophages require p110α activity for basal and CSF-1-induced p-
Akt.  BAC1.2F5 were starved of CSF-1 overnight prior to pre-treatment for 1 h with indicated 
inhibitors the following day: PW12 (0.5 µM), TGX155 (0.5 µM) or IC87114 (5 µM).  The cells were 
subsequently stimulated with CSF-1 (33 ng/ml) for 10 min.  The graph and western blot are 
representative of results of two experiments.  Graph presents data for the mean ± s.e.m. of these 
two experiments performed in duplicate (*p <0.05; **p <0.01; ***p <0.001). Percentages represent 
percentage decrease in p-Akt in the inhibitor treated sample compared to the p-Akt levels in the 
CSF-1-stimulated DMSO control. 
 
3.3. The contributions of Class IA PI3K isoform to Akt activation 
macrophage cell lines 
First, we determined the Class IA PI3K isoforms necessary for generation of CSF-1-
induced p-Akt in two additional macrophage cell lines; IC-21 and J774.2.  We 
observed decreased CSF-1-induced p-Akt in both of these cell lines after pre-
treatment with p110α, p110β or p110δ-selective inhibitors, but only the decrease 
observed in response to inhibition of p110α was found to be significant [Figure 
3.3].  Our data indicated that in IC-21 and J774.2 macrophages, p110α and not 
p110δ was the principal isoform responsible for CSF-1-induced p-Akt.   The 
contribution of p110α observed in the IC-21 and J774.2 macrophages was not as 
substantial as the contribution of p110α in BAC1.2F5 macrophages.   When we 
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calculated the percentage inhibition of p-Akt in the stimulated state we found a 
91% decrease in the presence of a p110α-selective inhibitor in BAC1.2F5 
macrophages [Figure 3.2] whereas in J774.2 and IC-21 we observed a 39% and 
56% decrease, respectively [Figure 3.3].  The percentage reduction in CSF-1 
induced p-Akt in the IC-21, J774.2 and the BAC1.2F5 macrophages in response to 
p110β inhibition was relatively consistent and appeared to be minimal with a 
decrease of between 15-17% observed across the cell lines [Figure 3.2, 3.3].  
 
Figure 3.3. Participation of Class IA PI3K isoforms in induction of p-Akt downstream of CSF-1 
varies in J774.2 and IC-21 macrophage lines. a. J774.2 cells cultured overnight in complete 
medium with FBS reduced from 10% to 5% prior to 1 h pre-treatment for with either DMSO or 
inhibitors the following day: PW12 (0.5 µM), TGX155 (0.5 µM) or IC87114 (5 µM).   The cells were 
stimulated with CSF-1 (30 ng/ml) for 10 b. IC-21 cells treated as described in a.  Graphs and 
western blots are representative of results of multiple experiments. Graphs presents data for the 
mean ± s.e.m. of two experiments performed in duplicate (*p <0.05; **p <0.01; ***p <0.001).  
Percentages represent percentage decrease in p-Akt compared to the p-Akt levels in the CSF-1-
stimulated DMSO control. 
 
In contrast to the BAC1.2F5 macrophages, which were only very minimally 
affected by p110δ-selective inhibition, there was a greater p-Akt reduction in IC-21 
and J774.2 macrophages treated with a p110δ-selective inhibitor. 
 
In a few instances, we noted that treatment with the p110β-selective inhibitor 
(TGX155) resulted in an elevated CSF-1-induced p-Akt signal in the IC-21 
macrophages [Data not shown].  Another member of the laboratory has also 
observed this stimulatory effect of p110β-selective inhibitors in other cell types 
and their data also indicates it is a highly variable/inconsistent effect of p110β-
inhibition.  The reason for this is currently unclear and is currently being 
investigated in the laboratory as part of a separate project.  In the majority of 
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experiments performed by either Dr Papakonstanti or myself, we observed a slight 
reduction of p-Akt in the presence of this inhibitor as illustrated in the graphical 
representation of our results [Figure 3.3b].   
 
3.4. The effects of inhibiting Class IA isoforms in RAW 264.7 
macrophages 
We next proceeded to determine the contributions of the Class IA PI3K isoforms 
downstream of CSF-1 in one more macrophage cell line, RAW 264.7.  The data that 
we obtained was unexpected in that we found that in most experiments (n=2) that 
the individual isoform selective inhibitors were unable to suppress CSF-1-induced 
p-Akt in these cells [Figure 3.4]. 
 
Figure 3.4. Inhibition of individual Class IA PI3K isoforms does not reduce CSF-1-induced p-
Akt in RAW 264.7 macrophages. RAW 264.7 macrophages were cultured overnight in a complete 
medium with FBS reduced from 10% to 5% before pre-treatment with the indicated inhibitors for 1 
h: PW12 (0.5 µM), TGX155 (0.5 µM) or IC87114 (5 µM).    The cells were subsequently stimulated 
with CSF-1 (30 ng/ml) and the p-Akt to Akt ratio was determined by western blotting.  The graph 
and western blot are representative of results of multiple experiments.  Graph presents data for the 
mean ± s.e.m. of two experiments performed in duplicate (*p <0.05; **p <0.01; ***p <0.001).  
 
At this point this part of the project was coming to a close, but we performed a few 
exploratory experiments to investigate the unexpected resistance of the RAW 
264.7 p-Akt to each of the Class IA inhibitors.  First, in order to determine whether 
the p-Akt could be reduced by targeting multiple PI3K isoforms we repeated the 
experiment but with the inclusion of a pan-PI3K inhibitor.  Indeed, pre-treatment 
with the pan-PI3K inhibitor LY294002 resulted in a substantial decrease (more 
than 50%) in the CSF-1-induced p-Akt [Figure 3.5].  Also, in this experiment we 
observed a reduction in p-Akt in response to individual inhibitors [Figure 3.5].  The 
quality of this blot is not ideal and thus no conclusions can be confidently made 
regarding the effects of the individual inhibitors.   
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Figure 3.5. Pan-PI3K inhibition reduced CSF-1-induced p-Akt in RAW 264.7 macrophages.  
RAW 264.7 macrophages were cultured overnight in a complete medium with FBS reduced from 
10% to 5% (v/v) prior to pre-treated for 1 h with the indicated inhibitors the following day: PW12 
(0.5 µM), TGX155 (0.5 µM), IC87114 (5 µM) or LY294002 (5 µM).   The cells were then prior to 
stimulation with CSF-1 (30 ng/ml).  The graph illustrates quantification of p-Akt to Akt ratio from 
the western blot presented. 
 
We performed another experiment alongside the one presented above in which we 
tested whether a dependence of p-Akt on individual isoforms could be observed in 
RAW 264.7 macrophages in normal culture conditions (10% (v/v) FBS in complete 
medium as opposed to 5% (v/v) FBS in complete medium used in the previous 
experiments).  The results of the experiment performed provide some evidence 
that in these conditions the inhibition of the individual Class IA isoforms was 
sufficient to reduce CSF-1-induced p-Akt and that in these conditions the RAW 
264.7 macrophages were more sensitive to the effects of these inhibitors [Figure 
3.6].  In this experiment we used the pan-PI3K inhibitor Wortmannin rather than 
LY294002, as we were aware that the latter has significant off-target effects in 
particular on the activity of mTOR.  These preliminary data suggest that the 
individual isoforms all contribute to the generation of p-Akt in RAW 264.7 
macrophages in normal culture conditions.  Further replicates would be needed 
before a firm conclusion could be drawn.  The mechanism behind the apparent 
variable redundancy of Class IA PI3K isoforms in RAW 264.7 macrophages remains 
unclear. 
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Figure 3.6.  Inhibition of p110δ reduces CSF-1-induced p-Akt in RAW 264.7 macrophages in 
medium containing 10% (v/v) FBS.  RAW 264.7 macrophages were plated in 10% FBS complete 
medium and pre-treated for 1 h the following day with inhibitors as indicated: PW12 (0.5 µM), 
TGX155 (0.5 µM), IC87114 (5 µM) or Wortmannin (50 nM).  The cells were then stimulation with 
CSF-1 (30 ng/ml).  The graph illustrates quantification of p-Akt to Akt ratio from the western blot 
presented. Western blot and graph are from a single experiment. 
 
 
3.5. Investigating the uncharacteristic dependence of BAC1.2F5 
macrophages on p110 alpha 
We reasoned that the unrepresentative dependence of BAC1.2F5 macrophages on 
p110α downstream of CSF-1 could be indicative of a mutation in Pik3ca, the gene 
encoding p110α.  Therefore, a member of the laboratory (Dr G. Nock) sequenced 
the Pik3ca gene in the BAC1.2F5 macrophages.  This sequence analysis did not 
reveal any mutations in the Pik3ca gene [1]. 
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3.6 Conclusion 
Primarily, these data support the hypothesis that p110α plays a greater role in the 
induction of CSF-1-induced p-Akt in macrophage cell lines compared to its minimal 
role in primary macrophages.  Thus, these results suggest that the two main 
isoforms responsible for generating CSF-1-induced p-Akt in macrophages are 
p110α and p110δ, and that their relative contributions are affected by cell state, 
with p110α dominating in the immortalised state and p110δ dominating in the 
primary state.  In addition, we have shown that in general, the inhibition of one 
isoform cannot be compensated for by the remaining uninhibited isoforms.  On the 
other hand, our data regarding RAW 264.7 macrophages, in which individual 
inhibitors were not always able to reduce CSF-1-induced p-Akt, gives the 
impression that in certain conditions uninhibited Class IA PI3K isoforms may have 
the capacity to compensate.  This apparent capacity to compensate for the loss of 
other isoforms seems to be the exception rather than the rule. 
 
3.6. Discussion 
The main conclusions of this part of the project are: 
1. The dependence of the immortalised BAC1.2F5 macrophage cell line on 
p110 is atypical of immortalised macrophages and is not due to a 
mutation in the Pik3ca gene 
2. The dominance of p110observed in primary macrophages is reduced in 
immortalised macrophages 
3. The contributions of the Class IA PI3K isoforms are variable across 
macrophage cell lines and are generally non-redundant  
With the generation and analysis of several mouse models of PI3K inactivation, it 
became clear that the Class I PI3K isoforms perform distinct, although at times 
overlapping, functions in cellular and physiological processes[3, 12, 81, 83, 133, 
153].  Delineating the distinct roles of the individual Class IA PI3K isoforms 
remains an area of intense research, which attempts to address several questions.  
First, which isoforms are associated with which processes and how do the 
isoforms couple to them?  Secondly, can remaining un-inhibited isoforms 
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compensate for the loss of function of an inhibited isoform?  This question of 
redundancy of function is fundamental to the capacity to selectively targeting 
specific disease-associated processes with isoform-selective inhibitors.  Indeed, 
isoform-selective inhibitors are now in clinical trials targeting a wide range of 
disease-related dysfunctions and are largely reported to have low toxicity. 
In line with the observations of distinct and non-redundant roles of PI3K isoforms, 
Dr Papakonstanti, a former member of the Centre for Cell Signalling, observed that 
in primary macrophages signalling downstream of CSF-1 was most dependent 
upon p110 activity, whilst inactivation of p110β or p110α had minimal impact 
[1].  In immortalised BAC1.2F5, this dominance of p110δ was lost and replaced 
with a striking degree of reliance upon p110α [1].  We reasoned that this switch 
from p110- to p110-dependence could be related to the immortalised state of 
the BAC1.2F5 macrophages.  We wanted to determine whether the state of a cell is 
correlated with the functionality of the PI3K Class IA isoforms.  To address this 
question, we compared the effects of each of the Class IA PI3K inhibitors on CSF-1-
induced p-Akt in three additional immortalised macrophage cell lines, namely 
J774.2, IC-21 and RAW 264.7.  We first confirmed that in BAC1.2F5 macrophages, 
CSF-1-induction p-Akt is highly dependent upon p110α activity.  Data obtained in 
J774.2 and IC-21 supported the correlation between a loss of p110δ dependency 
and immortalised status, but also revealed that the almost total reliance of 
BAC1.2F5 macrophages upon p110α to signal downstream of CSF-1, was not 
representative of the norm.  Indeed, the contributions of each of the PI3K Class IA 
isoforms were quite variable across the cell lines tested.  Interestingly, we 
observed a consistent low-level contribution of p110β activity across all of the 
macrophages tested, including the primary macrophages.  These data support the 
hypothesis that loss of p110δ dominance is correlated with immortalisation but 
reveal that the involvement of other isoforms in immortalised macrophages is 
variable.  With regards to non-redundancy, we have observed that in general, 
inhibition of individual PI3K Class IA isoforms is sufficient to partially suppress 
CSF-1-induced p-Akt.  The ability to suppress p-Akt induction with a single 
isoform-selective PI3K inhibitor led us to conclude that uninhibited isoforms are 
unable to compensate for the loss of the inhibited isoform’s activity.  We found it 
particularly interesting that this inability to compensate occurs even when the 
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other isoforms appear to be contributing alongside the inhibited isoform to CSF-1-
induced p-Akt production.   
 
Results obtained for the RAW 264.7 macrophage cell line were not consistent with 
those obtained for the other cell lines, in that these macrophages had an unusual 
insensitivity to inhibition of individual Class IA PI3K isoforms.  Indeed, in a later 
experiment we observed a minimal effect upon inhibition of individual isoforms.  
This result was observed only once and additionally the quality of the blot was 
poor, thus we can only state that we saw some indication that selective-isoform 
inhibition could affect p-Akt generation in these cells but generally we observed no 
effect.  These data suggested that either these cells are somewhat resistant to PI3K 
inhibition or that the uninhibited isoforms were capable of compensation.  We 
began a preliminary investigation into this insensitivity and acquired some 
preliminary evidence that pan-PI3K inhibition was sufficient to repress p-Akt 
induction.  This, if proven, would support the theory that the individual isoforms 
are functioning in a redundant manner.  We also observed a capacity for isoform-
selective inhibitors to repress p-Akt induction in different culture conditions to 
those in which their effects were originally tested.  Conclusions cannot be drawn 
confidently from these final experiments on RAW 264.7 macrophages because 
there were insufficient replicates and furthermore, the qualities of the blots were 
not suitable for reliable quantification.  Whilst working with the RAW 264.7 
macrophages in our main project we observed a decrease in basal and LPS-
stimulated p-Akt upon p110δ-selective inhibition when the macrophages were 
grown in complete medium containing 10% FBS.  We therefore suspect, but cannot 
conclusively state, that the observed insensitivity to PI3K inhibitors is not 
representative of PI3K functionality in RAW 264.7 macrophages.   
We noted that there was also a variation between the macrophage cell lines in 
terms of apparent basal Akt activation, as determined by p-Akt levels.  The primary 
macrophages, IC-21 and RAW 264.7 macrophages appear to have very little p-Akt 
in the unstimulated conditions whilst the J774.2 macrophages and the BAC1.2F5 
macrophages appear to have higher levels.  The p-Akt levels in the unstimulated 
BAC1.2F5 macrophages in fact appear similar to the stimulated levels.  This could 
indicate that the starvation conditions of 5% (v/v) FBS instead of the 10% used in 
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normal culture conditions were insufficient to reduce activation of Akt in these 
cells.  In relation to this observation we have also noted that the effects of the 
isoform-selective inhibitors on this variable unstimulated p-Akt also differ.  In the 
BAC1.2F5 the stimulated and high basal p-Akt are both repressed by treatment 
with the p110α-selective inhibitor PW12, whereas PW12 blocked unstimulated p-
Akt but did not fully inhibit stimulated p-Akt in J774.2 macrophages.  We are 
unable to explain this finding based on our data, but we acknowledge that although 
the apparent differences in basal levels of p-Akt across the cell lines could 
represent genuine cell line variability it may also be an artefact of differences in 
the exposure of x-ray films during the development of blots or other technical 
inconsistencies.  In order to confirm a difference in basal p-Akt levels or the 
differing effects of the inhibitors on unstimulated versus stimulated cells a 
quantitative method would be required. 
Ideally, in order to prove a causal relationship between immortalisation and the 
loss of p110δ dominance, one would need to observe this shift directly during and 
following immortalisation of primary macrophages.  It would be particularly 
interesting if it were possible to follow the process of immortalisation and 
transformation and observe at what point(s) the dependence on p110δ decreased.  
Assuming immortalisation directly results in a shift away from p110δ dominance, 
it would be useful to determine whether other changes in cellular signalling are 
correlated with this shift.  In the Centre for Cell Signalling, Dr G. Nock previously 
attempted to immortalise primary murine mast cells which retained functional c-
kit receptor dependence.  In the case of immortalisation by introduction of the 
Hox11 homeobox gene, the cells became growth factor (IL3)-independent and 
displayed undifferentiated characteristics including a lack of expression of the c-kit 
receptor [154].  A second mast cell line immortalised by expression of polyoma 
middle T remained growth factor-dependent (like BAC1.2F5 macrophages) and 
maintained the differentiated mast cell characteristics including c-kit receptor 
expression, but unfortunately the line could not be recovered after freezing [154].  
In principle, similar studies could be carried out for mouse macrophages in order 
to help elucidate the effects of immortalisation on isoform function.  We note that 
the documented ability of polyoma middle T expression to activate PI3K could 
render this method of immortalisation unsuitable for our PI3K-focused 
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investigations [155-157].  Below we summarize what is known in this context, and 
which strategies could be used. 
With regards to existing macrophage cell lines, J774.2 and RAW 264.7 were both 
derived from murine tumours [146, 148].  The IC-21 and BAC1.2F5 macrophage 
cell line were published as a macrophage line immortalised by SV40 infection in 
vitro [145, 147].  In the case of the BAC1.2F5 macrophages, we have been informed 
that this was later found to be incorrect [Pollard, personal communication to Prof. 
Vanhaesebroeck].  The BAC1.2F5 cells were found to lack SV40 DNA and may 
instead have arisen as a result of spontaneous immortalisation, potentially due to 
inactivation of the INK4a/Arf locus [Personal communication to Prof 
Vanhaesebroeck, J.W. Pollard].  In line with this, a later publication revealed that 
inactivation of INK4a can induce primary macrophage immortalisation [158].  This 
is therefore a strategy that could be attempted to immortalise primary mouse 
macrophages. 
We could perhaps have use previously published cell lines from the Pollard group.  
Indeed, Pollard et al. studied BAC1.2F5-derived mutants and compared these to 
the original BAC1.2F5 cells, which are dependent on CSF-1 for survival and 
proliferation [159].  The authors studied mutants with varying degrees of 
transformed character and observed a capacity of cells to separate the 
requirement for CSF-1 for survival and for proliferation [159]. 
1. Cells survive and proliferate in culture but only in the presence of CSF-1  
2. Cells survive but do not proliferate in the absence of CSF-1 
3. Cells survive and proliferate in the absence of CSF-1 but proliferate faster in 
the presence of CSF-1 
4. Cells that are entirely independent of and unresponsive to CSF-1 
We considered that these mutants with their varying degrees of immortalisation 
and transformation might potentially be excellent models in which to investigate 
the effect of cellular state upon PI3K Class IA isoform contributions.  We did not 
proceed with this primarily because this project was coming to an end, but also 
because of the unusual dependence on p110α in the BAC1.2F5 macrophages 
compared to the other macrophages cell lines, which made this otherwise ideal 
system unsuitable.  Of course, it is possible that had we investigated the effects of 
inhibiting each Class IA PI3K isoform in the BAC1.2F5-derived mutant lines that 
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are independent of CSF-1 for survival, we would observe a pattern more similar to 
that seen in the CSF-1-independent J744.2 and IC-21 macrophage cell lines.  Had 
we proceeded with this project we would certainly have attempted to immortalise 
primary macrophages, probably using INK4a inactivation, in order to follow any 
changes in PI3K Class IA isoform contributions during the transitions.  
The ability of either p110α or p110δ to be the predominant isoform, which induces 
p-Akt downstream of CSF-1 in different murine macrophages, suggests that the 
capacity of these isoforms to act downstream of CSF-1 is not dependent on a fixed 
and intrinsic factor.  Instead, the ability of the isoforms to function downstream of 
a particular stimulus appears to be affected by the state of the macrophages.  Based 
on these results we would advise that when investigating the role of a particular 
PI3K isoform or investigating the effects of isoform-selective inhibition, the cell 
type and perhaps, the growth conditions used, might have a substantial impact 
upon conclusions drawn.  
We conclude that this work contributed to the knowledge regarding the capacity of 
PI3K Class I isoforms to perform distinct and non-redundant functions in cultured 
cells.  Furthermore, our work highlighted the fact that the distinct roles played by 
each isoform are not fixed to one role in one cell type but are also influenced by the 
state of the cell.  Finally, in macrophages we found evidence that the dominance of 
p110δ is reduced in immortalised cells and that multiple isoforms can contribute 
in absence of p110δ dominance.  The contributions of the isoforms were generally 
found non-redundant and as such p-Akt was reduced by inhibition of any single 
isoform.  
 103 
CHAPTER 4 
 
4. INVESTIGATING THE EFFECTS OF 
PHARMACOLOGICAL INACTIVATION OF P110 DELTA ON 
THE TRANSCRIPTOME OF RAW 264.7 MACROPHAGES  
 
4.1. Introduction and aims of study 
From here on in, the focus of the project shifted to investigating the role of p110δ 
in transcriptional regulation.  At the time that we initiated this investigation, 
information regarding the role of PI3K in transcriptional regulation at the whole 
genome level was very limited.  In fact, there were no published studies detailing 
the effect of p110δ inactivation on the whole transcriptome of any cell type. 
We had intended to investigate the role of p110δ in transcriptional regulation in 
primary macrophages.  Unfortunately, at this point in the project the generation of 
differentiated primary macrophages was causing difficulties.  This challenge was 
overcome using a systematic problem solving approach, as described briefly in the 
next chapter.  In the mean time, we designed and performed a pilot genome-wide 
expression analysis using a macrophage cell line treated with the p110δ-selective 
inhibitor IC87114.  We hoped that this study would provide the first indication as 
to the magnitude and range of transcriptional deregulation that occurs in response 
to inactivation of p110δ in macrophages.  We reasoned that this was also an 
excellent opportunity to familiarise ourselves with microarray experiments and 
analysis.  This was particularly important as we were primarily performing the 
microarray experiment ourselves, with guidance from our pharmaceutical 
sponsor.  The preliminary work leading up to this genome-wide expression 
analysis and the results of the experiment are detailed below. 
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This and all subsequent experiments were designed in collaboration with our 
pharmaceutical sponsor UCB.  Being a pharmaceutical company, their interests 
naturally lay in translational rather than more fundamental scientific questions.  
With this borne in mind, experiments were designed with consideration for the 
potential translational relevance of resulting data.  In particular we considered one 
element of experimental design; the culture conditions of the cells prior to RNA 
extraction.  When considering the culture conditions, we proposed that performing 
these experiments in normal culture conditions (complete medium including 10% 
FBS) rather than pre-starving the cells might be preferable.  We reasoned that 
withdrawal of growth factors and or nutrients induces cellular and metabolic 
stress is not likely to be representative of the in vivo conditions that may occur in a 
clinical blood sample, for example.  We therefore made the decision to assess the 
genome-wide impact of p110δ inactivation on macrophages in the basal 
unstimulated exponentially growing state.  We also choose to reduce the 
concentration of IC87114 used in these and all subsequent experiments (unless 
clearly stated) from the 5 µM we had used in earlier experiments to 1 µM.  IC87114 
was originally published as a p110δ-selective drug when used a 5 µM in vitro but 
tests performed on p110δ KI cells revealed that above 1µM IC87114 affects the 
function of other Class I isoforms [135].  Based on this new isoform selectivity data 
and our desire to minimise off-target effects we therefore choose to reduce the 
concentration of IC87114 that we used in all subsequent experiments to 1 µM. 
 
4.2. Choosing a macrophage line to study 
It was imperative that we performed this investigation in a macrophage cell line 
that is dependent on p110δ activity to some degree in the basal.  From the outset, 
UCB had a preference for the use of the RAW 264.7 cell line because this is the 
macrophage cell line that they commonly use in their own immunological research.  
We were cautious about using this cell line based on our findings described in 
Chapter 3.  Consequently, before proceeding we tested whether inhibition of 
p110δ affected p-Akt levels in RAW 264.7 macrophages.  We included samples 
treated with a pan-PI3K inhibitor in order to compare the level of inhibition to that 
resulting from p110δ inhibition.  We included LPS-treated samples as a control to 
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check that the basal cells were not in an activated state and blotted for phospho-
p38 (p-p38) to confirm which samples had been stimulated with LPS. 
 
Figure 4.1. Inhibition of p110δ reduced basal and LPS-stimulated p-Akt in RAW 264.7 
macrophages. RAW 264.7 macrophages were plated in complete medium including 10% FBS.  The 
following day the cells were pre-treated with either DMSO, p110δ-selective IC87114 (1 µM) or pan-
PI3K inhibitor LY294002 (5 µM) prior to stimulation with LPS (1 µg/ml) for 30 min.  
 
 
Our results indicated that RAW 264.7 basal p-Akt is reduced by pharmacological 
inactivation of p110δ as is LPS-induced p-Akt [Figure 4.1].   The p-p38 confirmed 
that only the LPS-stimulated samples (+) had been exposed to LPS and showed 
that activation of p38 is unaffected by treatment with a pan-PI3K inhibitor or with 
a p110δ-selective inhibitor. 
Based on these results we felt confident to proceed with our genome-wide 
expression analysis using RAW 264.7 macrophages pre-treated with 1 µM of 
IC87114.   
 
4.3. Chronic pre-treatment with IC87114 reduced Akt activation  
We reasoned that in order to best mimic chronic administration of p110δ-selective 
inhibitors in a clinical setting it would be more representative to have an extended 
IC87114 treatment prior to sample extraction.  We performed a final preliminary 
experiment to compare the effects of 2 h IC87114 treatment to the effect of 72 h 
IC87114-treatment on the basal and also LPS-induced p-Akt.  A 2 h pre-treatment 
with LY294002 was also included to enable the effects of long-term p110δ-
selective inhibition to be compared to the effects of pan-PI3K inhibition [Figure 
4.2].  
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Figure 4.2. Inhibition of p110δ for 2 h or 72 h reduced basal and LPS-stimulated p-Akt in 
RAW 264.7 macrophages. RAW 264.7 macrophages were plated in complete medium containing 
10% FBS and pre-treated with DMSO or p110δ-selective IC87114 (1 µM) or pan-PI3K inhibitor 
LY294002 (5 µM) for the times indicated.  DMSO and IC87114 were added to the medium every 24 
h during the 72 h period.  Following 2 or 72 h incubation the cells were stimulated with LPS (1 
µg/ml) for 30 min prior to extraction of cell lysates.  Lysates were processed and analysed for the 
indicated proteins using standard immunoblotting techniques. 
 
 
These data confirmed that IC87114-treatment for 2 or 72 h both repressed basal 
and LPS-induced p-Akt levels in RAW 264.7 macrophages [Figure 4.2].  Based on 
this data we felt confident to pre-treat the RAW 264.7 macrophages with 1 µM of 
IC87114 for 72 h in order to represent chronic inactivation in vitro. 
 
4.3.1. Final experiment design 
We finalised our plans and set out to perform genome-wide transcriptional 
analysis on RAW 264.7 macrophages in the basal state grown in complete medium.  
We pre-treated RAW 264.7 macrophages with either DMSO or IC87114 for 72 h 
and then extracted RNA from six plates of grown in normal culture conditions 
(complete medium including 10% FBS).   
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4.4. Extraction and quality control of RNA 
The quality of the six RNA samples was confirmed using the Agilent Bioanalyser in 
accordance with the protocol described in the Materials and Methods section 
[Chapter 2, section 2.8.1.1].  All of the samples were assigned a RIN between 9.8 
and 10 indicating that they consisted of high quality RNA.  An example 
electropherogram is shown in Figure 4.3. 
 
Figure 4.3. RNA extracted from RAW 264.7 macrophages was intact and of high quality.  A 
representative electropherogram of the electoropheretic trace of sample DMSO 1 which was 
assigned a RIN of 10.  The axis 25-4000 represents nt with a peak representing the 18S rRNA at 
approximately 1500 nt and second larger peak representing 28S rRNA at approximately 4000 nt.  
Based on the area under the two main peaks an 18S to 28S ratio of 2.0 was calculated.  The gel 
image is shown to the right. The upper band represents the 28S rRNA whilst the lower represents 
the 18S rRNA and the green band at 25bp is the marker which can also be seen as a small peak on 
the electropherogram. 
 
 
4.5. Obtaining expression data 
The genome-wide expression of the three samples treated with DMSO and the 
three samples treated with IC87114 was determined using the 3’ IVT GeneChip® 
protocol and Affymetrix Mouse Genome GeneChip® 430 2.0 microarrays.  Each 
processed sample was hybridized to an individual chip, stained and subsequently 
scanned to obtain fluorescence data.  A visual check of the raw data image for each 
chip was performed and all Affymetrix GeneChip® internal controls and standards 
were checked and found to be satisfactory. In order to obtain comparative 
expression data for the samples included in the experiment we first had to 
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normalise across the entire experiment to account for chip to chip variation.  This 
chip to chip normalisation was performed on our behalf by three bioinformaticians 
Dr H. Edwards, Dr P. Hales and Ms E. Gadaleta using the standard GC-RMA 
algorithm.  With the help of these bioinformaticians the data set was subsequently 
reduced from the full 45,002 probe sets by filtering to extract the top 10,000 most 
variant probe sets.  
 
4.6. Multivariance analysis to identify sample clusters 
With the assistance of Dr H. Edwards, Dr P. Hales and Ms E. Gadaleta we employed 
PCA to reduce the dimensionality of the data in order to group samples and 
identify outliers.  PCA is a mathematical model that enables the most prominent 
variation within a data set to be identified, whilst retaining and representing as 
much of the original data as feasible [160-161].  This is achieved first, by taking all 
the values per sample and shrinking them into a smaller set of values, which still 
represent the variability within the original data set.  Secondly, the algorithm 
identifies the most apparent feature within the smaller set of values, which 
represents the greatest degree of variation between samples.   This feature is 
assigned as the Principal Component 1 (PC1), and PC2 is determined based on the 
feature creating the second greatest variation, which is not already explained by 
PC1.  PC3 represents other sources of variation not represented by either PC1 or 
PC2.  The algorithm identifies any remaining variability within the data set that is 
not accounted for by the three major PCs.  The two main PCs can be represented on 
a graph, on which the samples can be located to represent visually which PC each 
sample is best aligned with and their relationship, if any, with the other PC.   
 
4.6.1. Samples separate according to LPS-stimulation status  
The PCA revealed two clusters of samples, which represented the DMSO and 
IC87114-treated samples [Figure 4.4a].  This analysis also revealed variability 
within the treatment groups; the samples within the groups did not cluster tightly 
on a single principal component.  In fact, two outliers were identified based on the 
plot obtained and the values for each PC [Data not shown].  In fact PCA 1 was 
independent of the treatment effect in this PCA.  Consequently, the data from these 
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two outlier samples (DMSO 1 and IC87114 1) were excluded from further analysis.  
The PCA was re-run on the reduced data excluding the outliers to confirm that in 
their absence the PC1 was dependent on the IC87114-treatment [Figure 4.4b].  The 
removal of two outliers reduced the data to two replicates per condition which was 
sufficient to continue analysis but reduced the confidence with which any results 
can be presented.  Unless otherwise stated all subsequent analysis was performed 
on the dataset generated after the exclusion of the outlier samples data. 
 
Figure 4.4.  Samples clustered according to treatment groups but there was variability 
within groups.  PCA was performed on the data set acquired. a. The original PCA including the 
outlier samples. b. The PCA after removal of the two outlier samples.  After the exclusion of the two 
outliers, the greatest degree of variation represented by PC1 was dependent on treatment effects.  
 
4.7. Identification of individual probe sets affected by IC87114 
treatment 
We next obtained a list of probe sets differentially regulated in the IC87114-
treated RAW 264.7 macrophages by applying a  minimum threshold of 1 Log Fold 
Change (LogFC, calculated as the log to the base 2) to the list of the top 10,000 
most variably expressed probe sets.  The statistical significance of the changes 
were subsequently calculated using a standard two-tailed t-test.  The p values 
obtained were adjusted to take into account the multiple hypothesis testing that is 
inherent in genome-wide expression analysis.  This adjustment was performed 
using the B-H formula to generate an adjusted p value (adjp value)[151]. 
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Application of the cut off of a minimum logFC of greater than or equal to (≥) 1 and 
an adjusted p value of less than or equal to (≤) 0.05 reduced this list to 139 probe 
sets that were differentially regulated in RAW 264.7 macrophages treated with 
IC87114 compared to those treated with DMSO [Table 4.1].  Increasing the 
statistical stringency to p ≤ 0.001 did not eliminate any of these 139 probe sets, 
which indicated that the differential regulation detected for these 139 probe sets 
was very significant.  Within the 139 probe sets fifty-nine were specific to 
transcripts that were not associated with known genes and therefore lack gene 
symbols and protein names (designated NA).  These probe sets are complementary 
to sequences that have been found to be expressed sequences by the expressed 
sequence tag (EST) method.  ESTs are short DNA sequences generated from cDNA 
sequences that are generated by reverse transcribing cellular mRNAs into DNA 
sequences that do not contain intronic sequences.  As such they should represent 
sequences that are expressed within the cell from which the mRNA sequence was 
derived.  Scientists can search for sequence similarity to a gene or sequence of 
interest and as the sequences are mapped to the genome ESTs are assigned to 
chromosomal regions and known genes.  The probe sets interrogating EST 
sequences may therefore be associated with a known gene or protein product in 
the future and this will be linked to the relevant Affymetrix probe set identification 
numbers.   We have therefore included two tables, one including only those probe 
sets assigned a gene symbol or some other relevant annotation such as a RIKEN 
name [Table 4.1] and a further table includes those unassigned probes [Table 4.2].  
We have chosen to list these assigned probe sets because the information 
regarding unassigned expressed transcripts and RIKEN clones is continuously 
expanding.   
With regards to the assigned probe sets we found eighty that were differentially 
regulated in IC87114-treated RAW 264.7 macrophages.  Affymetrix GeneChips® 
include multiple redundant probe sets for some but not all genes.  This increases 
the reliability of data obtained by providing multiple independent measures of 
expression.  The number of unique differentially regulated genes or transcripts 
identified is often inflated by the detection of differential regulation by duplicate 
probe sets.  Multiple probe sets were identified for Cd28, Tribs3, Cox6a and Orly.  
The identification of multiple probe sets increases the confidence with which the 
effect of IC87114 on the expression of these genes can be presented. 
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Probe set ID Gene 
Symbol 
Protein name logFC adj.p value 
1433283_s_at Orly oppositely-transcribed, rearranged 
locus on the Y 
-4.647 2.90E-92 
1460500_at 5033421C21Rik RIKEN cDNA 5033421C21 gene -4.572 2.52E-89 
1444668_at Astx amplified spermatogenic transcripts X 
encoded 
-4.288 1.76E-78 
1442812_at Gm10482 predicted gene 10482 -4.094 1.79E-71 
1456340_at Mettl11a methyltransferase like 11A -4.059 2.69E-70 
1425881_at Psg28 pregnancy-specific glycoprotein 28 -3.903 5.25E-65 
1449832_at 1700091H14Rik RIKEN cDNA 1700091H14 gene -3.466 3.44E-51 
1459564_at Gm4670 predicted gene 4670 -2.971 1.76E-37 
1454437_at Orly oppositely-transcribed, rearranged 
locus on the Y 
-2.785 7.71E-33 
1430441_at 4933438K21Rik RIKEN cDNA 4933438K21 gene -2.759 3.18E-32 
1438620_x_at Sfrp1 secreted frizzled-related protein 1 -2.53 5.66E-27 
1421496_at Acer2 alkaline ceramidase 2 -2.515 1.16E-26 
1458854_at C78891 expressed sequence C78891 -2.202 2.52E-20 
1430324_x_at 1700049E17Rik1 RIKEN cDNA 1700049E17 gene, gene 
1 
-2.077 5.16E-18 
1431117_x_at 1810029B16Rik RIKEN cDNA 1810029B16 gene -2.013 6.86E-17 
1458243_at Gm7844 predicted gene 7844 -1.987 1.96E-16 
1422875_at Cd84 CD84 antigen -1.876 1.33E-14 
1422726_x_at Speer4a spermatogenesis associated 
glutamate (E)-rich protein 4a 
-1.702 6.39E-12 
1427514_at LOC624295 hypothetical protein LOC624295 -1.667 2.08E-11 
1452418_at 1200016E24Rik RIKEN cDNA 1200016E24 gene -1.63 6.75E-11 
1447749_at Smyd5 SET and MYND domain containing 5 -1.595 2.07E-10 
1433163_at 6230414M07Rik RIKEN cDNA 6230414M07 gene -1.587 2.60E-10 
1447182_at C77815 expressed sequence C77815 -1.562 5.63E-10 
1443213_at Gtdc1 glycosyltransferase-like domain 
containing 1 
-1.553 7.43E-10 
1432590_at 4930573O21Rik RIKEN cDNA 4930573O21 gene -1.551 7.79E-10 
1426243_at Cth cystathionase (cystathionine gamma-
lyase) 
-1.542 1.01E-09 
1416298_at Mmp9 matrix metallopeptidase 9 -1.538 1.12E-09 
1426065_a_at Trib3 tribbles homolog 3 (Drosophila) -1.524 1.72E-09 
1453668_at 3110052M02Rik RIKEN cDNA 3110052M02 gene -1.5 3.48E-09 
1456225_x_at Trib3 tribbles homolog 3 (Drosophila) -1.425 3.09E-08 
1428046_a_at Zfx zinc finger protein X-linked 1.322 5.08E-07 
1438050_x_at Gm9222 predicted gene 9222 -1.314 6.14E-07 
1422504_at Glrb glycine receptor, beta subunit -1.266 2.10E-06 
1441414_at Sfi1 Sfi1 homolog, spindle assembly 
associated (yeast) 
-1.264 2.18E-06 
1423072_at 6720475J19Rik RIKEN cDNA 6720475J19 gene -1.255 2.69E-06 
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Probe set ID Gene 
Symbol 
Protein name logFC adj.p value 
1438802_at Foxp1 forkhead box P1 1.253 2.83E-06 
1456504_at Zfp182 zinc finger protein 182 1.251 2.91E-06 
1456282_at 6720457D02Rik RIKEN cDNA 6720457D02 gene -1.249 3.01E-06 
1451382_at Chac1 ChaC, cation transport regulator-like 
1 (E. coli) 
-1.238 3.92E-06 
1423524_at Mastl microtubule associated 
serine/threonine kinase-like 
1.224 5.37E-06 
1441565_at LOC100039111 similar to cadherin 11 -1.222 5.66E-06 
1457633_x_at Cox6a2 cytochrome c oxidase, subunit VI a, 
polypeptide 2 
-1.213 6.86E-06 
1440144_x_at C330046E03 hypothetical protein C330046E03 -1.211 7.20E-06 
1441829_s_at Akap10 A kinase (PRKA) anchor protein 10 1.192 1.15E-05 
1455900_x_at Tgm2 transglutaminase 2, C polypeptide -1.185 1.33E-05 
1438874_at Nme7 non-metastatic cells 7, protein 
expressed in (nucleoside-diphosphate 
kinase) 
-1.179 1.50E-05 
1442453_at Fcho2 FCH domain only 2 1.178 1.51E-05 
1445047_at C79246 expressed sequence C79246 -1.158 2.43E-05 
1429717_at Ipo11 importin 11 1.153 2.68E-05 
1428827_at Whsc1 Wolf-Hirschhorn syndrome candidate 
1 (human) 
1.151 2.79E-05 
1459760_at Ndufs4 NADH dehydrogenase (ubiquinone) 
Fe-S protein 4 
1.147 3.06E-05 
1437923_at AI314760 expressed sequence AI314760 -1.145 3.14E-05 
1425177_at Shmt1 serine hydroxymethyltransferase 1 
(soluble) 
-1.138 3.71E-05 
1460304_a_at Ubtf upstream binding transcription 
factor, RNA polymerase I 
-1.134 4.03E-05 
1460469_at Tnfrsf9 tumor necrosis factor receptor 
superfamily, member 9 
-1.129 4.45E-05 
1419985_s_at Ccdc69 coiled-coil domain containing 69 1.122 5.07E-05 
1423467_at Ms4a4b membrane-spanning 4-domains, 
subfamily A, member 4B 
1.104 7.63E-05 
1460722_at Soat2 sterol O-acyltransferase 2 -1.089 1.06E-04 
1456296_at 5830418K08Rik RIKEN cDNA 5830418K08 gene 1.073 1.50E-04 
1458667_at Ninl ninein-like 1.07 1.56E-04 
1419721_at Niacr1 niacin receptor 1 -1.068 1.61E-04 
1449984_at Cxcl2 chemokine (C-X-C motif) ligand 2 -1.063 1.79E-04 
1444677_at C77673 expressed sequence C77673 1.048 2.43E-04 
1417262_at Ptgs2 prostaglandin-endoperoxide synthase 
2 
-1.048 2.43E-04 
1417607_at Cox6a2 cytochrome c oxidase, subunit VI a, 
polypeptide 2 
-1.048 2.43E-04 
1417597_at Cd28 CD28 antigen 1.047 2.43E-04 
1437285_at 1110020G09Rik RIKEN cDNA 1110020G09 gene 1.047 2.44E-04 
1460474_at 2610028L16Rik RIKEN cDNA 2610028L16 gene -1.043 2.64E-04 
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Probe set ID 
Gene 
Symbol Protein name logFC adj.p value 
1435728_at Tyw3 tRNA-yW synthesizing protein 3 
homolog (S. cerevisiae) 
1.042 2.67E-04 
1442311_at Zfr zinc finger RNA binding protein 1.034 3.12E-04 
1451577_at Zbtb20 zinc finger and BTB domain 
containing 20 
1.032 3.22E-04 
1443703_at Cd28 CD28 antigen 1.029 3.41E-04 
1428010_at Timm9 translocase of inner mitochondrial 
membrane 9 homolog (yeast) 
1.024 3.75E-04 
1432885_at 4632432E15Rik RIKEN cDNA 4632432E15 gene -1.024 3.79E-04 
1438831_at Cdk12 cyclin-dependent kinase 12 1.022 3.83E-04 
1433016_s_at Orly oppositely-transcribed, rearranged 
locus on the Y 
-1.021 3.88E-04 
1456667_at Htt huntingtin 1.019 4.07E-04 
1438063_at Mphosph9 M-phase phosphoprotein 9 1.012 4.68E-04 
1437025_at Cd28 CD28 antigen 1.01 4.82E-04 
1434798_at Atp6v0d2 ATPase, H+ transporting, lysosomal 
V0 subunit D2 
-1.008 5.01E-04 
Table 4.1. List of eighty probe-sets with assigned gene symbols identified as differentially 
regulated in RAW 264.7 macrophages treated with IC87114.  The probe sets are ranked based 
on largest to smallest LogFC. Those increased in RAW 264.7 macrophages pre-treated with IC87114 
(1 µM) for 72 h are highlighted in red whilst those that were found to be decreased are highlighted 
in green.   
 
Probe set ID Gene Symbol Protein name logFC adj.p value 
1420310_at NA NA -6.194 4.72E-164 
1458382_a_at NA NA -5.611 1.38E-134 
1447329_at NA NA -5.096 6.62E-111 
1446017_at NA NA -4.693 6.13E-94 
1457657_at NA NA -4.659 1.22E-92 
1428301_at NA NA -3.957 8.59E-67 
1434280_at NA NA -3.915 2.19E-65 
1452731_x_at NA NA -3.804 9.44E-62 
1447059_at NA NA -3.768 1.36E-60 
1439920_at NA NA -3.748 5.94E-60 
1448022_at NA NA -3.655 5.37E-57 
1426060_at NA NA -3.402 2.72E-49 
1426061_x_at NA NA -3.38 1.10E-48 
1434279_at NA NA -3.377 1.31E-48 
1427346_at NA NA -3.23 2.00E-44 
1417838_at NA NA -3.061 8.01E-40 
1440815_x_at NA NA -2.504 1.96E-26 
1424609_a_at NA NA -2.409 2.03E-24 
1452433_at NA NA -2.305 2.68E-22 
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Probe set ID Gene Symbol Protein name logFC adj.p value 
1424607_a_at NA NA -2.292 4.71E-22 
1459989_at NA NA -2.269 1.32E-21 
1440508_at NA NA -2.23 7.50E-21 
1445267_at NA NA -2.117 9.85E-19 
1460084_at NA NA -2.018 5.75E-17 
1424608_a_at NA NA -1.98 2.45E-16 
1438237_at NA NA -1.938 1.26E-15 
1458543_at NA NA -1.86 2.37E-14 
1442493_at NA NA -1.838 5.34E-14 
1429993_s_at NA NA -1.834 6.17E-14 
1447044_at NA NA -1.814 1.24E-13 
1420073_s_at NA NA -1.813 1.27E-13 
1447408_at NA NA 1.645 4.28E-11 
1442947_x_at NA NA -1.605 1.54E-10 
1447410_at NA NA -1.562 5.63E-10 
1443649_at NA NA 1.5 3.48E-09 
1452452_at NA NA -1.483 5.69E-09 
1457022_at NA NA -1.468 8.68E-09 
1445389_at NA NA -1.393 7.66E-08 
1435158_at NA NA 1.371 1.39E-07 
1448018_at NA NA 1.37 1.40E-07 
1441131_at NA NA 1.367 1.51E-07 
1445518_at NA NA 1.345 2.72E-07 
1446661_at NA NA -1.313 6.31E-07 
1442547_at NA NA 1.296 9.70E-07 
1449652_at NA NA -1.278 1.53E-06 
1441391_at NA NA 1.244 3.37E-06 
1437534_at NA NA -1.241 3.66E-06 
1440925_at NA NA 1.233 4.34E-06 
1447123_at NA NA -1.185 1.33E-05 
1458018_at NA NA 1.179 1.51E-05 
1441584_at NA NA 1.178 1.51E-05 
1439813_at NA NA 1.131 4.28E-05 
1457053_at NA NA 1.127 4.63E-05 
1435708_at NA NA 1.11 6.73E-05 
1447461_at NA NA -1.072 1.51E-04 
1439944_at NA NA -1.071 1.55E-04 
1460416_s_at NA NA -1.065 1.70E-04 
1455759_a_at NA NA 1.022 3.83E-04 
1447575_at NA NA 1.006 5.15E-04 
Table 4.2. List of fifty-nine probe-sets complementary to unassigned expressed sequences 
that were differentially regulated in RAW 264.7 macrophages treated with IC87114. The 
probe sets are ranked based on largest to smallest LogFC. Those increased in RAW 264.7 
macrophages pre-treated with IC87114 (1 µM) for 72 h are highlighted in red whilst those that 
were found to be decreased are highlighted in green.   
 
 115 
4.8. Identification enriched functions amongst the genes affected 
by IC87114 
We employed Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems) to 
determine whether the list of genes that we had found to be affected by IC87114 
treatment were enriched with genes involved in a particular molecular or cellular 
function.   The analysis was performed on the list of genes affected by 1 logFC or 
more and with a statistical significance of p ≤ 0.001 [Table 4.1].  IPA calculated the 
number of genes in the uploaded list that are associated with a molecular function 
and then calculated the statistical significance of any enrichment.  Enrichment is 
deemed statistically significant if there are more genes in the list associated with a 
particular function that would be expected by chance based on the total number of 
genes associated with that function.  IPA software identified several molecular 
functions including cellular compromise, cell signalling and molecular transport 
that were enriched in our gene list [Figure 4.5].   
 
Figure 4.5. The top ten molecular and cellular functions significantly enriched in the list of 
genes affected by IC87114-treatment. Functional enrichment analysis was performed using IPA 
software on the complete list of genes differentially regulated in RAW 264.7 macrophages 
chronically treated with p110δ-selective IC87114 (1 µM) for 72 h.  The statistical significance of the 
enrichment of genes associated with each listed molecular processes are indicated by the length of 
the position of the bar against the Y axis, which represents log p values determined using Fisher’s 
exact test.  The statistical significance threshold set at p ≤ 0.05 is indicated by the thin grey line. 
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Cellular compromise was identified as the most statistically significantly enriched 
function in the list of differentially regulated genes.  This was calculated based on 
the number of genes in this functional category in the input list with reference to 
the total number of genes in the category (Fisher’s exact test).  Six of the known 
genes found to be differentially regulated in RAW 264.7 macrophages treated with 
IC87114 are associated with cellular compromise in IPA’s database (p value 2.24 
x105). 
Cellular compromise is defined by Ingenuity as including “any functions that are 
associated with the damage or degradation of cells or any process that might 
compromise the functions of a cell” [IPA Help Manual 5.5 v1].  We were interested 
to note from the list of six genes (Mmp9, Ubtf, Htt, Ndufs4, Ptgs2 and Tgm2) that 
IPA assigned to this ontology four were associated with the subcategory of 
neurological damage or degeneration; Htt, Ndufs4, Ptgs2 and Tgm2.  Notably, the 
Htt gene, which encodes the huntingtin protein that is mutated in sufferers of the 
terminal neurodegenerative disorder Huntingdon’s disease, was included in this 
category.  The expression of Htt was increased by 1 logFC in the IC87114-treated 
samples according to our Affymetrix data.  The predominance of neuronal-related 
genes in our list that belong to this cellular compromise function could be of 
interest as p110δ is also expressed in neurons and might therefore regulate these 
genes affecting neuronal integrity in these cells. 
4.9. Identification of enrichment of pathway components 
amongst the genes affected by IC87114 
IPA software also allows users to place their results within the context of 
molecular networks.  We next set out to determine whether the components of any 
pathway or biological network were enriched within the genes that we had found 
in our study to be affected by IC87114-treatment.  This analysis highlighted two 
biological networks that may be relevant to our list of genes affected by IC87114 
treatment.  The most relevant network that was assigned a score of 20 consisted of 
Nutritional disease, Cellular movement, Haematological System Development and 
Function.  The second network scored 18 and also encompassed genes belonging 
to Haematological System Development and Function alongside Cellular Growth 
and Proliferation, and Cell death [Figure 4.6b]. 
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Figure 4.6. The top two networks found to be most relevant to our list of genes affected by IC87114-treatment.  The list of genes affected by IC87114-treatment 
was uploaded into IPA software and core analysis was performed to as determined by IPA software. Scores were attributed based on a right tailed t test of the enrichment 
of genes in our list in these networks. A score of 20 represents a p value of 10-20. Direct relationships are represented by full lines whilst indirect relationships or 
connections are indicated with a dashed line. Genes from the input list are indicated either in red or green for an increased or decreased expression in IC87114-treated 
cells respectively.  a. The highest scoring network (20) was Nutritional disease, Cellular movement, Haematological System Development and Function b. Cellular Growth 
and Proliferation, Haematological System Development and Function, Cell death was the second most relevant network which was designated a score of 18. 
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We noted that Akt was one of the central nodes in the top network identified 
[Figure 4.6a Akt is circled in red].  Moreover, Akt was shown to have reported 
direct or indirect relationships with several of the genes in our list [Figure 4.6a].  In 
addition, the network revealed that within this network the transcription factor 
NF-κB has reported indirect or direct relationships with the majority of the genes 
from the list, as well as with many of the other genes in the network [Figure 
4.6a][162-165].  This could indicate that NF-κB is one of the transcription factors 
through which p110δ may regulate the expression of genes.     
Further investigations revealed that the relationships between the input genes and 
Akt were largely spurious.  For example, the relationship designated between Akt 
and Htt is based on a publication which showed, amongst other things, that Akt 
activity was not affected by MK-801 [166].  Thus, this publication has triggered IPA 
to link Akt and HTT despite in fact stating the opposite, that MK-801, which affects 
Htt, does not affect Akt activation [166].  On the other hand, the direct relationship 
between Akt and TRIB3 is made in reference to a publication showing that Akt has 
been found bound to TRIB3 in human cells [167].  This does have possible 
functional implications but they are unlikely to be relevant to the regulation of 
Trib3 gene expression by p110δ, which is suggested by our data.  These findings 
highlights the caution with which these enrichment analyse must be analysed.  
This network analysis has perhaps not highlighted anything particularly pertinent 
to our analysis, except that it has identified NF-κB as a transcription factor 
associated with several of our affected genes.  Indeed, even this potential link with 
NF-κB may need to be treated with caution.  The fact that NF-κB and also PI3K-Akt 
are areas which are highly covered in the literature may result in their over-
representation in IPA networks.   Having said that, Mmp9 one of the genes 
identified in this study and in network one [Figure 4.6a] as discussed below, 
appears to be a genuine target of NF-κB in a manner that is at least partially 
dependent on PI3K activity.   Thus, the link between the genes we have identified 
in NF-κB may be relevant but perhaps not to the exclusion of other transcription 
factors that are less well covered in the literature. 
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4.10. Identification of potential biomarkers of p110 delta 
inactivation 
4.10.1.  Biomarker characteristics 
Biomarkers must be not only consistently correlated with a particular state or 
treatment such as IC87114 treatment, but ideally should also be relatively 
straightforward to measure.  For that reason, cell surface molecules that can be 
rapidly measured using FACS are considered as ideal biomarkers.  Secreted 
proteins can also often be easily monitored and quantified using ELISA techniques 
to determine their concentration in supernatant taken from cells.  In fact, in some 
instances, it may be possible to monitor the concentration of secreted products in 
blood plasma using an ELISA.   
4.10.2.  Identification of potential biomarkers within the gene list 
IPA software allows users to view enriched networks in either the standard view 
[Figure 4.6] or in a subcellular view [Figure 4.7].  This view allows the user to 
rapidly identify which subcellular location (extracellular, cytoplasm, plasma 
membrane, extracellular or unknown) each protein resides within.   
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Figure 4.7. Subcellular view of top two networks relevant to the list of genes affected by IC87114-treatment. Red brackets indicate areas encompassing 
extracellular space and the plasma membrane. 
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We can observe six unique proteins encoded by a gene derived from our list that 
reside within either the extracellular space or the plasma membrane as highlighted 
by red brackets [Figure 4.7].  These proteins include Cd84, Cd28, Sfrp1 and 
Tnfrfsf9 and which are located in the plasma membrane and therefore can be, 
quantified rapidly using FACS [Figure 4.7].  In addition, in the first network there 
are two genes encoding secreted proteins Mmp9 and Cxcl2, which can be measured 
by ELISA [Figure 4.7].  Thus, just by examining the subcellular location of the genes 
in the top two networks relevant to our gene list we have identified seven genes 
that represent potential biomarkers for p110δ inactivation.  We proceeded to 
analyse our complete list of genes affected by IC87114 treatment and identified a 
further three genes that were not included in the top two networks, which also 
encode proteins that are either located in the plasma membrane or are secreted 
into the extracellular space.  The nine genes in the complete list were Sfrp1, 
Tnfrsf9, Cd84, Cd28, Ms4a4c, Cxcl2, Mmp9, Glrp and Niacr1 [Table 4.3].  Although it 
should be pointed out that proteins located within the cytosol or nucleus can 
usually be measured by immunoblotting and it is also not out of the question for 
the differential expression of an mRNA to be measured as a biomarker using qPCR.  
The remaining genes if found to be reproducibly affected by IC87114 treatment 
could therefore, in principle also be validated and developed into biomarkers.  
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Gene 
Symbol 
Protein Sub-cellular location Method of detection logFC 
Cd28 Cd28 Antigen Plasma membrane FACS  1.029 
Cd84 Cd84 Antigen Plasma membrane FACS -1.876 
Cxcl2 Chemokine Extracellular ELISA -1.063 
Glprp Glycine receptor, 
beta subunit Sf1 
homolog 
Plasma membrane FACS -1.266 
Mmp9 Matrix 
metallopeptidase 9 
Extracellular ELISA/Zymography -1.538 
Ms4a4c  membrane-spanning 
4-domains, subfamily 
A, member 4C 
Plasma membrane (?) FACS (?) 1.104 
Niacr1 Niacin R1 Plasma membrane FACS -1.068 
Sfrp1 Secreted frizzled-
related protein 1 
Plasma membrane FACS -2.530 
Tnfrsf9 TNF receptor 
superfamily, member 
9 
Plasma membrane FACS -1.129 
Table 4.3. Potential biomarkers of p110δ-inactivation identified by genome-wide expression 
analysis. Genes identified were grouped according to sub-cellular locations and those found to be 
expressed on the plasma membrane or in the extracellular space were considered to be the most 
promising biomarker candidates. Ms4a4c is a predicted protein encoded on chromosome 19 and 
for this reason the location of the protein is uncertain (symbolised by ?).  The proteins predicted 
structure indicates it would be located within the plasma membrane. 
 
4.10.3.  Two potential biomarkers of p110δ inactivation 
Below I have briefly outlined the functions of two of the genes that we have found 
to be affected by IC87114 treatment.  The two genes chosen have the potential to 
be used as biomarkers for the rapid determination of the p110δ activity status of 
macrophages. 
 
4.10.3.1. Cd28 expression was increased by IC87114 treatment  
Data obtained from three probe sets revealed that Cd28 expression was increased 
by greater than 1 logFC in IC87114-treated RAW 264.7 macrophages compared to 
control cells [Table 4.1 & 4.2].  These data would suggest that p110δ is a negative 
regulator of the expression of Cd28 in RAW 264.7 macrophages.  This result is 
puzzling because Cd28 is a T cell marker, which recognises cell surface molecules 
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expressed on APCs and is to the best of our knowledge, not known to be expressed 
by macrophages.  Specifically, Cd28 functions as a co-stimulatory molecule for the 
TcR and activation of the TcR.  In the absence of this co-stimulation from bound 
CD28, TcR activation actually suppresses the activity of the T cells by inducing 
anergy [168].  Assuming Cd28 expression is induced to a detectable level in 
IC87114-treated RAW 264.7 macrophages, this could be a useful marker of p110δ 
inactivation.  The expression of Cd28 on RAW 264.7 macrophages could be 
measured using Cd28-specific immune-fluorescent antibodies and FACS analysis. 
 
4.10.3.2. Mmp9 expression was reduced by IC87114 treatment 
Mmp9 is a matrix metallo proteinase (mmp9) that is secreted during the 
inflammatory reaction by a range of immune cells including macrophages.  Mmp9 
has dual gelatine and collagen degradation activity and as such, degrades 
extracellular matrix components including collagen IV, which is a major 
component of the basement membrane.  Secretion of Mmp9 remodels the 
extracellular matrix to facilitate leukocytes transmigration, which is necessary for 
immune cell recruitment to and entry into a site of infection.  We consider that this 
differential expression of Mmp9 in IC87114-treated RAW 264.7 macrophages may 
warrant further investigation and potentially could be measured  using a simple 
gelatine zymography experiment.  
 
4.11. Conclusion 
As a consequence of the exclusion of two outlier samples (one from each treatment 
group), our results have been generated based on data obtained from only two 
replicates per condition.  This small number of replicates certainly reduces the 
confidence with which these results can be presented.  Statistical analysis was 
nevertheless performed and revealed that 139 probe sets were differentially 
regulated in IC87114-treated RAW 264.7 macrophages by 1 logFC or more with a p 
≤ 0.001 [Table 4.1].  Within this 139 probe sets were fifty-four known genes, 
including several that encode proteins that are expressed on the surface of the cell 
or are secreted.  These genes represent potential biomarkers of p110δ inactivation 
but we would of course need to validate the effect of IC87114 on their expression 
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in an independent experiment.  By the time we had acquired these results, we were 
ready to perform a microarray to test the effect of p110δ inactivation on primary 
macrophages.  Thus, we decided not to validate any of the potential hits in this 
pilot study at this stage.    
 
4.12. Discussion 
Before proceeding with our main microarray study on primary macrophages, we 
performed a pilot microarray study to determine the impact of inactivating p110 
on the RAW 264.7 transcriptome.  Specifically, we compared the genome-wide 
expression of RAW 264.7 macrophages chronically (72 h) treated with IC87114 to 
RAW 264.7 macrophages treated with vehicle control.  This study provided an 
excellent opportunity to familiarise ourselves with RNA work and especially with 
microarray studies both at a practical level but also in terms of data analysis.   
All of the results from this study are presented with one major caveat, in 
consequence of which, we have been cautious not to draw any firm conclusions 
from them.  The caveat is this: the results are based on a data set consisting of just 
two replicates per condition, after the removal of one outlier from each condition.  
The necessity to remove one outlier per condition is in itself somewhat troubling, 
especially as these replicates are derived from a single cell line source.  We were 
nevertheless advised that it was acceptable to perform statistical analysis on the 
remaining data.  This statistical analysis revealed that the differential regulation of 
the 139 probe sets is very highly significant (p ≤ 0.001).  It may be relevant that we 
originally analysed these data with the outlier samples’ data included and in fact, in 
this original analysis we also identified Cd28, Tgm2 and Mmp9 as genes amongst 
many others that were differentially regulated in IC87114-treated RAW 264.7 
macrophages.  Indeed, if one were keen to follow up these results, without 
performing another microarray, it would be useful to obtain a list of the probe sets 
identified irrespective of the inclusion or exclusion of outliers.  This problem of 
outliers certainly highlighted the importance of including sufficient replicates in a 
microarray experiment, in order to retain statistical power even if samples need to 
be excluded as outliers.  Specifically, based on this experience, we decided that any 
future arrays that we perform should include at least four replicates per condition. 
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Briefly, we found that 139 probe sets were differentially regulated in RAW 264.7 
macrophages chronically treated with IC87114 compared to their control 
counterparts.  Within the list of probe sets identified were a number of genes that 
potentially represent useful biomarkers of p110δ activity, including Cd84, Cd28 
and Mmp9.   
Mmp9 is secreted by cells in response to a wide range of stimuli including TNF-α 
and LPS [169-170].  The available literature points to a requirement for NF-κB 
activity for the induction of Mmp9 expression in response to immunological 
stimuli, which is in keeping with the presence of several NF-κB binding sites within 
the Mmp9 promoter.  Interestingly, induction of Mmp9 expression and the 
subsequent increase in the secretion of mmp9 have been reported to be 
significantly repressed by pan-PI3K inhibition [169, 171].  This involvement of 
PI3K was shown to occur alongside other LPS-activated signalling pathways such 
as the MAPK (p38 activation) or the Notch signalling pathways [169, 171].   These 
publications support our finding regarding decreased Mmp9 expression in RAW 
264.7 macrophages treated with IC87114.  In light of our result it is tempting to 
speculate that p110δ is responsible for the regulation of Mmp9 expression, but 
without further investigation we cannot rule out a contribution of other PI3K 
isoforms.  Interestingly, Mendes et al. found that Rapamycin treatment, which 
inhibits mTORC1 had a resulted in significantly increased expression of Mmp9 in 
RAW 264.7 macrophages stimulated with LPS [48].  These publications also 
highlight that immunological stimuli are potent activators of Mmp9 expression.  
We therefore speculate that a more substantial and importantly more easily 
detectable deregulation of Mmp9 expression might be observed in response to 
IC87114 treatment if RAW 264.7 macrophages were stimulated with LPS.  In 
theory, enhancing the differential regulation of Mmp9 in RAW 264.7 macrophages 
treated with IC87114 by stimulation with LPS could improve its usefulness as a 
biomarker of p110δ inactivation. 
The identification of the Cd28 as a gene differentially regulated in these 
macrophages was somewhat unexpected because Cd28 is a T cell marker.  To our 
knowledge Cd28 is not expressed in macrophages and it is possible that this 
regulation is functionally irrelevant as Cd28 is not actually transcribed, translated 
or expressed on the surface of these cells.  Alternatively, we speculate that this 
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could be a clue to indicate that these cells have, as a result of transformation or 
prolonged culture, lost their macrophage phenotype to some degree or aberrantly 
express T cell genes.  We recognise that this may also be an indication of cross-
contamination within this cell line. 
Despite the limitations of this study, we propose that the data could provide a 
useful starting point for the development of an assay to validate the activity of 
potential p110δ-selective inhibitors.  Before developing an assay it would be 
necessary to validate the results.  Validation would require the effect(s) to be 
observed consistently in at least three additional samples at the RNA level and 
preferably, depending on the final assay design, at the protein level.  To ensure that 
the effect of IC87114 on the gene expression is related to its inhibition of p110δ, 
the effect(s) would also need to be observed consistently in response to treatment 
with several other p110δ-selective inhibitors.  The development of novel p110δ-
selective agents is ongoing within the pharmaceutical industry and consequently, 
the ability to screen agents reliably and rapidly for p110δ-selective activity is 
much sought.  We suggest that, subject to validation, the differential regulation of 
one or a number of the genes identified could be developed into an in vitro assay to 
screen for agents that inactivate p110δ.  The potential to perform this type of assay 
using a fast-growing, readily-cultured cell line has advantages for development 
into the high throughput format, which is preferred by pharmaceutical companies.  
We conclude that despite some major limitations, the results of this study could 
potentially be of use in the development of an in vitro assay for the inactivation of 
p110δ activity.  Furthermore, we gained useful experience in genome-wide 
expression analysis and have learned valuable lessons and as such we feel this 
study fulfilled its role as a pilot study.   
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CHAPTER 5 
 
5. INVESTIGATING THE EFFECTS OF GENETIC 
INACTIVATION OF P110 DELTA ON THE TRANSCRIPTOME 
OF PRIMARY MACROPHAGES 
5.1. Development and validation of a modified primary 
macrophage extraction and differentiation protocol 
 
At the beginning of this project we had substantial difficulties culturing primary 
macrophages.  This had to be resolved before we could proceed with our genome-
wide expression analysis using primary macrophages.  As such this caused some 
delay to the start of our work with primary macrophages, but during this delay we 
performed the study described in Chapter 4.  The problem and its resolution are 
briefly described here.  Several consecutive cultures failed to differentiate and cells 
appeared to be dying within three days of extraction.   
 
5.1.1. Addressing difficulties with the differentiation of primary 
macrophages 
Initially we replaced all reagents with fresh bottles to ensure none of the reagents 
were contaminated and changed all plastic-ware to certified endotoxin-free 
products.   Unfortunately these measures did not resolve the issue.  Initially we 
checked with a more experienced member of the Centre for Cell Signalling, that the 
original protocol was being performed appropriately to eliminate any technical 
errors.  No technical errors or good lab practice concerns were identified.  The 
current protocol was therefore deemed to be no longer suitable and we decided to 
develop a modified protocol. 
 
 
 128 
5.1.2. The modified protocol for production of differentiated macrophages  
The most substantial difference between the modified and original protocol is the 
increased addition of CSF-1.  The modified protocol requires addition of CSF-1 to 
the progenitors more frequently and at a higher dose during the differentiation 
period.  We also adjusted the method of splitting the cells to reduce stress caused 
during differentiation.   The original and the modified protocol are described in 
detail in Materials and Methods alongside the original protocol [Chapter 2, section 
2.3.2]. 
We consistently obtain differentiated primary macrophages using the modified 
protocol.  Moreover, we have significantly increased the yield of macrophages 
produced from each mouse from an average of around ten million to an average of 
between thirty and forty million.   We now suspect/infer that the original protocol 
may have become ineffective due to altered potency in the commercially produced 
CSF-1. 
5.1.3. Validation of macrophages generated using modified protocol 
Photographs of differentiated macrophages have been included here to record the 
macrophage-like morphology of the cells generated [Figure 5.1].  Two pictures are 
included in order to illustrate the range of morphologies observed in primary 
macrophages including more rounded and more extended cell shapes [Figure 5.3]. 
 
Figure 5.1.  Photographs showing the normal range of morphology displayed by 
differentiated primary macrophages generated using the modified protocol. Macrophages 
were extracted and differentiated in accordance with the modified protocol. Photographs of 
macrophages in the presence of CSF-1 on Petri dishes were taken seven days after extraction using 
a digital camera and a light microscope (objective 20X).  
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5.1.3.1. Phenotypic analysis of macrophages generated with modified protocol 
We performed basic phenotypic analysis using FACS to assess the expression of the 
classic macrophage surface marker F4/80 on the cells generated using the 
modified protocol to confirm that they were indeed macrophages.  We observed 
expression of F4/80 in both the WT and p110δ KI macrophages [Figure 5.2].  It has 
previously been shown that surface expression of F4/80 is normal in p110δ KI 
macrophages [79].  These data indicated that there was modest difference between 
the expression of F4/80 on the WT and p110δ KI macrophages [Figure 5.2].  The 
experiment would need to be repeated to confirm this, but we suggest the 
difference is not sufficient to be of any importance.  
 
Figure 5.2. WT and p110δ KI macrophages both express F4/80.  A. WT macrophages were 
allowed to adhere overnight and the following day were scraped into FACS buffer, washed and 
stained at RT for 1 h with an F4/80 specific-PE conjugated antibody.  B. p110δ KI macrophages 
were prepared and treated as described in A.  C. WT BMMs were treated with LPS at 1 μg/ml 
overnight and prepared as described in A.  The histograms are representative of results of two 
samples for both WT and p110δ KI macrophages. 
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5.1.3.2. Testing the LPS-responsiveness of the differentiated macrophages 
To test whether the cells are responsive to LPS, we assessed the expression of 
IA/IE (the mouse homolog of MHC II).  Unstimulated immature macrophages 
express low levels of IA/IE and upon LPS-stimulation, LPS-responsive 
macrophages, i.e. ones that have not been tolerised to LPS by previous exposure, 
upregulate expression of the antigen presenting complex IA/IE.  We observed that 
the unstimulated-macrophages of both genotypes were IA/IE-low and that they 
did indeed upregulate IA/IE surface expression following stimulation with LPS 
[Figure 5.3]. 
 
Figure 5.3. WT and p110δ KI macrophages express IA/IE at low levels in the unstimulated 
state and upregulate IA/IE significantly on LPS stimulation.  Cells were stimulated with either 
control or LPS (1 μg/ml) for 24 h  The following day cells were scraped into FACS buffer and 
washed, before staining at RT for 1 h with F4/80 and IA/IE specific antibodies and were 
subsequently analysed.  Histograms shown are representative of results of two samples for both 
WT and p110δ KI macrophages. 
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These two findings, regarding F4/80 and IA/IE expression, are consistent with the 
expected profile of immature macrophages, and therefore, based on these results 
we are confident that the modified protocol can be used to produce a pure 
population of LPS-responsive macrophages. 
 
5.2. Aims of genome-wide expression analysis of p110 delta KI 
and WT macrophages 
After completing the pilot genome-wide expression analysis study and 
concurrently solving our problems with primary macrophage culture we were 
ready to proceed with our main experiment.  Our objectives remained the same, 
first, to gain insight into the contribution and role of p110δ activity in 
transcriptional activation and secondly, to identify potential biomarkers of p110δ 
inactivation.  We reasoned that primary macrophages derived from p110δ KI mice 
would be an ideal model with which to address these questions.  Primary cells are 
often preferable to cell lines when work being performed has a translational 
element because the inherent abnormalities in cell lines can complicate the 
interpretation of results.  The p110δ KI mutation is considered to be an excellent 
model of selective pharmaceutical inactivation of p110δ.  We were interested to 
observe whether any of the genes affected by chronic IC87114 treatment in RAW 
264.7 macrophages, would also be differentially regulated in p110δ KI primary 
macrophages.   
 
5.3. Conditions used for genome-wide expression analysis 
We wanted to assess the contribution of p110δ to transcriptional regulation in 
normal culture conditions that we deemed most relevant to physiological 
conditions.  Primary macrophages are dependent on CSF-1 for growth and survival 
and are ubiquitously exposed to CSF-1 in vivo.  Assessment of genome-wide 
expression analysis in primary macrophages was therefore performed on primary 
macrophages in complete media containing 10% FBS and CSF-1 (20 ng/ml).  We 
chose to expand our investigation to include the identification of changes to the 
transcriptome of primary macrophages lacking p110δ activity in an activated as 
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well as basal state.  Specifically, we decided to determine the transcriptome of 
p110δ KI macrophages compared to WT macrophages in the basal and LPS-
stimulated state [Figure 5.4].  LPS has a rapid and dramatic impact on the 
macrophage transcriptome and PI3K inactivation has been shown to impact upon 
this transcriptional regulation induced by LPS in macrophages and other immune 
cells [96].  We predicted that if the impact of p110δ inactivation on basal 
macrophages was minimal in terms of magnitude of deregulated expression that 
these effects might be amplified in the presence of LPS.  We therefore felt that the 
inclusion of paired samples treated with LPS would assist us in gaining a greater 
insight into the contributions of p110δ to macrophage transcriptional regulation.  
Furthermore, our pharmaceutical sponsors proposed that if an altered expression 
of a certain gene identified in LPS-stimulated p110δ KI macrophages translated to 
LPS-stimulated human monocytes that this would represent a suitable biomarker. 
 
Figure 5.4. Scheme of genome-wide expression analysis of p110δ KI macrophages and WT 
macrophages.  Primary macrophages derived from four WT mice and four p110δ KI mice were 
plated in complete media containing 10% FBS and 20 ng/ml of CSF-1.  The following day the cells 
were stimulated with LPS (1 µg/ml) for 6 h and the RNA was extracted for genome-wide expression 
analysis.    
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5.4. Obtaining genome-wide expression data for WT and p110 
delta KI macrophages 
Macrophages were derived from four WT mice and four p110δ KI mice and treated 
with control or LPS for 6 h.  Genome-wide expression data was subsequently 
obtained for each of the sixteen samples using Affymetrix GeneChip® Mouse 
Genome 430 2.0.  Firstly we visually appraised the data image files and all 
Affymetrix internal controls were checked and found to be satisfactory.  We then 
processed the data in the same way as described in Chapter 4 with assistance from 
Dr H. Edwards, Dr P. Hales and Ms E. Gadaleta [Chapter 4, section 4.5].  Briefly, this 
included chip to chip normalisation using the GC-RMA algorithm and subsequently 
reducing the data set from the full 45,002 probe sets by filtering to extract the top 
10,000 most variant probe sets. 
 
5.4.1. Analysis of clustering within the dataset 
5.4.1.1. Samples clustered by LPS-stimulation status and not genotype 
We performed PCA, which revealed that the key principal component (PC1) 
represented the variation between the basal and LPS-stimulated samples [Figure 
5.5].  Thus the samples clustered according to LPS-stimulation status and not by 
genotype. 
 
Figure 5.5. PCA revealed that the samples separate by LPS-stimulation status and not by 
genotype.  PCA was performed on expression data to determine separation of samples.  Samples 
separate according to basal and LPS-stimulated status and not according to genotype (WT versus 
p110δ).   
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5.4.1.2. Hierarchical clustering reveals an outlier and a batch effect  
Bearing in mind the impact of LPS on the transcriptome, it was not surprising to us 
that basal versus LPS-stimulated status represents the greatest differential within 
our data set.  Furthermore, our ability to detect this LPS-driven effect provided a 
useful internal control for the power of the Affymetrix to identify biologically 
relevant changes in gene expression within our samples.  We subsequently 
employed hierarchical clustering and confirmed that LPS-stimulation represents 
the biggest differential in our data set and that the samples did not cluster 
according to their genotype [Figure 5.6].  In fact, whilst the samples did not cluster 
by genotype within the basal and LPS branches, we noticed that they did cluster by 
day of extraction or effectively by batch [Figure 5.6].   Hence WT 2 clusters with 
DKI 2 as the mice from which the macrophage precursors were extracted on the 
same day and were subsequently differentiated over the same seven day period 
[Figure 5.6].  Batch effects are caused by systemic errors which result from non-
biological experimental variation introduced when samples are not processed 
together, as in our experiment.   Whilst every effort was made to make sure that 
batches were treated according to an identical protocol, with consistent reagents 
used throughout, the only way to completely eliminate intra-array variation is to 
process all samples together.  Thus, ideally all the macrophages should have been 
extracted on the same day and consequently differentiated over the same period 
and finally processed on the same day.   We reason that this batch effect is not a 
significant problem as we are aiming to identify differences that can potentially be 
used as biomarkers in clinical work, which therefore must be apparent despite 
background variation.   In fact if anything we would expect a much higher variation 
in both sample processing and also individual variation associated with collection 
of clinical samples. 
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Figure 5.6. Hierarchical clustering identified an outlier and a batch effect. Hierarchical clustering was employed to identify the relationships between the samples.  
Samples separated into two main branches, unstimulated and LPS-stimulated and did not cluster according to genotypes.  One outlier sample was identified; DKI 4 
(indicated by the red star) an unstimulated sample clustered with the LPS-stimulated samples. A batch effect where samples extracted on the same day clustered together.   
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The HCA analysis also revealed that sample p110δ KI 4 (DKI4-indicated by red 
star) was an outlier as it was aligned with the LPS-stimulated samples in the 
hierarchical tree [Figure 5.6].  This sample may have been accidentally exposed to 
LPS or some other stimulant.   The data set from this outlier was excluded from 
further analysis, unless otherwise stated. 
 
5.4.2. Identification of individual genes affected by p110δ inactivation 
We proceeded to extract the probe sets that were differentially regulated by a 
logFC of 1 or more and a statistical significance of p ≤ 0.05.  We found twenty-five 
probe sets that met theses criteria; seventeen probe sets including fourteen known 
genes and three RIKEN sequences were affected in the basal state [Table 5.1 & 5.3], 
whilst twenty probe sets including the same three RIKEN sequences were affected 
in the LPS-stimulated state [Table 5.2 & 5.3].    The proportion of increases 
compared to decreases in expression was relatively balanced with 54.2% of the 
probe sets decreased and 45.8% increase overall.   Within these probe sets twelve 
were affected irrespective of the LPS-stimulation status, whilst five were affected 
only in basal macrophages and eight were only identified as differentially 
regulated in LPS-stimulated genes [Figure 5.7].  A summary of these probe sets is 
provided in Tables 5.1, 5.2 & 5.3. 
 
 
Figure 5.7. Venn diagram of the twenty-five probe sets that were found to be differentially 
regulated in p110δ KI macrophages compared to in WT macrophages.  Twelve probe sets 
(nine known genes and three RIKENs) are differentially expressed irrespective of LPS treatment.  
Five known genes are only differentially regulated in basal p110δ KI macrophages and eight only in 
LPS-stimulated p110δ KI macrophages.  The probe sets within the black ring were identified in the 
basal state and those within the red ring were identified in the LPS-stimulated state 
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 Basal 
Probe Set ID Gene Symbol Protein logFC adjP value 
1434914_at Rab6b RAB6B, member RAS oncogene family -2.368 2.14E-05 
1419078_at Nin Ninein 2.316 2.14E-05 
1421861_at Clstn1 calsyntenin 1 1.737 7.60E-03 
1423024_at Sh2d1b1 SH2 domain protein 1B1 1.286 4.02E-02 
1417120_at Miip migration and invasion inhibitory protein -1.092 3.05E-02 
Table 5.1. The expression of five genes was differentially regulated in p110δ KI macrophages 
compared to in WT macrophages in basal conditions. The expression of two genes (Rab6b and 
Miip) was decreased in basal p110δ KI macrophages.  The expression of three genes (Clstn1, 
Sh2d1b1 and Nin) was increased in basal p110δ KI macrophages.  Genes are ordered by magnitude 
of change irrespective of the direction of logFC and red and green highlighting indicate whether 
expression of the gene is increased or decreased in p110δ KI macrophages respectively. 
 
 LPS-stimulated 
Probe Set ID Gene Symbol Protein logFC adjpValue 
1450498_at Mthfr 5,10-methylenetetrahydrofolate reductase -2.194 1.70E-04 
1432499_a_at Ube4b ubiquitination factor E4B, UFD2 homolog (S. 
cerevisiae) 
-1.802 1.38E-04 
1425270_at Kif1b Kinesin family member 1b 1.409 1.72E-02 
1438239_at Mid1 midline 1 1.408 1.64E-02 
1421365_at Fst Follistatin 1.305 1.07E-03 
1416995_at Pacsin3 protein kinase C and casein kinase substrate in 
neurons 3 
1.304 3.10E-03 
1442140_at Tnn tenascin N -1.083 3.47E-02 
1454760_at Htatsf1 HIV TAT specific factor 1 1.078 4.33E-02 
Table 5.2.  The expression of eight genes was differentially regulated in LPS-stimulated 
p110δ KI macrophages compared to LPS-stimulated WT macrophages. The expression of 
three genes, (Mthfr, Ube4b, Tnn) was decreased in LPS-stimulated p110δ KI macrophages.  The 
expression of five genes was increased in LPS-stimulated p110δ KI macrophages (Kif1b, Mid1, Fst, 
Pacsin3 and Htatsf1). Genes are ordered by magnitude of LogFC irrespective of the direction of 
change. Known genes are highlighted in bold and red and green highlighting indicate whether 
expression of the gene is increased or decreased in p110δ KI macrophages respectively 
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 Basal LPS-stimulated 
Probe Set ID Gene 
Symbol 
Protein logFC adjpValue logFC adjpValue 
1419309_at Pdpn Podoplanin -3.629 2.14E-05 -3.321 2.71E-05 
1425521_at Paip1 polyadenylate binding protein-
interacting protein 1 
3.110 6.79E-06 3.350 8.71E-07 
1449141_at Fblim1 filamin binding LIM protein 1 -2.927 3.61E-04 -3.892 4.42E-03 
1453145_at Pisd-ps3 phosphatidylserine decarboxylase, 
pseudogene 3 
2.230 2.24E-03 1.849 4.57E-03 
1431106_a_at 9530053H
05Rik 
RIKEN cDNA 9530053H05 gene 2.157 1.20E-02 1.329 2.04E-02 
1416289_at Plod1 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 
-1.886 5.93E-04 -1.771 4.08E-04 
1424213_at Ubiad1 UbiA prenyltransferase domain 
containing 1 
1.811 9.11E-03 2.345 2.95E-04 
1437478_s_at Efhd2 EF hand domain containing 2 -1.782 4.66E-04 -1.541 7.10E-04 
1436574_at 1700029I0
1Rik 
RIKEN cDNA 1700029I01 gene -1.685 6.82E-03 -1.752 1.83E-03 
1439279_at 3110007F
17Rik 
RIKEN cDNA 3110007F17 gene -1.662 2.24E-03 -1.230 1.33E-02 
1451349_at Efcab7 EF-hand calcium binding domain 7 -1.583 4.08E-03 -1.409 4.57E-03 
1437708_x_at Vamp3 vesicle-associated membrane protein 
3 
-1.088 3.05E-02 -1.121 1.11E-02 
Table 5.3.  Differential regulation of twelve probe sets interrogating nine known genes and 
three RIKEN transcripts in p110δ KI macrophages compared to WT macrophages in both 
basal and LPS-stimulated conditions. Six known genes and two RIKEN clones (Fblim1, Pdpn, 
Plod1, EFhd2, Efcab7 and Vamp-3 were found to be decreased in basal and LPS-stimulated p110δ KI 
macrophages.  Three known genes and one RIKEN were found to be increased in basal and LPS-
stimulated p110δ KI macrophages. Probe sets are ordered by magnitude of logFC irrespective of the 
direction of change and known genes are in bold and red and green highlighting indicate whether 
expression of the gene is increased or decreased in p110δ KI macrophages respectively 
 
The most substantial deregulation was a logFC of -3.89 Fblim1 in LPS-stimulated 
p110δ KI macrophages compared to WT macrophages.  This is equivalent to a 
decrease of Fblim1 transcription by 14.8 times compared to its transcription in WT 
macrophages.  Although this is a very substantial decrease the majority of the 
logFCs were relatively modest.  The mean increase in expression of genes affected 
by 1 logFC or more (p ≤ 0.05) was a logFC of 1.79 (3.45 times more) and the 
average decrease was 1.9 logFC (3.73 less). 
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5.4.3. Identification of functions enriched in the list of differentially genes 
We next employed IPA software to determine which, if any, molecular and or 
cellular functions were enriched in the list of genes differentially regulated in 
p110δ KI macrophages.  The results indicated that a number of functions were 
enriched including amino acid metabolism, cell cycle, and cell-to-cell signalling and 
interaction [Figure 5.8].  The majority of the enriched functions do not overlap 
with those identified as most enriched in the RAW 264.7 gene list.  Although, one of 
the enriched functions in the RAW 264.7 gene list was cellular compromise and we 
note that there is also an enrichment of genes differentially regulated in p110δ KI 
macrophages belonging to this category [Figure 5.8].  Four of the genes 
differentially regulated in p110δ KI macrophages are categorised by IPA under 
cellular compromise: Ube4b, Mid1, Plod1 and Nin. 
 
Figure 5.8. The top ten most statistically significant molecular and cellular functions 
enriched in the list of genes differentially regulated in p110δ KI macrophages. Functional 
enrichment analysis was performed using IPA software on the complete list of genes differentially 
regulated in basal and/or LPS-stimulated p110δ KI macrophages.  The statistically significance of 
the enrichment of genes associated with each listed molecular processes are indicated by the length 
of the position of the blue bar against the Y axis, which represents log p values determined using 
Fisher’s exact test.  The statistical significance threshold set at p ≤ 0.05 is indicated by the thin grey 
line. 
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5.4.4. Identification of most relevant networks using IPA 
Although we only identified twenty-five unique genes or transcripts, we were 
nevertheless interested to determine whether this list of genes was enriched for 
any particular molecular networks.  We found that the scores assigned to the top 
two networks relevant to the gene list were much smaller than those assigned to 
the top two networks relevant to the RAW 264.7 gene list [Chapter 4, Figure 4.11].  
The most relevant network identified by IPA was inflammatory response, 
antimicrobial response, cell-to-cell signalling and interaction network [Figure 5.9].  
This network was assigned a score of 6 (equivalent to p≤ 10-6) based on the 
relationships between five of the genes in the input list (Fblim1, Vamp3, Htatsf1, 
Pdpn, Tnn and Fst) and other network components [Figure 5.9]. 
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Figure 5.9. IPA analysis revealed the Inflammatory Response, Antimicrobial Response, Cell-To-Cell Signalling and Interaction network as relevant to the list of 
genes differentially regulated in p110δ KI macrophages.  IPA identified the most relevant molecular networks based on the twenty-five probe sets differentially 
regulated in basal and or LPS-stimulated p110δ KI macrophages.  Scores were assigned based on right tailed t tests of the enrichment of genes in the list in the networks.  
Full and dashed lines represent direct relationships and indirect relationships or connections respectively. Red or green indicates increased or decreased expression 
respectively.  The network of Inflammatory Response, Antimicrobial Response, Cell-To-Cell Interactions was identified as most relevant network to the gene list and was 
assigned a score of 6. 
 142 
 
 
The second network IPA software identified as most relevant to the gene list was 
cancer, embryonic development and tissue morphology.  On closer inspection, 
despite a score of three, the network consisted of just two components Rab6b and 
a micro RNA miR122.  Although this result serves to highlight the possible 
regulation of Rab6b by miR122, the classification of this as a network seems a little 
spurious.  Indeed, this rather limited “network” and the statistical significance 
assigned to it despite its composition of just two components, highlights the 
caution with which IPA results should be treated. 
 
5.5. Identification of potential biomarkers for p110 delta 
inactivation 
We observed a lack of overlap between the genes differentially regulated in p110δ 
KI primary macrophages with those genes found to be differentially regulated in 
RAW 264.7 macrophages chronically treated with IC87114.  Had any gene(s) been 
identified in both studies, they would have represented prime candidates for 
development as p110δ biomarkers.  The absence of overlap raised several 
questions, which are discussed in the subsequent chapter and in the discussion in 
the context of later results.  We reasoned that it was still important to proceed with 
validation and to choose genes that represented the most promising candidates for 
development as potential biomarkers.  Within the gene list there were six genes 
encoding proteins that are identified by IPA as encoding proteins that are located 
in the plasma membrane or extracellular space; Clstn1, Fst, Fblim1, Pdpn, Tnn and 
Vamp3 [Table 5.4].   
Gene Symbol Protein Location (IPA) 
Fst Follicle-stimulating hormone Secreted* 
Clstn1 Calsyntenin Plasma membrane 
Fblim1 filamin binding LIM protein Plasma membrane 
Pdpn Podopalin Plasma membrane 
 143 
Tnn Tenascin N Plasma membrane 
Vamp3 Vesicular-associated membrane protein 3 Plasma membrane* 
 
Table 5.4.  Potential biomarkers identified include six genes encoding proteins that are 
either secreted or expressed on the plasma membrane.  The sub-cellular locations of the 
twenty-five unique probe sets were identified using in silico analysis. Fst encodes a secreted 
protein, whilst Clstn1, Fblim1, Pdpn, Tnn, and Vamp3 all encode proteins expressed on the plasma 
membrane. * denotes that the subcellular location stated may not be the exclusive location of this 
protein. 
 
In fact, although the proteins may associate with the plasma membrane, they are in 
fact intracellular and for the purposes of a biomarker we ideally wanted to identify 
genes encoding transmembrane proteins that can be measured using FACS.  One of 
the genes, Fst, encodes follicle-stimulating hormone which is indeed secreted, 
although we are not confident based on what is known about its function, that it 
will actually be secreted by macrophages.   
 
5.5.1. Identification of the differential regulation most representative of 
p110δ inactivation 
With the help of Dr P. Hales, we employed GeneData Expressionist Software to aid 
us in the unbiased identification of the genes that are most representative of p110δ 
inactivation in primary macrophages.  Classifier analysis distils large data sets 
down to a number of key changes in expression that are the most representative of 
the states investigated.   The algorithm performed on our complete dataset 
(excluding outlier DKI4) identified that the expression values of six probe sets are 
necessary and sufficient for separation of samples into the four categories; WT 
basal, WT LPS, DKI basal or DKI LPS [Figure 5.10].  The six probe sets consisted of 
two duplicate probe sets for Paip1, two duplicate probe sets for Fblim1, a probe set 
for Pdpn and a probe set for RIKEN sequence A430071A18Rik.  This would suggest 
that the expression values of just three known genes and one RIKEN sequence 
would be sufficient to confidently distinguish between p110δ KI and WT samples 
and furthermore, also to differentiate basal from LPS-stimulated samples within 
those genotypes. 
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Figure 5.10. Classifier algorithm identified four genes (six probe sets) that were most 
representative of the four different conditions (WT basal, WT LPS, DKI DKI LPS).   GeneData 
Expressionist software was used to perform a classifier analysis that identified the top variations 
between the four groups of samples.   The expression of six probe sets specific to three unique 
genes, Paip1, Fblim1, Pdpn and one RIKEN sequence was identified as highly indicative of p110δ KI 
status. 
 
We had anticipated that a larger number of probe sets would be necessary to 
categorise the sample groups particularly in light of the lack of clustering by 
genotype that was identified by PCA and hierarchical clustering [Figures 5.5 & 5.6].     
The results of the classifier suggest that despite the lack of clustering and the 
relatively small number of genes differentially regulated by p110δ inactivation, it 
is possible to distinguish between genotypes.  We reasoned that the three genes 
identified could, following further validation, be used as biomarkers for p110δ 
inactivation.   
 
5.6. Validation of the differential expression of genes in p110 
delta KI macrophages 
 
5.6.1. The necessity to validate relationships identified by genome-wide 
analysis 
Affymetrix GeneChips®, alongside other microarrays are excellent tools for gaining 
a global perspective of the impact of a mutation or treatment on gene expression.  
Validation of the identified “hits” is usually considered to be necessary before any 
further conclusions can be confidently drawn.  In particular, with regard to the 
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differential regulation of individual genes as a result of the investigated variable 
validation is important.  To state with any confidence that the genes identified in 
our genome-wide analysis are genuinely differentially regulated in p110δ KI 
macrophages we therefore needed to perform validation analyses. 
 
5.6.2. Validation of differential expression using Low Density Taqman Array 
(LDA) 
We chose to perform our validation using low density TaqMan® arrays (LDAs) 
[Materials and Methods].  LDAs allow semi-high throughput comparative 
expression analysis of up to twenty-eight genes (chosen by the end-user) across 
multiple samples simultaneously.  Despite the semi-high throughput format the 
enhanced dynamic range of TaqMan compared to Affymetrix GeneChip® arrays is 
maintained.  We had already identified three unique genes that were found by an 
unbiased computer algorithm to be representative of the p110δ KI genotype 
[Figure 5.10].  We were keen to validate more than three genes as potential 
biomarkers and we therefore ranked all the unique probe sets found to be 
differentially regulated in p110δ KI macrophages by 1 logFC or more (p ≤ 0.05).  
Magnitude of deregulation, irrespective of the direction of change, was prioritised 
as larger differences in protein concentration will usually be easier to reliably 
detect and quantify.  The list of fifteen genes/transcripts to validate based on this 
ranking included the two of the three genes identified by the classifier algorithm as 
most representative of the four categories [Table 5.5. & Figure 5.10].  The third 
gene identified by the classifier algorithm, Paip1 was not available in the LDA 
format at the time we designed and ordered our LDA cards.  We recognise that it 
would be of interest to validate this gene independently to confirm whether it is 
genuinely differentially regulated in p110δ KI macrophages compared to their WT 
counterparts. 
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Gene 
symbol Protein 
Basal 
Fold Change 
(p110δ/WT) logFC adjp value 
Fblim1 filamin binding LIM protein 1 -13.12 -3.71 1.36E-02 
Pdpn Podoplanin -12.73 -3.63 2.14E-05 
Mthfr 
5,10-methylenetetrahydrofolate 
reductase -6.39 -2.80 2.66E-05 
Ubiad1 
UbiA prenyltransferase domain 
containing 1 5.08 2.34 2.95E-04 
Rab6b RAB6B, member RAS oncogene family -5.07 -2.37 2.14E-05 
Nin Ninein 4.98 2.32 2.14E-05 
Rex2   4.54 2.16 9.93E-03 
Plod1 
procollagen-lysine,2-oxoglutarate 5-
dioxygenase 1 -3.70 -1.89 5.93E-04 
Clstn1 calsyntenin 1 3.33 1.74 7.60E-03 
Efhd2 EF hand domain containing 2 -2.91 -1.54 7.10E-04 
Efcab7 EF-hand calcium binding domain 7 -2.66 -1.41 7.10E-04 
Kif1b kinesin family member 1B 2.66 1.41 4.13E-05 
Fst Follistatin 2.47 1.31 1.07E-03 
Htatsf1 HIV TAT specific factor 1 2.11 1.08 4.33E-02 
Ube4b 
ubiquitination factor E4B, UFD2 
homolog (S. cerevisiae) -1.80 -3.49 1.38E-04 
Table 5.5 List of fifteen genes chosen for validation by LDA.  The probe sets listed were chosen 
as candidates for further validation.  The unique probe sets were ranked first, by magnitude of fold 
change and then secondarily to that by p value using Microsoft Office Excel software. Red 
represents an increase and green a decrease in expression in the p110δ KI macrophages compared 
to the WT macrophages.  The two genes identified by classifier analysis that were also found to be 
expressed at the plasma membrane are highlighted in red. 
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5.6.2.1. Validation of differential regulation of chosen genes using additional 
samples 
We reasoned that it was important to perform validation on fresh RNA samples, i.e. 
not the ones that were used for the original Affymetrix experiment. We therefore 
decided to perform validation on new samples from additional WT and p110δ KI 
mice derived from the same colony as those mice used for the Affymetrix 
experiment.   We reasoned that using additional samples would increase our 
confidence in any validation results and in the relationships between the identified 
genes and p110δ [Table 5.6]. 
Assay p110δ KI 
mice 
Mouse source WT control 
mice 
Mouse source 
Affymetrix RNA from 
four p110δ 
KI mice 
Source A 
[Lymphocyte 
Signalling and 
Developments 
Laboratory,Babraham 
Institute, Cambridge] 
Colony:  
homozygous x 
homozygous 
RNA from 
four WT mice 
Source A 
Colony: 
Separate WT x WT line 
originally derived from 
commercial breeder 
LDA RNA from 
three p110δ 
KI mice 
& RNA set  
from 
Affymetrix 
assay  
Source A 
Colony: 
homozygous x 
homozygous 
RNA from 
three WT 
mice 
Source A 
Colony: 
Separate WT x WT line  
Table 5.6. Source of RNA and mice used for Affymetrix and LDA experiments.  Mice were 
sourced from the Lymphocyte Signalling and Developments Laboratory, Babraham Institute, 
Cambridge.  p110δ KI mice were breed as a homozygous line and the WT control mice were 
obtained from a separate WT C57BL/6 line, which was started using mice obtained from a 
commercial breeder (Charles River). 
 
We compared the genome-wide expression of the chosen fifteen genes in WT and 
p110δ KI macrophages in the basal and the LPS-stimulated state using three new 
sets of samples [Table 5.6].  Alongside these, we included a set of the original 
Affymetrix samples to provide a reference point and gain information regarding 
the reproducibility of Affymetrix data by LDA TaqMan®. 
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5.6.3. Validation confirmed differential regulation of seven genes in p110δ 
KI macrophages  
Using LDA comparative expression analysis we obtained quantitative data to 
substantiate the effect of p110δ inactivation on the expression of seven of the 
fifteen genes tested.  The data obtained for these genes and a summary of the data 
obtained by LDA is presented below [Figure 5.11]. 
 
Figure 5.11. Heatmap of comparative gene expression data obtained by LDA and Affymetrix.  
LDA analysis of fifteen genes validated the effect of p110δ inactivation on seven of the genes.  The 
increased expression of Clstn1 in of p110 KI macrophages was confirmed.  The decreased 
expression of Clstn1, Fblim1, Mthfr, Pdpn, Plod1, Rab6b and Ube4b in p110 KI macrophages was 
confirmed. Data qualitatively indicated that Nin expression was also decreased in p110 KI 
macrophages but quantitative data was not obtained due to variation between technical replicates. 
 
5.6.3.1. The expression of Pdpn1, Fblim1, Plod1 and Rab6b was decreased in 
p110δ KI macrophages 
The validation confirmed that the expression of Pdpn, Fblim1, Plod1 and Rab6b was 
decreased in p110δ KI macrophages [Figure 5.12].  Specifically, consistent with the 
data from the Affymetrix analysis we found that Pdpn1 expression was reduced in 
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both the basal and LPS-stimulated p110δ KI macrophages [Figure 5.12a].  The 
expression of Fblim1 was decreased in both basal and LPS-stimulated 
macrophages, with a more substantial repression in the LPS-stimulated state 
[Figure 5.12b].  This result is consistent with the decreased expression of Fblim1 
identified in the basal and LPS-stimulated p110δ KI macrophages in the original 
Affymetrix experiment [Table 5.3].  Furthermore, the same pattern of a more 
substantial decrease in the LPS-stimulated state (logFC –3.89) compared to in the 
basal state (logFC –2.95) was observed in the Affymetrix experiment [Table 5.3 & 
Figure 5.12].   
 
Figure 5.12. Expression of Pdpn1, Fblim1, Plod1 and Rab6b was decreased in p110δ KI 
macrophages. RNA samples derived from three batches of WT and p110δ KI macrophages 
stimulated with control or LPS (1 μg/ml) for 6 h and an additional set of samples from the original 
Affymetrix (Affy samples) experiment were analysed on a LDA microfluidics card to determine gene 
expression.  Expression data were obtained using SDS RQ Manager Software.   Data are presented 
as a ratio of the expression in the p110δ KI macrophages to WT macrophages. 
 
The data obtained regarding the expression of Rab6b in p110δ KI macrophages 
confirmed that Rab6b expression is decreased in p110δ KI basal macrophages and 
also revealed that the magnitude of change may be greater than was initially 
suggested by Affymetrix data.  Additionally, these data revealed that Rab6b 
expression may also be affected to a lesser extent in LPS-stimulated than in p110δ 
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KI basal macrophages.  This difference in magnitude of change compared to the 
Affymetrix data and the observation of an effect in the LPS-stimulated state are 
both likely to be as a result of the enhanced sensitivity and dynamic range of 
TaqMan assays compared to Affymetrix GeneChips®.  Together these results 
confirm our Affymetrix results and strongly suggest that p110δ activity positively 
regulates the expression of Pdpn, Fblim1, Plod1 and Rab6b in macrophages.  
 
5.6.3.2. Expression of Clstn1 was increased in basal and LPS-stimulated p110δ 
KI macrophages 
Our validation has confirmed the increased expression of Clstn1 in p110δ KI 
macrophages in the basal state that was observed in the Affymetrix experiment 
[Figure 5.13].  In the Affymetrix experiment we identified Clstn1 as differentially 
regulated in basal but not LPS-stimulated p110δ KI macrophages.  This data is 
therefore consistent with the original Affymetrix data.  We noticed that there was 
also an increase in the LPS-induced state in all samples tested including those from 
the original Affymetrix experiment [Figure 5.13 & 5.15].  Therefore, the increased 
expression of Clstn1 may also occur in LPS-stimulated p110δ KI macrophages but 
to a lesser extent [Figure 5.13].  As with the detection of differential regulation of 
Rab6b in LPS-stimulated p110δ KI macrophages, we suggest that this difference to 
the Affymetrix data reflects the enhanced sensitivity of qPCR compared to 
Affymetrix microarrays. 
 
Figure 5.13. Expression of Clstn was increased in basal and to a lesser extent LPS-stimulated 
p110δ KI macrophages.  RNA samples derived from three batches of WT and p110δ KI 
macrophages stimulated with control or LPS (1 μg/ml) for 6 h and an additional set of samples 
from the original Affymetrix (Affy samples) experiment were analysed on a LDA microfluidics card 
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to determine gene expression.  Expression data was obtained using SDS RQ Manager Software.   
Data are presented as a ratio of the expression in the p110δ KI macrophages to WT macrophages. 
 
5.6.3.3. Expression of Mthfr and Ube4b was decreased in LPS-stimulated p110δ 
KI macrophages  
Our validation study also confirmed that both Mthfr and Ube4b were unaffected in 
basal p110δ KI macrophages but were decreased in LPS-stimulated p110δ KI 
macrophages [Figure 5.14].   In fact in both cases there does seems to be a minimal 
effect in the basal state but this is below the threshold of twofold (1 log FC) [Figure 
5.14].  These data together with the original Affymetrix data suggest that p110δ 
activity may be required for the LPS-induced expression of Mthfr and Ube4b in 
macrophages.   
 
Figure 5.14. Expression of Mthfr and Ube4b was decreased in LPS-stimulated p110δ KI 
macrophages. a. RNA samples derived from three batches of WT and p110δ KI macrophages 
stimulated with control or LPS (1 μg/ml) for 6 h and an additional set of samples from the original 
Affymetrix (Affy samples) experiment were analysed on a LDA microfluidics card to determine 
comparative expression of Mthfr.  Expression data were obtained using SDS RQ Manager Software.   
Data are presented as a ratio of the expression in the p110δ KI macrophages to WT macrophages. b. 
Samples were prepared and analysed as described in a. to determine comparative expression of 
Ube4b. 
 
5.6.6.3. The differential expression of Nin in p110δ KI macrophages was not 
confirmed  
The data obtained regarding the expression of Nin were inconclusive.  We did not 
performed fold change calculations on the data obtained for the expression of this 
gene as the CT values were not sufficiently tight across the three technical 
replicates.  We suspect this is as a result of very low expression of this gene, which 
was outside of the range of accurate quantification by TaqMan.  Nevertheless, the 
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raw CT values provided some qualitative evidence that the expression of this gene 
may be affected by p110δ inactivation [Table 5.7]. 
 
Stimulation WT sample WT CT p110δ KI sample p110δ KI CT 
Control Affymetrix 5 35.02 Affymetrix 11 30.31 
Control Affymetrix 5 36.48 Affymetrix 11 33.27 
Control Affymetrix 5 33.13 Affymetrix 11 33.54 
LPS Affymetrix 6  32.3 Affymetrix 12 33.51 
LPS Affymetrix 6 32.90 Affymetrix 12 37.55 
LPS Affymetrix 6 39.35 Affymetrix 12 33.24 
Control WT 1 32.94 p110δ KI 1 33.17 
Control WT 1 34.14 p110δ KI 1 35.94 
Control WT 1 29.41 p110δ KI 1 36.37 
LPS WT 1 30.85 p110δ KI 1 33.78 
LPS WT 1 Undetermined p110δ KI 1 35.64 
LPS WT 1 35.05 p110δ KI 1 33.56 
Control WT 2 32.67 p110δ KI 2 32.58 
Control WT 2 28.96 p110δ KI 2 34.26 
Control WT 2 32.61 p110δ KI 2 32.41 
LPS WT 2 29.80 p110δ KI 2 32.37 
LPS WT 2 31.68 p110δ KI 2 35.82 
LPS WT 2 35.16 p110δ KI 2 33.80 
Control WT 3 31.49 p110δ KI 3 32.11 
Control WT 3 30.58 p110δ KI 3 33.07 
Control WT 3 31.64 p110δ KI 3 35.70 
LPS WT 3 30.53 p110δ KI 3 34.22 
LPS WT 3 35.29 p110δ KI 3 35.84 
LPS WT 3 31.21 p110δ KI 3 37.37 
Table 5.7 Raw CT values obtained for Nin expression in Wt and p110δ KI macrophages. Raw 
CT values were obtained for the expression in Nin in four Wt basal sample, four WT LPS-stimulated 
samples alongside four p110δ KI basal and p110δ KI LPS-stimulated samples.  The CT values were 
all “flagged” by the SDS RQ software indicating that they should not be used for data analysis. 
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5.6.4. Summary of validation findings 
In summary, we have confirmed that the expression of seven genes was 
differentially regulated in p110δ KI macrophages in the same manner as observed 
in our Affymetrix study [Figure 5.15].  The expression of Clstn1 was increased in 
p110δ KI macrophages in the basal state and to a lesser extent in the LPS-
stimulated state [Figure 5.13 & 5.15].  Fblim1, Pdpn, Plod1, and Rab6b were found 
to be decreased in both basal and LPS-stimulated macrophages [Figure 5.12 & 
5.15].   Two of the genes, Ube4b and Mthfr were found to be affected by p110δ 
inactivation only in LPS-stimulated cells, suggesting p110δ activity may contribute 
to the induction of these genes by LPS [Figure 5.14 & 5.15]. 
 
Figure 5.15. Heatmap summary of the validation of the differential regulation of seven genes 
p110δ KI macrophages compared to in WT macrophages in basal (-) and LPS-stimulated (+) 
conditions. Data obtained by LDA confirmed the differential expression of seven genes Clstn1, 
Fblim1, Mthfr, Pdpn, Plod1, Rab6b and Ube4b) in p110δ KI macrophages compared to their WT 
counterparts.  
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5.7. Validation of p110 delta-regulated gene expression at the 
protein level 
We decided to focus our attention on the relationship between Rab6b expression 
and p110δ activity for a number of reasons.  First, there is a correlation between 
the highly restricted tissue distributions of Rab6b and of PIK3CD expression.  
Rab6b is reported to be highly expressed in the brain and is apparently absent or 
minimally expressed in other major organs [172].  Asides from in brain tissue, 
Rab6b cDNA was found to be abundant in human melanocytes suggesting it may be 
highly expressed in these cells [172-173].   Likewise, p110δ is also expressed in 
both melanocytes and neurons [15-16].  In addition, the SK-N-SH neuroblastoma 
cell line that Fransen’s group found is also highly enriched with Rab6b mRNA also 
expresses significant levels of p110δ [172].  In fact, melanocytes and brain cells are 
two of the non-immunological cell types in which p110δ is expressed at detectable 
levels.  A second reason that we chose to focus on Rab6b was that at the time we 
obtained our LDA validation results, an independent laboratory identified Rab6b as 
a gene affected by p110δ inactivation [50].  The authors identified reduced 
expression of Rab6b in p110δ KI Tregs in a genome-wide expression analysis [50].   
There was a final compelling reason that directed us to focus on the link between 
p110δ activity and Rab6b expression as opposed to following up one of the genes 
we have highlighted as promising biomarker candidates.  We had significant 
reason to believe that unlike the majority of the genes that we had validated with 
regards to their differential expression in p110δ KI macrophages, Rab6b may be 
genuinely affected by the loss of p110δ activity.  The evidence leading us to doubt 
the genuine effect of inactivation of p110δ on the expression of the other genes but 
not Rab6b are discussed in detail in the subsequent chapter.  Here we simply state 
that we discovered that the majority of the genes identified are located within very 
close proximity (within or next to) of the locus where the Pik3cd gene encoding 
p110δ is located, whilst Rab6b is encoded on a separate chromosome.  The 
potential implications of this finding are the discussed alongside its discovering in 
the following chapter. 
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5.7.1. Rab6b protein was reduced in p110δ KI macrophages 
There were no published data regarding the expression of Rab6b in leukocytes and 
so our first task was simply to confirm whether rab6b protein is expressed at 
detectable levels in macrophages.   We used a commercially available antibody that 
the manufacturers claimed is specific to rab6b.  Using the antibody we were able to 
detect a band at the appropriate molecular weight in macrophage lysates [data not 
shown].  We subsequently compared the levels of rab6b in WT and p110δ KI 
macrophages derived from three mice per genotype, and we found it was 
consistently decreased in the later genotype [Figure 5.16].  This result is consistent 
with both our Affymetrix and subsequent LDA data, which indicated that Rab6b 
expression was reduced in p110δ KI macrophages.  Moreover, we have shown that 
this decrease in gene expression translates into a significant decrease in protein 
expression.  We included both basal and LPS-stimulated samples and found that 
that LPS-stimulation had no impact upon the expression of Rab6b [Figure 5.16].  
We also probed the membrane for rab6a and found it was expressed at similar 
levels in both WT and p110δ KI macrophages [Figure 5.16].  These results strongly 
suggest that in primary murine macrophages p110δ regulates Rab6b expression 
and does not affect Rab6a expression. 
 
Figure 5.16. Decreased expression of rab6b protein in p110δ KI macrophages compared to 
WT macrophages.  Primary macrophages were plated in complete medium containing CSF-1. The 
following day the cells were stimulated with LPS for 30 min and cell lysates were extracted and 
immunoblotting was used to measure the indicated proteins.  
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We note that the decrease in rab6b in p110δ KI samples was consistent, 
irrespective of the p-Akt level.  The level of p-Akt in the p110δ KI macrophages 
does not appear to be reduced.  In fact, the trend in the three samples was towards 
increased p-Akt in p110δ KI macrophages compared to the WT samples in the 
basal state.  This is not consistent with previous publications in which p-Akt levels 
have been shown to be lower in p110δ KI macrophages but all previous data that 
we are aware of was gained from macrophages deprived of CSF-1 for 12-24 h [1, 
79].  In this experiment and all our other experiments with primary macrophages 
we have used normal growth conditions including CSF-1.  We did note that in the 
p110δ KI macrophages the induction of p-Akt in response to LPS appears to be less 
substantial than in the WT macrophages [Figure 5.16].  We also noted that in this 
experiment, the LPS-stimulated induction of p-p38 in the p110δ KI macrophages 
was significantly repressed [Figure 5.16].  This reduction in LPS-induced p-p38 in 
p110δ KI macrophages has previously observed by another member of our 
laboratory in CSF-1-deprived macrophages [174].  In our experiments using 
immortalised macrophage cell lines we consistently observed that p110δ-selective 
inhibition did not affect LPS-induced p-p38 [Chapter 4, Figure 4.1].   
 
5.7.2. Normal expression of rab6b protein in whole brain tissue derived 
from p110δ KI mice 
As stated above rab6b was initially reported as a brain-specific rab6 isoform [172] 
and p110δ is expressed in neurons[15].  We were therefore interested to 
determine whether brain tissue derived from p110δ KI mice would express 
reduced levels of rab6b.  We compared the expression of rab6b in brain tissue 
from three p110δ KI mice and three WT mice.  We probed for the expression of 
Rab6b and p110δ as well as p-Akt.  The results firstly confirm that rab6b is highly 
expressed in brain tissue as published by Opdam et al. [172][Figure 5.17].  
Interestingly, we found that the expression of rab6b was unaffected in the p110δ 
KI brain samples [Figure 5.17].  The p-Akt in the WT and p110δ KI brain samples 
also appears to be consistent [Figure 5.17].  
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Figure 5.17.  Expression of rab6b is unaffected in p110δ KI brain tissue compared to 
expression in WT brain tissue.  Brains were removed from culled mice and washed with PBS to 
remove excess blood before being immediately lysed in ice-cold lysis buffer.  The expression of the 
indicated proteins was measured in the lysates using immunoblotting. 
 
The normal expression of Rab6b in p110δ KI whole brain suggests that our theory 
that the highly restricted Rab6b tissue expression that correlated with p110δ 
expression could be regulated by p110δ activity is incorrect.  It instead points us 
towards a hypothesis that the regulation of Rab6b expression by p110δ is 
leukocyte-specific.  Interestingly one of the brain cell types in which rab6b is 
reported to be highly expressed was microglial cells.  Microglial cells are in fact 
tissue-specific resident macrophages that are derived from leukocyte precursors.  
It would be interesting to assess whether p110δ KI microglial cells express 
reduced levels of Rab6b, or whether other leukocytes from p110δ KI mice express 
less Rab6b. 
Indeed, shortly after we completed our LDA validation of our Affymetrix results 
another group published a study linking p110δ inactivation to reduced levels of 
Rab6b.  Patton et al. compared the genome-wide expression of p110δ KI Tregs to 
WT Tregs and identified differential expression of 125 genes (1 logFC, p≤ 0.01) 
including Rab6b, which was decreased in the p110δ KI Tregs [50].  Patton et al. did 
not confirm that this decreased expression of Rab6b translated into reduced rab6b 
protein [50].  Together the results of this publication and our data on Rab6b 
strongly support a role for p110δ in the positive regulation of Rab6b expression in 
leukocytes. 
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5.7.3. Validation of the specificity of the commercial rab6b-specific antibody  
Whilst rab6a is ubiquitously expressed, rab6b is reported to be highly expressed in 
brain but with no detectable expression in the liver amongst other tissues.  At the 
time we took brains for the previous experiment we also removed livers from the 
mice.  We therefore reasoned that if the rab6b-specific antibody is indeed specific 
to rab6b then we would observe a strong signal in brain but not in liver.  We also 
probed for p110δ which is also expressed in brain tissue but not in livers as a 
control and found higher p110δ expression in the brain samples than the liver 
samples [Figure 5.18].  The rab6b antibody detected a strong signal in the brain 
and but detected no signal in the liver cells [Figure 5.18].  These results support 
the manufacturer’s claims regarding the specificity of this antibody for rab6b and 
not rab6a [Figure 5.18].  These results do strongly support the specificity of the 
rab6b antibody but ideally we would confirm its specificity by testing its ability to 
detect recombinant rab6b and rab6a protein. 
 
Figure 5.18  The Rab6b-selective antibody detects a signal in murine brain tissue but not 
liver tissue.   Brain tissue was lysed as described in Figure 5.17 and livers were extracted and 
processed in the same way as the brains.  The expression of rab6b, p110δ and p-Akt in the samples 
was compared by immunoblotting. 
 
 
5.8. Conclusion 
Our genome-wide expression analysis of p110δ KI macrophages compared to WT 
macrophages identified only twenty-five differentially regulated unique probe sets 
in the former cells.  Specifically our Affymetrix data revealed that seventeen probe 
sets, interrogating fourteen known genes were differentially regulated in basal 
growing p110δ KI macrophages compared to their counterparts.  In LPS-
stimulated p110δ KI macrophages twenty probe sets were differentially regulated, 
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of which twelve were common to those affected in the basal state.  This represents 
less than 0.1% of the genome and furthermore, a number of these genes are likely 
to represent false positives and therefore it is apparent that the role of p110δ in 
the regulation of macrophage gene expression is restricted to a small number of 
genes.  Even after LPS-stimulation only eight additional genes are regulated by 
p110δ.  This suggests that p110δ plays a minimal role in the induction of 
transcriptional changes in response to LPS in macrophages.  Yet, in fact we cannot 
conclude from this data that p110δ plays a minimal role in LPS-stimulated gene 
regulation as we have merely taken a snapshot of the LPS-induced responses.  It is 
possible that at either an earlier or a later time point after LPS-stimulation a much 
larger number of genes are affected by p110δ inactivation.  The role of p110δ in 
LPS-driven responses was not our focus but if this had have been our primary 
interest a time course experiment might be most suitable.  
We have identified more than 100 less probe sets differentially regulation in p110δ 
KI macrophages compared to the number the Okkenhaug group identified in 
p110δ KI Tregs [50].  This could imply that p110δ activity is less important in 
macrophages than it is in adaptive immune cells such as Tregs.  Such theories 
would need further data analysis as the experiments were performed separately 
and the protocols used may not have been similar.  Ideally a comparison across 
experiments requires normalisation across all chips and adjustment for inter-
experiment batch effects [175]. 
The most relevant network identified by IPA which relates to three key functions 
integral to immune function (Inflammatory response, antimicrobial response and 
cell-to-cell contacts) is consistent with what is known about the impact of p110δ 
loss on in vivo or in vitro immunity.  Having said that, we did not identify any 
“classic inflammatory” genes and we identified just eight genes that were 
specifically affected by p110δ activity downstream of LPS in the genome-wide 
expression analysis.  We have confirmed that Ube4b and Mthfr expression are 
repressed in specifically in p110δ KI macrophages stimulated with LPS and 
therefore it would be interesting to learn more about how this might impact upon 
LPS-driven responses. 
We have found that the expression of Rab6b is reduced in p110δ KI macrophages 
by Affymetrix and subsequently confirmed this finding in an additional set of RNA 
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using Taqman® LDAs.  Importantly, we have confirmed that this differential 
expression translates to reduced levels of rab6b protein in p110δ KI macrophages 
[Figure 5.16].  The fact that we and another independent group have both 
identified Rab6b downstream of p110δ inactivation in primary leukocytes strongly 
supports our findings.  We have also expanded on this finding by investigating the 
effect of the p110δ KI mutation on the expression of rab6b in the brain, where it 
was reported to be highly enriched.  Our data indicated that rab6b expression is 
unaffected in p110δ KI brain tissue.  We suggest based on these data that p110δ 
may regulate Rab6b expression in a leukocyte specific manner. 
There was no overlap between the genes affected by p110δ inactivation in these 
primary macrophages and in our pilot study using RAW 264.7 macrophages.  We 
were aware that there were two variables that might be responsible for this 
difference.  First, this is a comparison between primary macrophages and a 
transformed macrophage cell line.  Secondly, the method of p110δ inactivation was 
different as in the RAW 264.7 study, p110δ was inhibited using a selective p110δ-
inhibitor, whilst in this study p110δ was genetically inactivated.  In theory, the 
p110δ KI mutation should have a very similar effect as pharmaceutical 
inactivation.  We were curious to note that substantially more genes were found to 
be differentially regulated by p110δ inactivated RAW 264.7 macrophages than in 
primary p110δ KI macrophages.  This is perhaps the converse of what we might 
have predicted based on data regarding the decreased dependence of macrophage 
cell lines on p110δ activity at the signalling level.  On the other hand, IC87114 may 
have off-target effects which could account for a number of the gene expression 
changes.  We also must bear in mind that after the removal of outliers the RAW 
264.7 macrophage pilot study was performed on just two samples per condition.  
This makes the results less reliable, and may have increased the number of genes 
that reached the statistical stringency threshold that we set, thereby increasing the 
number of false positives.   Therefore, the difference in number of genes identified 
in RAW 264.7 macrophages chronically treated with IC87114 compared to those 
identified in the p110δ KI macrophages should be treated with caution and no 
conclusions can reliably be drawn on this point.  What we can perhaps say with 
greater confidence is that the genes identified as differentially regulated in p110δ 
KI macrophages are not differentially regulated in RAW 264.7 macrophages 
chronically treated with a p110δ-selective inhibitor.   To be certain of this 
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conclusion we would need to confirm this with an additional batch of RAW 264.7 
macrophages chronically treated with IC87114.   
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CHAPTER 6 
 
6. INVESTIGATING THE EFFECTS OF PHARMACOLOGICAL 
INACTIVATION OF P110 DELTA ON THE PRIMARY 
MACROPHAGE TRANSCRIPTOME 
 
6.1. Introduction 
We chose to continue to pursue our objective of identifying potential biomarkers of 
p110δ inactivation.  We therefore decided to set aside the results of the pilot study 
and proceeded by determining which genes are differentially regulated in primary 
macrophages chronically treated with IC87114.  We hoped that some of the genes 
identified in the p110δ KI macrophages would also be affected in primary 
macrophages chronically treated with IC87114.   
 
6.2. The effect of IC87114 treatment on Akt activation 
Before proceeding with the microarray we confirmed that basal and LPS-induced 
p-Akt was indeed repressed by IC87114 in primary macrophages.  Our results 
indicate a roughly twofold decrease in the p-Akt in both conditions [Figure 6.1]. 
 
Figure 6.1. p110δ-selective inhibition reduced basal and LPS-induced p-Akt.  WT primary 
macrophages were plated in complete media containing 10% FBS and CSF-1 (20 ng/ml).  The 
following day the cells were pre-treated with p110δ-selective IC87114 (1 µM), pan-PI3K inhibitor 
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LY294002 (5 µM) or DMSO control for 2 h prior to 30’ stimulation with LPS (1 µg/ml).  Lysates 
were analysed for the indicated antibodies using standard immunoblotting techniques. 
 
6.2.1. Activation of Akt in macrophages differentiated in the presence of 
IC87114 
We decided to compare the expression of macrophages that had been 
differentiated in the presence of IC87114 to those differentiated in the presence of 
DMSO.  In doing so, we aimed to mimic the p110δ null conditions during that exist 
during the differentiation period of p110δ KI macrophages.   As with the longer 
term inhibition used in the RAW 264.7 study, we felt that this was also more 
relevant to clinical use of p110δ inhibitors than a brief post-differentiation 
treatment.  We therefore assessed the levels of p-Akt in primary macrophages after 
differentiation in the presence of DMSO or IC87114, compared to macrophages 
treated with IC87114 or LY294002 for 2 h or 24 h [Figure 6.2]. 
 
Figure 6.2. Long-term pharmacological inactivation of p110δ in WT macrophages represses 
p-Akt.  WT primary macrophages were extracted and cultured in the presence of DMSO or p110δ-
selective IC87114 (1 µM) for the duration of the differentiation period (7 d).  The cells were plated 
on day seven in complete medium containing 10% FBS and CSF-1 (20 ng/ml) and pre-treated with 
the indicated inhibitors.  24 h later the cells were stimulated with LPS (1 µg/ml) for 30 min and cell 
lysates were obtained and analysed for the indicated proteins using immunoblotting. 
 
6.3. Genome-wide expression analysis experimental design and 
implementation  
We decided to obtain genome-wide expression data for WT macrophages that had 
been differentiated and cultured in the presence of either IC87114 (1 µM) or DMSO 
for the duration of the differentiation period and during the final experiment 
[Figure 6.3].  As with the previous microarray experiment, we treated the two 
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groups with either control or LPS for 6 h prior to extracting total RNA for 
microarray analysis [Figure 6.3]. 
 
 
Figure 6.3. Schematic of the differentiation of WT macrophages in the presence of IC87114 
or DMSO. Bone marrow derived macrophage precursor cells were extracted from WT mice and 
cultured in medium containing a starting concentration of p110δ-selective 1 μM IC87114.  Plates 
were topped up with 5 ml of complete medium containing 10% FBS, CSF-1 (20-30 ng/ml) and 
IC87114 (1 μM) on day 1 (d1), day 4 (d4) and day 6 (d6).  The plates were split as per the modified 
protocol on day 3 (d3) and cells were replated in fresh complete medium containing 10% FBS, CSF-
1 (20-30 ng/ml) and IC87114 (1 μM). 
 
6.4. Investigating the genome-wide expression impact of 
IC87114 treatment 
 
6.4.1. Extraction of raw expression data and normalisation 
The samples were analysed as described in Chapters 4 and 5.  Briefly, labelled 
fragmented RNA samples were hybridised to GeneChips® before staining.  
Subsequently fluorescence data was obtained and extracted and processed to 
obtain raw expression values.  The raw data was then extracted on our behalf by 
Dr H. Edwards, Dr P. Hales and Ms E. Gadaleta.  Briefly the dataset was normalised 
using the standard GC-RMA normalisation algorithm and data for the top 10,000 
most variable probe sets was then extracted.    
 
6.4.2. Multivariance Analysis to determine sample clusters 
First, we performed PCA, which indicated that the major differential factor in the 
data set was the treatment of LPS, as was the case with the p110δ KI compared to 
WT study [Figure 6.4].  More in-depth analysis revealed that the samples did not 
cluster according to p110δ activity status (IC87114 versus DMSO).  
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Figure 6.4.  PCA analysis revealed samples clustered according to LPS stimulation status 
rather than genotype. PCA was performed on expression data to determine separation of samples.  
Samples separated according to stimulation status (unstimulated or LPS-stimulated but not 
according to genotype (WT or p110δ KI).  
 
6.4.3. The expression of the classifier probe sets was not sufficient to 
identify inactivation of p110δ 
The best way to confirm the validity of the set of computer-identified classifiers 
found to be most representative of the p110δ KI state is to test the algorithms 
ability to assign a new data set to the appropriate categories.  We were interested 
to find out whether the classifier algorithm would assign the IC87114-treated 
samples as p110δ KI and the DMSO samples as WT.  In fact, with the help of Dr P. 
Hales we found that the algorithm failed to assign the samples to the “correct” 
categories and assigned all samples to the WT genotype.  The classifier set was 
sufficient to correctly identify whether or not samples were treated with LPS 
[Figure 6.5].   
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Figure 6.5. The classifier probe set produced by analysis of p110δ KI versus WT study did not 
classify WT IC87114 samples as p110δ KI.  The data from the WT IC87114 study was entered 
ungrouped into the programme and the algorithm failed to assign the IC87114-treated samples to 
the p110δ KI group based on the expression of the six classifier probe sets.    
 
6.4.4. Identification of genes differentially regulated in WT macrophages 
differentiated in IC87114  
We next extracted a list of probe sets affected by differentiation in the presence of 
IC87114 in basal and or LPS-stimulated conditions with the help of Dr H. Edwards.  
Eight probe sets, or seven interrogating known genes, were differentially 
expressed in basal WT macrophages differentiated in the presence of IC87114 
compared to in DMSO [Table 6.1].  In the LPS-stimulated state, just three probe 
sets were differentially regulated, interrogating two genes and one RIKEN 
sequence.  The genes affected in the LPS and basal states were all different [Table 
6.2].  
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Basal 
Probe Set ID Gene 
Symbol 
Protein logFC adjP value 
1418057_at Tiam1 T-cell lymphoma invasion and 
metastasis 1 
-1.448 2.02E-02 
1456212_x_at Socs3 suppressor of cytokine signaling 3 1.421 2.29E-02 
1424727_at Ccr5 chemokine (C-C motif) receptor 5 -1.367 4.54E-02 
1424896_at Grp85 G protein-coupled receptor 85 -1.363 2.29E-02 
1426278_at Ifi27I2a interferon, alpha-inducible protein 
27 like 2A 
-1.202 4.54E-02 
1415949_at NA NA -1.156 4.54E-02 
1449799_s_at Pkp2 plakophilin 2 -1.090 4.54E-02 
1428663_at Sgms2 sphingomyelin synthase 2 1.019 4.54E-02 
Table 6.1. Probe sets differentially expressed in basal WT macrophages differentiated and 
cultured in the presence of IC87114. Genes are ranked according to magnitude of deregulation, 
known genes are highlighted in bold and genes increased or decreased in p110δ KI macrophages 
are highlighted in red or green respectively. 
 
 
 LPS-stimulated 
Probe Set 
ID 
Gene Symbol Protein logFC adjP value 
1440047_at Socs1 suppressor of cytokine signaling 1 -1.038 3.43E-03 
1456509_at 1110032F04Rik RIKEN cDNA 1110032F04 gene -1.142 4.94E-02 
1451322_at Cmbl carboxymethylenebutenolidase-like 
(Pseudomonas) 
-1.462 3.82E-02 
Table 6.2. Probe sets differentially regulated in LPS-stimulated WT macrophages 
differentiated and cultured in the presence of IC87114. Genes are ranked according to 
magnitude of deregulation and known genes are highlighted in bold and genes increased or 
decreased in p110δ KI macrophages are highlighted in red or green respectively. 
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6.5. Comparison of pharmacological and genetic inactivation of 
p110 delta 
 
We subsequently compared these lists to the list of probe sets found to be 
differentially regulated in p110δ KI macrophages and were surprised to find that 
there was no overlap.  The genes identified as differentially regulated in WT 
macrophages differentiated in IC87114 were not differentially regulated in p110δ 
KI macrophages.  Furthermore, the genes were also entirely dissimilar to those 
affected by IC87114-treatment in RAW 264.7 macrophages.  We decided to 
attempt to investigate the unexpected finding that the genes identified in the two 
primary macrophages do not overlap with each other or with those identified in 
the pilot study using RAW 264.7 macrophages. 
 
6.5.1. The genes differentially regulated in p110δ KI macrophages were 
not affected by IC87114 
We reasoned that when using the more sensitive TaqMan-based LDA cards we 
might observe some impact of IC87114 on the genes affected in p110δ KI 
macrophages.  We therefore obtained comparative expression data for the fifteen 
p110δ KI validation genes [Chapter 5, Table 5.5] in WT macrophages differentiated 
in IC87114 (WT-IC87114) compared to those differentiated in DMSO (WT-DMSO).  
In fact, the results confirmed the Affymetrix results; these fifteen genes are not 
differentially regulated in WT-IC87114 macrophages [Data not shown].  These 
data are consistent with the results of the two Affymetrix arrays and thus, allow us 
to confirm with a greater degree of certainty, that the effects of genetic and 
pharmacological inactivation on macrophage transcription are distinct.  Although, 
we only included genes identified in the p110δ KI study on the LDA cards and were 
as such unable to perform the same analysis in reverse.  We cannot therefore state 
as confidently that the genes affected by IC87114-treatment are indeed not 
affected by the p110δ KI macrophages, but our genome-wide expression analysis 
suggests this is the case. 
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We formulated a number of theories to explain this surprising lack of overlap 
between the effects of IC87114 treatment of a cell line, primary macrophages and 
of genetic inactivation of p110δ.  We have addressed a number of them, but due to 
time constraints or resource limitations some of the theories have not been tested 
and are considered beyond the scope of this project/PhD.  We first considered in 
what ways the WT IC87114-treated macrophages were different to the p110δ KI 
macrophages.  The first obvious difference is of course the mode of inactivation of 
p110δ; pharmacological compared to genetic.  Secondly, the timing of the 
inactivation of p110δ differs as the WT-IC87114 macrophages were differentiated 
from WT precursor cells extracted from the WT bone marrow environment of a 
WT mouse, whereas the p110δ KI cells are cultured from p110δ KI precursors 
extracted from a p110δ KI environment. 
 
 
Figure 6.6. Comparison of the genome-wide expression analysis of the effects of genetic and 
pharmacological inactivation of p110δ. The same macrophage extraction and differentiation 
protocol was followed for both studies.  The major differences between the two studies are firstly, 
the precursor cells and marrow from which they are derived that are p110δ KI or WT in the genetic 
and pharmacological study respectively.  Secondly, the WT macrophages are of supplemented with 
IC87114 (1 μM) to inhibit p110δ activity throughout and after differentiation, whilst the p110δ KI 
macrophages lack p110δ activity as a result of the mutation. 
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6.5.1.1. Testing the concentration of IC87114 in the medium during 
differentiation 
We first decided to address a potential technical issue that could be responsible for 
the lack of deregulation of the same genes in the WT-IC87114 macrophages as in 
the p110δ KI macrophages. We reasoned that the IC87114 stability could have 
been insufficient to maintain an inhibitory concentration between fresh medium 
additions which contained the inhibitor.  We therefore analysed the concentration 
of IC87114 in media samples that had been previously taken throughout the seven 
day differentiation process to test whether this was the case and whether the 
IC87114 was maintained throughout at a suitable inhibitory concentration.  The 
mass spectrometry was kindly performed by Dr M. Jairaj at UCB.  The samples 
were taken from the experiment used to generate the WT-IC87114 and WT-DMSO 
macrophages analysed on the LDA card as detailed above.  The results indicate that 
the concentration of IC87114 was maintained at sufficient levels throughout the 
seven day differentiation period [Figure 6.7].  We therefore felt confident that 
insufficient concentration of IC87114 in the media was not responsible for the 
absence of overlapping effects of the genetic and pharmacological inactivation of 
p110.   
 
Figure 6.7.  The concentration of IC87114 in the medium was within a suitable range 
throughout the course of the experiment. Medium samples were taken throughout the course of 
the experiment and the concentration of the IC87114 was then measured against a set of medium 
standards with IC87114 at concentrations from 0 μM to 100 μM [This analysis was performed by 
Dr. M. Jairaj, UCB]. 
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6.5.2. Analysis of the chromosomal locations of the genes identified  
We decided to map the locations of the genes affected by the p110δ KI mutation in 
primary macrophages.  The results revealed that twelve of the nineteen probe sets 
that are mapped to chromosomal locations (63% of the genes) are located on 
chromosome four [Table 6.3].   
Gene Symbol Protein Chromosome 
Fblim1 filamin binding LIM protein 1 4 
Pdpn Podoplanin 4 
Kif1b Kinesin family member 1b 4 
Plod1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 4 
Ubiad1 UbiA prenyltransferase domain containing 1 4 
Efhd2 EF hand domain containing 2 4 
Efcab7 EF-hand calcium binding domain 7 4 
Vamp3 vesicle-associated membrane protein 3 4 
Mthfr 5,10-methylenetetrahydrofolate reductase 4 
Ube4b ubiquitination factor E4B, UFD2 homolog (S. 
cerevisiae) 
4 
Clstn1 calsyntenin 1 4 
Miip migration and invasion inhibitory protein 4 
Fst Follistatin 13 
Pacsin3 protein kinase C and casein kinase substrate in 
neurons 3 
2 
Htatsf1 HIV TAT specific factor 1 X 
Sh2d1b1 SH2 domain protein 1B1 1 
Paip1 polyadenylate binding protein-interacting protein 1 13 
Rab6b RAB6B, member RAS oncogene family 9 
Nin Ninein 12 
Table 6.3.  Location of nineteen mapped probe sets differentially regulated in p110δ KI 
macrophages.  The chromosome on which each gene is located in the murine genome was 
identified using a genome browser. Genes found to be expressed at higher levels in p110δ KI 
macrophages compared to WT macrophages are highlighted in red, those expressed at lower levels 
in these mutant macrophages are highlighted in green. 
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6.5.2.1. A cluster of the differentially regulated genes around the Pik3cd gene 
Next, we performed positional gene enrichment (PGE) analysis to determine the 
statistical significance of the clustering of the genes found to be differentially 
regulated in p110δ KI macrophages.  To do this we employed an open access PGE 
web tool [176].  This analysis confirmed that the enrichment of genes differentially 
regulated in p110δ KI macrophages on chromosome four was highly significant.    
Importantly this analysis also identified a specific locus (E1) in which this 
enrichment was concentrated.  Indeed, the statistical significance of this enriched 
region was assigned an adjp value of 1.74 x10 -25 [Figure 6.8].  The Pik3cd gene that 
encodes p110δ is encoded within this same locus. 
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Figure 6.8. Positional gene enrichment analysis revealed a very highly statistically significant cluster of genes enriched on chromosome four, locus E1. The list 
of probe sets differentially regulated in p110δ KI macrophages was uploaded to the PGE analysis tool and the enrichment of those genes mapped to specific chromosome 
locations was calculated.  The p value was adjusted to account for the multiple testing integral to the algorithm [176]. 
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We also checked for PGE in the lists of genes identified in the WT-IC87114 study 
and the pilot RAW 264.7 study and found no significant PGE within either of these 
gene lists [data not shown].   
 
6.5.3. Unlinked genes such as Rab6b are not affected by IC87114 
This enrichment is in fact the final compelling reason why we chose to follow up 
the expression of Rab6b at the protein level.  Unlike the other genes that we 
validated, Rab6b was found to be differentially regulated in p110δ KI macrophages 
but importantly is not linked to Pik3cd. [Figure 6.8 & Table 6.3].  Nevertheless, 
despite its independence from the E1 locus, our LDA analysis of Rab6b mRNA 
expression in WT-IC87114 macrophages had confirmed that it was also not 
affected by pharmacological inactivation of p110δ.  This suggested to us that there 
may be multiple factors contributing to the differential effects of genetic and 
pharmacological inactivation of p110δ on the transcriptome. 
We reasoned that perhaps Rab6b expression required a more complete inhibition 
of p110δ activity that was achieved by 1 µM of IC87114 and we have performed 
two experiments to test this theory.  We first compared the expression of the 
fifteen “p110δ KI genes” represented on the LDA cards, including Rab6b in WT and 
heterozygous p110δ KI macrophages.  The preliminary data regarding the 
expression of these genes, including Rab6b indicated that they are not 
differentially regulated in heterozygous p110δ KI macrophages [data not shown].  
These data would need to be confirmed with an additional experiment before it 
could be presented confidently.  Nevertheless, this apparent lack of differential 
regulation of Rab6b in heterozygous p110δ KI macrophages supports the 
possibility that disruption of Rab6b expression requires a complete ablation of 
p110δ activity.  Consequently, we chose to test whether differentiation in the 
presence of a higher dose of IC87114 was sufficient to reduce rab6b protein levels.  
We extracted primary macrophages from three WT mice and differentiated them 
separately in the presence of either DMSO, 1 µM IC87114 or 5 µM IC87114 for the 
duration of the seven day differentiation period.  Analysis of lysates obtained from 
these macrophages revealed that the repression of p-Akt was enhanced in the cells 
grown in the presence of 5 µM IC87114 compared to those grown in 1 µM IC87114 
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[Figure 6.9].  Rab6b was not reduced in macrophages differentiated in the 
presence of IC87114 at 1 µM as expected based on our Affymetrix and LDA data 
and importantly, rab6b expression was also unaffected by differentiation in the 
presence of 5 µM IC87114 [Figure 6.9].   
 
 
Figure 6.9. Expression of rab6b protein is unaffected in WT macrophages differentiated in 
either 1 µM or 5 µM IC87114 as indicated.  Macrophage precursor cells were extracted from 
three WT mice and split into three groups that were differentiated in the presence of DMSO, p110δ-
selective IC87114 at 1 µM or at 5 µM as indicated.  After seven days of differentiation cells were 
stimulated with LPS (1 µg/ml) for 30 min prior to cell lysis.  Total cell lysates were analysed for the 
expression of the indicated proteins using immunoblotting. 
 
 
We note that in this experiment rab6b was induced by LPS-stimulation [Figure 
6.9].  This was not observed in our previous experiment in which rab6b levels 
were compared in WT and p110δ KI macrophages in basal and LPS-stimulated 
conditions [Chapter 5, Figure 5.16].  These data indicate that although increasing 
the dose of IC87114 reduced the activation of Akt this had no detectable impact on 
rab6b protein levels.   These data would suggest that the reason behind the 
differential effects of genetic and pharmacological inactivation on Rab6b 
expression may not be incomplete inhibition of p110δ in the later case.    
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6.6. Conclusion 
Firstly, based on our Affymetrix data we have identified just nine genes that are 
differentially regulated in WT-IC87114 macrophages [Table 6.1 & 6.2].  We did not 
validate the effect of IC87114 on the expression of these genes and therefore the 
potential link between p110δ activity and the expression of these genes is 
presented with caution. It is possible that they are false positive results or that 
they represent off-target effects of IC87114.  It would be interesting to determine 
which of these genes stand-up to validation, and furthermore to check that they 
are not affected in p110δ KI macrophages.  In terms of a biomarker if the 
expression of any gene(s) is validated, it would then be necessary to determine 
whether the same effect is observed in human leukocytes such as readily 
accessible blood derived monocytes or macrophages differentiated from them. 
Perhaps our most important and unexpected result was the identification of a 
potential problem with the p110δ KI mouse model.  PGE analysis has revealed a 
highly statistically significant enrichment of the genes differentially regulated in 
p110δ KI macrophages on chromosome four.   Their localisation specifically, 
within or proximal to the locus where Pik3cd lies is certainly a cause for concern.  
We proposed three possible explanations for this localisation of genes 
differentially regulated in p110δ KI macrophages.  First, it could indicate that 
disruption of epigenetic structure or modifications have occurred on the mutant 
chromosome.  Alternatively we proposed that the genetic engineering may have 
interfered with a regulatory sequence such as a micro RNA (miRNA).  Our third 
hypothesis is that the expression of these genes is not affected by the mutation per 
se but as the result of the retention of genetic material from the mouse strain in 
which the mutation was originally generated.  To put this simply, the D910A 
mutation was first generated in embryonic stem cells derived from a 129 strain 
mouse, whereas the p110δ KI mouse colony we now use is of the C57BL/6 
background.   The mice were backcrossed for at least nine generations to 
homogenise the genetic background to C57BL/6 genetic material but we suggest 
that by selecting for p110δ KI mutants we may have selected those mice that have 
retained the 129 genetic material surrounding the Pik3cd gene.   Finally we must 
acknowledge that the differential regulation of the genes linked to Pik3cd might 
genuinely occur as a result of inactivation of p110δ in macrophages.  The possible 
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explanations for the unexpected enrichment of genes differentially regulated in 
p110δ KI macrophages are described and considered in detail in the discussion, 
which follows. 
We also noted that macrophages differentiated in IC87114 had repressed p-Akt 
whilst this was not apparent in the p110δ KI macrophages.   Previous data 
regarding the reduced activation of Akt in p110δ KI macrophages was always 
obtained from macrophages deprived of CSF-1 for 12-24 h [1, 79], whilst we have 
observed no decrease in the presence of CSF-1.  We have also observed that a 
decrease in p-p38 occurred in p110δ KI macrophages, but not in our experience in 
either primary macrophages or macrophage cell lines treated with IC87114.  This 
result regarding p-p38 being affected by the mutation but not the drug could also 
be relevant to our findings but would first need to be confirmed with additional 
experiments.
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CHAPTER 7 
 
7. DISCUSSION 
7.1. The effects of genetic and pharmacological inactivation of 
p110 delta on transcriptional regulation 
 
The main conclusions of this study are: 
1. p110 plays a minimal role in the regulation of transcription in primary 
macrophages 
2. Expression of Rab6b is reduced in p110 KI macrophages but is unaffected 
in macrophages differentiated in the presence of IC87114 
3. The effects of genetic and pharmacological inactivation of p110 in primary 
macrophages are entirely disparate 
4. The expression of twelve genes proximal to the Pik3cd gene on 
chromosome four are differentially expressed in p110 KI macrophages 
7.1.1. Genetic inactivation of p110 has a minimal effect on gene 
expression 
When we set out to perform our genome-wide expression analyses of 
macrophages lacking p110δ activity we had two key objectives in mind.  First, we 
wanted to gain an insight into the role that p110δ plays in transcriptional 
regulation in macrophages and which processes are regulated by p110δ at this 
level.  Secondly, by identifying individual genes affected by p110δ inactivation we 
hoped to identify a unique signature of p110δ inactivation, which could be used to 
develop biomarkers.   
We initially chose to identify genes regulated by p110δ in primary macrophages 
using the genetic p110δ KI model.  We reasoned that comparing the expression of 
p110δ KI macrophages to WT macrophages was the cleanest system in which we 
could elucidate the specific effects of p110δ inactivation on transcriptional 
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regulation.  Specifically, we felt that starting our investigation using genetic 
inactivation was preferable to using pharmacological inactivation, as the latter 
method is likely to have off-target effects.  Instead, we preferred to investigate the 
genes affected by the p110δ KI mutation and subsequently identify which of these 
were also common to macrophages treated with p110δ-selective inhibitors.  An 
alternative to this strategy would have been to determine the effect of several 
different p110δ-selective inhibitors on the genome-wide expression of primary 
macrophages.  Those genes found to be affected by all of the drugs could be 
considered as most likely to be genuinely downstream of p110δ-inactivation. 
The comparison of the genome-wide expression of p110δ KI and WT macrophages 
revealed that the regulation of transcription in growing macrophages is minimally 
affected by loss of p110δ activity.  The effects were restricted to just twenty-five 
probe sets that were differentially regulated in either basal or LPS-stimulated 
p110δ KI macrophages.  Specifically, in growing unstimulated p110δ KI 
macrophages, just seventeen probe sets, or fourteen known genes were 
differentially regulated [Table 7.1 & 7.3].  Whilst in LPS-stimulated p110δ KI 
macrophages twenty probe sets, or seventeen genes were affected, and strikingly, 
only eight of these genes were unique to the LPS-stimulated state [Table 7.2 & 7.3].  
This data was obtained from four biological replicates per condition and statistical 
analysis identified these probe sets had p values of ≤ 0.05 which are considered 
very significant.   
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 Basal 
Gene 
Symbol 
Protein logFC adjP value 
Rab6b RAB6B, member RAS oncogene family -2.368 2.14E-05 
Nin Ninein 2.316 2.14E-05 
Clstn1 calsyntenin 1 1.737 7.60E-03 
Sh2d1b1 SH2 domain protein 1B1 1.286 4.02E-02 
Miip migration and invasion inhibitory protein -1.092 3.05E-02 
Table 7.1. The expression of five genes was found to be differentially regulated in p110δ KI 
macrophages compared to WT macrophages in unstimulated conditions only. Genes are 
ordered by magnitude of change irrespective of the direction of logFC and genes increased or 
decreased in p110δ KI macrophages are highlighted in red or green respectively. The expression of 
two genes Rab6b and Miip were decreased in basal p110δ KI macrophages.  The expression of three 
genes (Clstn1, Sh2d1b1 and Nin) was increased in basal p110δ KI macrophages.   
 
 LPS-stimulated 
Gene 
Symbol 
Protein logFC adjpValue 
Mthfr 5,10-methylenetetrahydrofolate reductase -2.194 1.70E-04 
Ube4b ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) -1.802 1.38E-04 
Kif1b Kinesin family member 1b 1.409 1.72E-02 
Mid1 midline 1 1.408 1.64E-02 
Fst Follistatin 1.305 1.07E-03 
Pacsin3 protein kinase C and casein kinase substrate in neurons 3 1.304 3.10E-03 
Tnn tenascin N -1.083 3.47E-02 
Htatsf1 HIV TAT specific factor 1 1.078 4.33E-02 
Table 7.2.  The expression of eight genes was found to be differentially regulated in LPS-
stimulated p110δ KI macrophages compared to LPS-stimulated WT macrophages. Genes are 
ordered by magnitude of LogFC irrespective of the direction of change and genes increased or 
decreased in p110δ KI macrophages are highlighted in red or green respectively.  Increased 
expression of four genes (Htatsf1, Pacsin3, Fst and Mid1) was identified in LPS-stimulated p110δ KI 
macrophages. The expression of four genes (Mthfr Ube4b, Kif1b and Tnn) was reduced. 
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 Basal LPS-stimulated 
Gene 
Symbol 
Protein logFC adjpValue logFC adjpValue 
Fblim1 filamin binding LIM protein 1 -2.927 3.61E-04 -3.892 4.42E-03 
Pdpn Podoplanin -3.629 2.14E-05 -3.321 2.71E-05 
Paip1 polyadenylate binding protein-interacting 
protein 1 
3.110 6.79E-06 3.350 8.71E-07 
Pisd-ps3 phosphatidylserine decarboxylase, 
pseudogene 3 
2.230 2.24E-03 1.849 4.57E-03 
9530053H05
Rik 
RIKEN cDNA 9530053H05 gene 2.157 1.20E-02 1.329 2.04E-02 
Plod1 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 
-1.886 5.93E-04 -1.771 4.08E-04 
Ubiad1 UbiA prenyltransferase domain 
containing 1 
1.811 9.11E-03 2.345 2.95E-04 
Efhd2 EF hand domain containing 2 -1.782 4.66E-04 -1.541 7.10E-04 
1700029I01
Rik 
RIKEN cDNA 1700029I01 gene -1.685 6.82E-03 -1.752 1.83E-03 
3110007F17
Rik 
RIKEN cDNA 3110007F17 gene -1.662 2.24E-03 -1.230 1.33E-02 
Efcab7 EF-hand calcium binding domain 7 -1.583 4.08E-03 -1.409 4.57E-03 
Vamp3 vesicle-associated membrane protein 3 -1.088 3.05E-02 -1.121 1.11E-02 
Table 7.3.  The expression of twelve probe sets interrogating nine known genes and three 
RIKEN transcripts were differentially regulated in unstimulated as well as LPS-stimulated 
p110δ KI macrophages. Probe sets are ordered by magnitude of logFC irrespective of the 
direction of change and known genes are in bold and genes increased or decreased in p110δ KI 
macrophages are highlighted in red or green respectively. Six known genes and two RIKEN clones 
were found to be decreased in basal and LPS-p110δ KI macrophages.  Three known genes and one 
RIKEN were found to be increased in basal and LPS-stimulated p110δ KI macrophages. 
 
We have confirmed the differential expression of fifteen of the twenty-five unique 
probe sets identified in a validation study.  We felt that it was important to obtain 
these confirmatory data using a new set of samples, as opposed to validating the 
observed changes in the original samples. We therefore, performed comparative 
expression analysis on three new sets of RNA samples derived from WT or p110δ 
KI macrophages in the basal and LPS-stimulated state.  Additionally, we included 
one of the four sets of original RNA samples, which we had analysed by microarray.  
In total, we have now analysed the expression of this sub-set of genes in seven 
biological replicates (p110δ KI and WT macrophages in basal and LPS-stimulated 
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state) and thus we are confident of our findings regarding their differential 
regulation in p110δ KI macrophages. 
We have presented quantitative data supporting our Affymetrix findings regarding 
the differential regulation of seven genes in p110 KI macrophages.  Specifically, 
we have confirmed that the expression of Clstn1 is increased in p110 KI 
macrophages and the expression of Rab6b, Fblim1, Pdpn and Plod 1 are decreased 
in p110 KI macrophages.  We also confirmed that Mthfr and Ube4b expression is 
decreased in LPS-stimulated p110 KI macrophages.  In the case of Rab6b, the 
Affymetrix results had indicated that it was only differentially expressed in the 
basal state whereas an effect in both basal and LPS-stimulated states was observed 
in the validation study.  This highlights the benefit of utilising TaqMan for 
validation of Affymetrix results because of its increased sensitivity and dynamic 
range compared to a microarray.  This increased sensitivity may explain why we 
observe a much greater fold change in Rab6b expression in the validation study, 
compared the fold change observed in the Affymetrix study.  Below we have 
considered the implications of our results in terms of the role that p110δ appears 
to play in the regulation of macrophage transcription.  Subsequently, we discuss 
the data regarding the possible impact of decreased expression of Rab6b in p110δ 
KI macrophages. 
 
7.1.2. The genome-wide perspective 
As well as aiming to identify individual genes regulated by p110δ, we were also 
keen to gain insight into the extent to which p110δ contributes to the regulation of 
the macrophages transcriptome as a whole.  We knew that p110δ has a significant 
role to play in signalling in macrophages and that macrophages lacking p110δ 
display defective motility and migration as well as have defects in certain secretory 
pathways [1, 79, 114].  Yet what remained unclear was to what extent these and 
other processes regulated by p110δ are modulated or controlled at the level of 
transcription.  At the time we initiated this study there were no publications 
detailing the effects of either genetic or pharmacological inactivation of p110δ on 
the transcriptome as a whole.  We were therefore keen to observe, how many 
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genes overall were affected by p110δ inactivation and which processes if any 
might be partially regulated at the level of transcription. 
We had read several publications that indicated that a number of transcription 
factors can be affected by PI3K-Akt activity.  These include the FOXO family of 
transcription factors, NF-κB and CREB, which between them regulate the 
expression of hundreds of genes [35-36, 40, 42-43].  Therefore, one might expect 
that inactivation of p110δ would affect the expression of hundreds of genes as a 
result of altered activity of these transcription factors in the absence of p110δ.  
Having said that, the majority of this research into transcription factors 
downstream of PI3K-Akt has been performed using pan-PI3K inactivation or PI3K 
activation and thus the observed effects on transcription factor activity might be 
mediated by other PI3K isoform.  Yet, even when we consider the impact of pan-
PI3K modulation, Cook et al. identified just forty genes differentially regulated in 
cardiomyocytes expressing constitutively active Akt [46].  Thus it seems that 
distortion of PI3K activity in isolation may be in sufficient to induce significant 
transcriptional deregulation. 
In this thesis, we have presented data indicating that the contribution of p110δ to 
the regulation of macrophage transcription is very limited in unstimulated 
growing murine macrophages.  We make this assertion based on our observation 
that the expression of only fourteen known genes was found to be differentially 
regulated in unstimulated growing macrophages.  We postulate that instead the 
fundamental regulation of the transcriptome might fall to one of the other 
ubiquitously expressed PI3K isoforms such as p110α or p110β.  Alternatively, we 
recognise that it is possible that PI3K as a family does not play a central role in 
transcriptional regulation.  Our results could indicate that whilst PI3K-Akt activity 
does, in some instances modulate transcription factor activity, it is one of many 
inputs into the regulation of transcription and thus its inactivation does not result 
in a dramatic shift.  This would make sense in the context of the many feedback 
loops and regulatory controls that have evolved to ensure a single defect cannot 
drive a cell into malignancy.  For example, we know that the loss of a single 
tumour-suppressor gene is rarely enough to induce oncogenesis, but instead an 
oncogene must generally also be deregulated [177].  In the same way, inactivation 
of p110δ may not be able to deregulate transcription in the absence of other 
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cellular abnormalities.  Perhaps, if p110δ were to be inhibited alongside another 
canonical signalling pathway, a role in transcriptional regulation would become 
more apparent.   
Whilst we have been investigating the effect of the p110δ KI mutation on 
macrophage transcription, Patton et al. examined its effects on the transcriptome 
of Tregs [50].  The authors report that the effects of inactivating p110δ in Tregs 
were also relatively restricted [50].  Specifically, 125 probe sets were found to be 
differentially regulated in p110δ KI Tregs [50].  This represents a very small 
proportion of the entire genome, but is approximately 100 more than we identified 
in p110δ KI macrophages [50].  In view of our results and those obtained by Patton 
et al. [50], we can suggest with greater confidence that the effects of p110δ 
inactivation on transcription are not wide-spread.  It is interesting that the 
transcriptome of Tregs appears to be more dependent upon p110δ activity than 
the transcriptome in macrophages.  We are tempted to speculate that in adaptive 
immune cells such as Tregs p110δ may play a more significant, even if still limited, 
role in transcriptional regulation than it does in innate immune cells such as 
macrophages.  Based purely on these two studies, this is of course nothing more 
than speculation, but we suggest that it might be interesting to compare the effects 
of p110δ inactivation on the transcriptome of a panel of innate and adaptive 
immune cells.   
Comparisons between two microarray studies, such as our own and that published 
by Patton et al. must always be made with caution, particularly as we have found 
that even on a single data set, the data analysis performed can impact upon the 
number and the list of genes identified.  As such, if one were especially keen to 
compare and confidently draw conclusions from two studies, it would be wise to 
normalise the data across both studies and then analysis the data together.  Of 
course, it is not just data analysis that can affect the results: the exact protocols 
applied and even the colony of mutant mice used, can affect microarray results.  In 
this respect, we can compare the effects of the p110δ KI mutation in macrophages 
and Tregs more confidently because we actually used mice from the same WT and 
p110δ KI colonies as Patton et al. because of shortages in our own mouse colonies 
[50].  We were especially keen to identify any genes that were affected by p110δ 
inactivation in both Tregs and macrophages.  Just four genes were differentially 
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regulated in both p110 KI Tregs and p110 KI macrophages: Vamp-3, Rab6b, Kif1 
and Ubiab1.  The identification of these genes in both studies supports the validity 
of our results regarding their differential expression and we speculate that they 
may be involved in a specialised function that is common to leukocytes.   
Below we present a summary of the evidence that leads us to propose that Rab6b 
and also potentially Vamp-3 are regulated by p110δ in order to modulate a 
specialist leukocyte functions.  Although we must point out that the linkage of 
Vamp-3 to the E1 encoding Pik3cd locus, which is discussed in detail later, may 
indicate that this is a false lead.  Alternatively, it is also possible that some of the 
disruption observed in p110δ KI macrophage functions mentioned below in 
relation to Rab6b and Vamp-3 might in fact be due to differential regulation of 
Vamp-3 independent of p110δ activity.  With this caveat put temporarily to one 
side, we have considered the possible function implications of differential 
regulation of Rab6b and additional Vamp-3 in p110δ KI macrophages. 
 
7.2.  Investigating the effects of p110 delta activity on Rab6b 
expression  
 
7.2.1. Reduced expression of Rab6b in p110δ KI macrophages but not in 
p110δ KI brain tissue 
In this thesis, we have presented data that reveal that the expression of Rab6b is 
reduced in p110δ KI macrophages.  As described above, these data were obtained 
using two methods across a total of seven biological replicates, which increases 
our confidence in this finding.  Importantly, we have also presented evidence that 
this decreased expression results in a decrease in rab6b protein in p110δ KI 
macrophages.  Our results at the protein level reveal that Rab6b expression is 
decreased in both unstimulated and stimulated p110δ KI macrophages, which is 
consistent with our TaqMan® LDA results. 
We were struck by two findings regarding Rab6b, first that the expression of Rab6b 
has also been found to be decreased in p110δ KI Tregs, another type of leukocyte 
[50].  This independent identification of differential regulation of Rab6b in p110 
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KI cells further enhanced our confidence in this result.  Secondly, we noticed a 
remarkable degree of overlap between the tissues within which p110δ and rab6b 
are reported to be expressed: leukocytes, neurons and melanocytes [50, 172-173].  
Based on this observation, we postulated that p110δ activity might regulate the 
tissue-specific distribution of rab6b.  We tested this hypothesis by comparing the 
expression of rab6b in brain tissue derived from p110 KI and WT macrophages.  
Our results indicate that rab6b is expressed at WT levels in p110δ KI brain tissue, 
which disproved our hypothesis.  Together these data suggest that the regulation 
of Rab6b by p110δ may instead be restricted to, but potentially common across, 
the haematopoietic cell lineage.  It would be pertinent to compare the levels of 
rab6b in other WT and p110 KI leukocytes to determine whether this is correct.  
In summary, we have identified Rab6b, amongst other genes as a potential 
regulatory target of p110 activity and we have shown that this results in a 
reduced expression of rab6b protein in p110 KI macrophages.   
 
7.2.2. Possible functional consequences of reduced rab6b in p110δ KI 
macrophages 
It was beyond the scope of this project to investigate the functional implications of 
this reduced expression of Rab6b in macrophages.  Addressing this question 
potentially represents an entire project in itself, particularly in light of the very 
limited information regarding rab6b function.  Nevertheless, we have considered 
the potential implications of our findings based on what is known about rab6b and 
our own knowledge regarding macrophages and p110 functions in them. We have 
identified two processes that are integral to the specialised functions of 
macrophages in which rab6b might function.  Furthermore, we have found 
evidence supporting a potential involvement of Vamp-3 (one of the other genes 
differentially regulated in p110 KI macrophages) in these processes.  
 
7.2.2.1. The role of rab6b in the endomembrane trafficking network 
We must consider what is known about the functions of rab6b and that of its 
family members in order to formulate informed hypotheses regarding the possible 
implications of reduced expression of Rab6b.  We know that rab6b belongs to the 
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large rab family consisting of around fifty small-GTPase proteins, which perform 
regulatory functions within the endomembrane network.  Within the rab family, 
rab6b is a member of a small sub-family alongside rab6a and its splice-variant 
rab6a’, which are both ubiquitously expressed [172].  The endomembrane network 
facilitates the transport of proteins and lipids to and from appropriate intracellular 
organelles or membranes.  Much of the flow through this network is devoted to the 
transport of new translated protein cargo from the endoplasmic reticulum (ER) to 
the Golgi apparatus and subsequently onwards within vesicular carriers to the 
organelle or endomembrane in which the cargo functions [Figure 7.1].  The ability 
to regulate the fusion of the vesicular carriers that pass between the 
compartments is crucial for the spatial regulation of proteins and lipids.  The rab 
family of proteins are integral to this regulation of vesicular fusion.  In their 
specific localisations, they form a sort of molecular signature or gatekeeper 
ensuring that only the appropriate vesicles are able to fuse and unload their 
protein/lipid cargo. 
 
 
 
Figure 7.1. Schematic of vesicle trafficking in the endomembrane system. Transport of cargo 
from the ER to Golgi and on to the appropriate subcellular location is mediated through highly 
regulated vesicular transport.  Opposing this flow is retrograde transport (red lines) which returns 
proteins to the Golgi and/or ER. 
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Retrograde transport moving against the predominant flow of newly-translated 
cargo is required to return the molecular machinery and lipids to the ER and Golgi 
in order to enable further cycles of transport to proceed.  A large proportion of 
retrograde cargo including ER are recognised and bound by coatomer protein I 
(COP-I) which facilitates their vesicular transport back to the ER.  Current data 
including subcellular localisation studies suggest that rab6a and rab6b perform 
non-identical functions within retrograde transport.  Both were initially reported 
to be localised to the Golgi apparatus, and additionally to be enriched in specific 
peripheral sites [172, 178-179].  These peripheral sites are thought to be 
retrograde transport entry sites on the ER and thus this enrichment is consistent 
with a role for rab6a and rab6b in retrograde transport [172, 179].  Rab6a was 
found to perform retrograde transport independently of the COP-I-dependent 
pathway [178-179].  In contrast, rab6b has been localised to ERGIC-53-containing 
vesicular structures, which are associated with COP-I-dependent retrograde 
transport [172].  This indicates that rab6b, unlike rab6a, may function within the 
canonical COP-I-dependent retrograde transport pathway [172, 179].  An 
additional role for rab6b that might be relevant to its tissue-specific expression in 
neurons, macrophages and melanocytes has been uncovered.  Bicaudal-D1 was 
found to interact with rab6b and both were then shown to co-localise to 
microtubule bound dynein-dynactin complexes [180].  Interestingly, the authors 
visualised live dynamic bi-directional movement of rab6b along microtubules 
[180].  This observation reveals that rab6b contributes to both anterograde and 
retrograde transport of vesicles containing unknown cargo along the extended 
microtubule network within neural cell processes.   
 
Neural processes often extend long distances from the cell body and thus it seems 
plausible that the capacity to regulate bi-directional transport along extended 
microtubules tracks might require cell-specific components such as rab6b [Figure 
7.2].   
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Figure 7.2. Schematic of a nerve cell with extended axon and dendrites along which 
numerous cargo must be transported.  Anterograde transport away from the cell body utilises 
plus-end directed molecular motors such as Rabkinesin. Retrograde transport returns cargo to the 
cell body utilising minus-end directed molecular motors such as dynein-dynactin. 
 
7.2.2.2. Rab6b function in macrophages? 
There is no data regarding the function or even localisation of rab6b in 
macrophages therefore, one can only extrapolate these observations in neurons to 
predict what functions rab6b might perform in macrophages.  Based on the limited 
expression of rab6b we propose that this is likely to be a cell-specific function.  In 
terms of macrophage biology, we know that macrophages also form protrusions in 
order to fulfil two of their major functions.  First, they form pseudopodia, which 
are membranous extensions with which they reach for and engulf pathogens by 
phagocytosis.  Secondly, macrophages must be able to migrate efficiently across a 
wide-range of extracellular matrix in order to reach sites of infection.  To do this 
macrophages, form broad membranous extensions known as lamellapodia at the 
leading edge of the cell.  The protrusion of the leading edge is facilitated by the 
extension of actin networks and actin-rich adhesive structures known as 
podosomes.  Podosomes bind integrin complexes to create the contractile force 
needed to move the cell forward across the extracellular matrix.  The podosomes 
and their integrin partners must be repeatedly re-distributed to the leading edge of 
the cell as the migration progresses.  The plasma membrane at the leading edge 
must also be continuously supplemented with lipids to allow the protrusion to 
extend.  This re-distribution of lipids and protein components is thought to require 
both endocytic and exocytic transport mechanisms.  It is therefore tempting to 
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propose that rab6b might be involved in this specialised recycling function 
transporting membranous vesicles to the leading edge of the migrating 
macrophages.  In particular, the observed capacity of rab6b to support bi-
directional trafficking along microtubule networks might be advantageous in this 
highly dynamic process.   
Interestingly, we have found publications by the Murray group revealing that 
Vamp-3, which we have found to be down-regulated in p110 KI macrophages (not 
validated), contributes to macrophage migration by regulating this endocytic-
exocytic process [181-182].  Vamp-3 facilitates the recycling of integrin complexes 
to the leading edge via the long-loop recycling pathway, which diverts the cargo via 
recycling endosomes [182].  Consequently, reduction of vamp-3 results in 
disorganisation of podosomes because the integrin partners of the actin structures 
are not re-distributed to the advancing leading edge.  A more recent publication 
revealed that the passage of the integrin-containing vamp-3-positive vesicles via 
recycling endosomes allows the vesicles to deliver recycling endosome membrane 
to the leading edge [183].  Accordingly, vamp-3 in association with other SNARE 
complexes, is necessary to facilitate appropriate adhesion through integrin-
podosome structures and additionally to allow and membrane expansion.   
The observed effects of suppressing vamp-3 activity in macrophages include a 
reduced capacity to migrate, a more rounded phenotype due to a reduced adhesive 
area and a disorganisation of podosomes.  This is particularly interesting because 
p110 KI macrophages have migratory defects and display a more rounded 
phenotype with a reduced adhesive surface [79].  Furthermore, p110 KI dendritic 
cells have been found to lack normal podosome structures [Dr Aksoy, Centre for 
Cell Signalling, unpublished data].  We suggest that it would be informative to test 
whether re-expression of Vamp-3 in p110 KI macrophages rescues or improves 
the migratory and adhesion defects in these cells.  
As rab6b has been shown to function in retrograde transport, and vamp-3 is 
clearly implicated in this particular form of retrograde transport it is tempting to 
speculate that these two proteins rab6b and vamp-3 both function in the same 
specialised process.  Thereby, co-ordinated regulation of both Rab6b and Vamp-3 
expression by p110 might act to modulate this specialised intracellular trafficking 
function.  If one were to investigate this possibility, one would need to investigate 
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the localisation of rab6b as suggested above but also to assess whether Rab6b null 
cells have a similar defect in migration.  In fact, a functional association between 
rab6b and vamp-3 is supported by a publication that found both of these proteins 
in purified synaptic vesicle preparations [184].  We caution the reader that no co-
localisation studies were performed and that these two proteins were identified 
alongside many other proteins [184].  Nevertheless, this could indicate that rab6b 
and vamp-3 both regulate secretion within neurons or more specifically 
contributes to the delivery and recycling of neurotransmitter release at neuronal 
synapses.   This would be consistent with the observation of rab6b tracking in both 
directions along the microtubules of neuronal dendrites [180] and it is possible 
that vamp-3 is also involved in recycling the vesicles.  
Furthermore, we propose that if rab6b is involved in neurotransmitter release in 
neurons, this might translate to an involvement in the release of inflammatory 
mediators by macrophages.  The expression of Rab6b in these cells could be 
required to facilitate regulated secretion.  In order to address this theory, it would 
first be pertinent to assess whether rab6b is associated with secretory vesicles in 
macrophages.  Indeed, if one were to follow up the observed decrease of rab6b in 
p110 KI macrophages at the functional level, the most appropriate starting point 
might well be to determine where and with what rab6b co-localises in 
macrophages.  This would help to elucidate which process or processes within 
macrophages involve rab6b activity and thus which might be affected by its 
inactivation.  We know that p110δ activity is directly involved in the regulation of 
secretion in macrophages [114].  Specifically, p110 is transiently recruited to the 
TGN where its localised activity appears to be essential to recruit dynactin-2 a 
regulator of vesicular fusion and release [114].  Hence, it seems plausible that as 
well as regulating the recruitment of regulatory proteins, p110δ might also achieve 
an additional level of control over secretory processes by modulating the 
expression of regulatory proteins.  
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7.3. Comparing the effects of pharmacological and genetic 
inactivation of p110 delta on primary macrophage 
transcriptome 
 
7.3.1. Pharmacological inactivation of p110δ results in minimal changes 
to the transcriptome 
We also investigated the effect of pharmacological inactivation of p110δ.  
Comparing the results obtained from this experiment to the effects of genetic 
inactivated of p110δ has been very interesting.  In this study, we chose to compare 
the effects pharmacological inactivation of p110δ on primary macrophages.  We 
decided to culture and differentiate bone marrow precursor cells to macrophages 
in the presence of IC87114, a p110δ-selective inhibitor.  We reasoned that 
differentiating these cells into macrophages in the presence of IC87114 was most 
comparable to the p110δ KI macrophages.  Furthermore, we reasoned this was 
more representative of chronic administration of a p110δ-selective drug in the 
clinic than a short treatment.  We predicted that we would observe a significant 
overlap between the genes affected by IC87114 and by the p110δ KI mutation and 
we anticipated that some genes might be differentially affected by the drug or 
mutation.  In particular, we hypothesised that we might see genes affected by the 
drug and not by the genetic inactivation as a result of off-target affects of IC87114.  
In fact, our assumptions were proved entirely wrong. First, we actually observed 
fewer genes affected by IC87114 than we found affected by the p110δ KI mutation.  
We found just eleven probe sets or nine known genes affected [Table 7.4 & 7.5].  
Specifically, seven known genes were affected in the unstimulated state [Table 
7.4], whilst only two known genes were differentially regulated in LPS-stimulated 
p110δ KI macrophages [Table 7.5].  Interestingly, the genes affected in the basal 
state were different to those that were affected in the LPS-stimulated 
macrophages.  We have not validated these results and therefore the regulation of 
these genes in response to p110δ inactivation is presented with caution. 
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 Unstimulated 
Gene Symbol Protein logFC adjP value 
NA NA -1.156 4.54E-02 
Tiam1 T-cell lymphoma invasion and metastasis 1 -1.448 2.02E-02 
Ccr5 chemokine (C-C motif) receptor 5 -1.367 4.54E-02 
Grp85 G protein-coupled receptor 85 -1.363 2.29E-02 
Ifi27I2a interferon, alpha-inducible protein 27 like 
2A 
-1.202 4.54E-02 
Sgms2 sphingomyelin synthase 2 1.019 4.54E-02 
Pkp2 plakophilin 2 -1.090 4.54E-02 
Socs3 suppressor of cytokine signaling 3 1.421 2.29E-02 
Table 7.4. Differential expression of eight probe sets was observed in unstimulated WT 
macrophages differentiated and cultured in the presence of IC87114 compared to WT 
control macrophages.  
 LPS-stimulated 
Gene Symbol Protein logFC adjP value 
Socs1 suppressor of cytokine signaling 1 -1.038 3.43E-03 
1110032F04Rik RIKEN cDNA 1110032F04 gene -1.142 4.94E-02 
Cmbl carboxymethylenebutenolidase-like 
(Pseudomonas) 
-1.462 3.82E-02 
Table 7.5. Differential regulation of three probe sets was detected in LPS-stimulated  
WT macrophages differentiated and cultured in the presence of IC87114 compared  
to WT control macrophages. 
 
7.3.2. Comparison of genetic and pharmacological inactivation of p110δ 
Not only did we observe fewer genes affected by the pharmacological inactivation 
of p110δ, but we also found that, contrary to our expectations, no genes were 
affected by both genetic and pharmacological inactivation. The results of our two 
genome-wide expression studies revealed that the genes affected by IC87114 and 
by the p110δ KI mutation were entirely distinct at the transcriptional level.  Thus, 
the effects of genetic inactivation of p110δ in macrophages are more similar to the 
effects of genetic inactivation in Tregs than they are too pharmacological 
inactivation in macrophages!  To our knowledge, this is the first instance in which 
the effects of genetic and pharmacological inactivation of p110δ or, for that matter, 
any Class IA PI3K isoform have not been the same or similar.  Of course, we were 
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concerned that this might have been due to a technical error or experimental 
design error such as insufficient addition of IC87114 to maintain an inhibitory 
dose.  We decided to test the results and concurrently to obtain medium samples 
to assess the concentration of IC87114 in the medium throughout the experiment.  
We compared the expression of the genes affected by the p110δ KI mutation in 
WT-IC87114 macrophages to their expression in WT-DMSO macrophages.  The 
results of this experiment support the findings drawn from the Affymetrix data 
regarding expression of genes in p110δ KI macrophages compared to WT 
macrophages.  We recognise that ideally it would be informative to confirm the 
results of the Affymetrix experiment in which we compare the transcriptome of 
WT-IC87114 macrophages to that of WT-DMSO macrophages.  Having done this, 
one could then additionally obtain the data in reverse, i.e. compare the expression 
of genes confirmed to be differentially regulated in WT-IC87114 macrophages in 
p110δ KI macrophages.  Assuming some or all of the genes affected by IC87114 
were validated, it would also be pertinent to test whether other p110δ-selective 
drugs have a similar effect.  Additionally, we suggest that differentiating and 
culturing p110δ KI macrophages in the absence and presence of IC87114 would be 
a useful control to discover whether these effects are p110δ dependent. 
 
7.3.3. Enrichment of genes differentially regulated in p110δ KI 
macrophages flanking the Pik3cd locus 
We have found one striking commonality between the majority of the genes that 
we found were differentially regulated in p110δ KI macrophages in the Affymetrix 
experiment.  The majority of the genes are located on chromosome four and, more 
precisely, are within or proximal to the E1 locus where the Pik3cd gene located.  
The enrichment was found to be highly significant by PGE analysis with a p value 
of 1.74 x10-25, which virtually rules out the possibility that these genes are 
clustered in this tiny region of the genome by chance [Figure 7.3][Table 6.3]. 
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Figure 7.3. PGE reveals a significant enrichment of genes differentially regulated in p110δ KI 
macrophages in the region proximal to Pik3cd. The list of probe sets differentially regulated in 
p110δ KI macrophages was uploaded to the PGE analysis tool and the enrichment of those genes 
mapped to specific chromosome locations was calculated.  The p value was adjusted to account for 
the multiple testing integral to the algorithm. [176] 
 
7.4. Explaining PGE of genes differentially regulated in p110 
delta KI macrophages 
This discovery was made towards the end of this project and, therefore, we have 
not been able prove any one hypothesis explains this linkage, but we have found 
substantial amounts of literature and several publications supporting one 
particular hypothesis.  We initially formulated a number of hypotheses as to why 
these differentially regulated genes might be clustered around the Pik3cd gene. 
1. Genetic engineering of the D910A mutation has disrupted the expression of 
these genes in a manner independent of its effect on p110δ activity 
2. These genes are genuinely regulated by p110δ activity by a mechanism 
which is unaffected by differentiation in IC87114 
3. Differential regulation of these genes represents differential regulation of 
these genes in the mouse strain in which the D910A mutation was 
generated compared to the strain recipient strain into which the mutation 
has been backcrossed 
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7.4.1. Disruption to the expression of linked genes as an artefact of the 
D910A mutation 
The engineering of the p110δ KI mutation represented a step forward in the 
generation of mouse models because the p110δ protein is still transcribed and 
translated at WT levels, just in an inactive form.  The ability to engineer a gene to 
encode an inactive protein resulted in a cellular state that was predicted to closely 
mimic the effects of pharmacological inactivation.  This circumvented a number of 
off-target effects occurring in earlier deletion techniques, which included the 
induction of compensatory changes to the other PI3K isoforms and regulatory 
subunits.  Although the inactivation of p110δ function was achieved by the 
introduction of a point mutation, other elements including a lox-p site and a myc-
tag were also inserted into the region.  We reasoned that either the process of 
introducing the point mutation or associated elements or alternatively the actual 
presence of these elements in the region, could disrupt expression of nearby genes.  
If the differential regulation of these linked genes is occurring as a result of the 
mutation or associated elements, we proposed two mechanisms that could be 
involved.  Either a regulatory sequence such as a miRNA could have been disrupted 
or potentially the epigenetics of the region could have been disturbed.   We do not 
consider these possibilities further here as we believe there is sufficient evidence 
to support an alternative hypothesis, so that these become highly unlikely. 
 
7.4.2. Differential regulation represents the retention of 129-derived 
genetic material  
It is well known that phenotypic variation between inbred mice strains and even 
between sub-strains occurs in part as a result of genetic polymorphisms which 
affect gene expression [185]. A visual example of genetic variation between mouse 
strains is coat colour; some mice strains are white (BALB/c), whilst others are 
agouti (129) and others are black (C57BL/6).  Of course, it is not only visible 
phenotypes that are affected by genetic variation; behavioural traits and indeed 
cellular function can be affected by differential expression or genes.  For instance, a 
recent publication detailed the investigation of the twofold lower expression of 
integrin-α2 in the FVB mouse strain as compared to several other inbred strains, 
which amongst themselves had similar expression of this protein [186].  We 
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theorised that the differential regulation of genes flanking Pik3cd may represent a 
strain difference between the expression of these genes in the strain in which the 
mutation was first generated and the strain in which the mutation is maintained.  
This we reasoned could be the case if the region flanking Pik3cd had been 
maintained in its original form, which was derived from a 129 strain mouse, whilst 
this region in a WT mouse contains genetic material of the C57BL/6 mouse.  In this 
case, the differential regulation of genes in this region would be entirely unrelated 
to the effects of inactivating p110δ.  In fact, after some research, it became 
apparent that this retention of ES cell derived genetic material flanking a mutation 
in a genetically engineered mouse line is a recognised phenomenon.  Moreover, it 
is an almost unavoidable consequence of the strategy used to generate the p110 
KI mice.  If we consider the protocol used to generate these mice, this phenomenon 
becomes much clearer.  The strategy will be described in generic terms for ease of 
explanation and has been described in detail in several publications [187]. 
 
7.4.2.1. Strategy used to generate mutant mice 
The mutation is initially generated in vitro in an embryonic stem (ES) cell line 
derived from a 129 strain mouse using a targeting vector containing the gene of 
interest carrying the desired mutation and a neomycin selection cassette [Figure 
7.4].  The targeting vector was cloned from 129 strain genetic material to ensure it 
was homologous to the region in the ES cell.  This targeting vector is recombined 
into the ES cell DNA in the appropriate position as a result of homologous 
recombination [Figure 7.4a].  Those ES cells in which the targeting vector has been 
integrated are selected for using treatment with neomycin [Figure 7.4a].  The 129-
derived ES cell carrying the point mutation is then microinjected into a blastocyst 
derived from a C57BL/6 mouse and the blastocyst is subsequently implanted in a 
C57BL/6 mouse for gestation [Figure 7.4b & c].  Within the resulting litter, some 
pups will be genetically heterogeneous because they will consist of cells derived 
from the donor ES cell (129 genetic material) and also cells derived from the 
original recipient blastocyst (C57BL/6 genetic material) [Figure 7.4d]. 
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Figure 7.4.  Schematic of the generation of genetically heterogenous/chimerical mice using 
129-derived ES cell line and a C57BL/6 blastocyst.  a. The 129-derived ES cells are 
electroporated with targeting construct, which is then integrated by homologous recombination.  
ES cells in which the construct has been integrated are selected by neomycin treatment.  b. The 
selected ES cells are injected into a blastocyst derived from a C57BL/6 mouse c. The blastocyst is 
microinjected into a pseudopregnant C57BL/6 mouse. d. Chimeric progeny carrying both donor 
129 genetic material and recipient C57BL/6 genetic material are born. [Figure reproduced and 
adapted with permission from Dr Martin-Berenjeno]. 
 
The crucial next step is to achieve germline transmission of the mutation.  This is 
achieved by crossing the chimeric pups [Figure 7.5a].  The next generation will 
include mice that are homozygous, heterozygous and WT for the targeted locus in 
Mendelian ratios [Figure 7.5a].  Having transmitted the mutation to the germ line, 
the final stage is to purify or fix the genetic background, as the mice are currently 
heterogeneous for 129 and C57BL/6 genetic material.  This mixed genetic 
background could confound phenotypic analysis of the effects of the mutation.  
Purification of the genetic background is performed by backcrossing the mutant 
mice to the recipient mouse strain (C57BL/6) for numerous generations [Figure 
7.5b].   
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Figure 7.5. Schematic of strategy to generate congenic mutant mouse line.  a. Cross the 
chimeric mice resulting germ line transmission of the mutation and an F1 generation consisting of 
pups heterozygous, homozygous and WT for the targeted gene. b. The homozygous mice must be 
backcrossed to inbred C57BL/6 mice for several generations to minimise 129-derived genetic 
material in the mice. [Figure reproduced and adapted with permission from Dr Martin-Berenjeno]. 
 
With every generation backcrossed to recipient homogenous C57BL/6 mice there 
is a logarithmic decrease in the donor (129) genetic material in the progeny due to 
meiotic recombination.  As a result, the number of loci that are homozygous for 
C57BL/6 alleles will consistently increase every generation, whilst any loci 
heterozygous for the 129 alleles will diminish [Figure 7.6]. 
 
Figure 7.6. Increasing C57BL/6 allele homozygosity and concomitant decrease in 
heterozygosity for the donor 129 alleles with additional backcrosses. Mutant mice are 
backcrossed for multiple generations in order to reach genetic homozygosity.  With each successive 
cross the mice reduce the number of 129 alleles remaining in the genome.  
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The ultimate aim of these backcrosses is to generate a congenic strain, allowing the 
effects of the mutation to be determined in a homogenous genetic background.  
The definition of a congenic strain is one in which all genetic material is identical 
with the exception of the target locus and its flanking region.  Herein lies the crux 
of the problem: however many generations you backcross mice to the recipient 
strain, it is virtually impossible to eliminate the donor genetic material flanking the 
targeted locus.  This region that is retained in the donor form is referred to as the 
differential chromosomal segment.  Once the mice have been backcrossed for more 
than five generations, the approximate length of the differential chromosomal 
segment in centimorgans (cM) can be calculated using the equation 200/N.  This 
retention of donor genetic material occurs because continual selection for the 
genetically linked mutation causes linkage disequilibrium in the region 
surrounding a targeted locus.  To be precise, the probability of recombination is 
inversely related to the distance between the site and the selected gene, which 
results in the preferential retention of donor 129 genetic material in the flanking 
region.  This is therefore likely to account for the differential expression of the 
genes that we identified flanking Pik3cd.  This assumes that these genes are 
differentially expressed in macrophages derived from WT 129 strain mice 
compared to those derived from WT strain C57BL/6 mice.  We suggest that 
comparing the expression of these genes in the aforementioned macrophages 
would test if this were true.  In addition, by utilising known DNA markers that vary 
between 129 and C57BL/6 strain mice the strain origin of the differential 
chromosomal segment in WT controls and in p110δ KI mice could be determined. 
 
7.4.2.2. Implications of retention of 129 genetic material flanking a targeted 
gene 
The potential confusion that can be caused by the presence of these differential 
chromosomal segments has been reviewed in terms of its impact on behavioural 
and neuroscience studies [188-189].  In this field, the problem is confounded by 
the fact that the different mice strains have different behavioural traits, and 
moreover, the fact that the 129 donor strain is the most distinct strains in terms of 
behaviour and neuro-anatomy [190].  Gerlai points out that in a number of early 
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publications regarding the behavioural impact of null mutations, the null-mutant 
mouse phenotypes were actually similar to those observed in the mouse strain 
from which the donor ES cell line was derived (129) [189] & references herein].  
This led Gerlai to suggest that the phenotypes are regulated by genes in the region 
flanking the targeted mutation rather than by the mutation itself [189].  When the 
strategy described above was used to generate a mouse line with a mutation in the 
K-Cl co-transporter, this phenomenon was very visible [187, 191].  The K-Cl co-
transporter is encoded by Kcc2 on chromosome two, close to the location of the 
gene which determines fur coat colour.  In the 129 mice from which the donor ES 
cell line was derived the fur colour gene encodes the agouti allele, whilst in 
C57BL/6 mice in which the Kcc2 mutation was maintained, the gene encodes the 
black allele.  As a result of the proximity of the genes and the linkage 
disequilibrium induced by selecting the mutation, fur coat colour and the Kcc2 
mutation co-segregated.  Had this gene affected a behavioural trait or a 
biochemical process, the authors would have very probably attributed the effects 
to the Kcc2 mutation. It is probable that this was irrelevant to the function of the K-
Cl co-transporter and investigated further because it caused such a visible effect.  
The authors of this publication report that even after eleven generations of 
backcrossing, fur coat colour still co-segregated with the mutation [187].  It is 
significant that in fact, the gene encoding fur coat colour and the Kcc gene are 5 cM 
apart on chromosome two, and importantly, there are many genes between them 
and also on the other side of Kcc2, which will presumably also be retained in the 
129 form.   
By some estimates, after as many as sixteen backcrosses the size of the flanking 
region retained in the donor form can be as large as 16 cM.  Indeed, one 
publication reported a significantly larger flanking region [192].  This retention of 
donor strain genetic material surround a mutation appears to have been largely 
forgotten, at least in biochemical and cellular research.  This is despite several 
publications that highlight the problem, including the rather scathing review by 
Crusio in 2004 [188-189].  Indeed, the assumption that phenotypic differences 
between mutants and WT controls are due to the mutation is pervasive in the 
world of mouse genetics and yet, in fact, there may be tens if not hundreds of genes 
also differing between the mutant and the WT control.  This could account for, or 
contribute to, observed phenotypes of mutant mice.  Thus, it is possible that there 
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are publications describing effects of mutations that are, in fact, independent of the 
mutation studied.   
To our knowledge, there are no publications highlighting the impact that this 
retention of donor genetic material can have on the analysis of genome-wide 
expression analysis.  Microarrays are now more affordable than ever and, 
furthermore, there is increasing pressure to maximise the insight gained from each 
mutant mouse strain generated.  As such, we expect that the number of genome-
wide expression studies analysing the effect of mutations on the transcriptome will 
continue to increase over the coming years.  It is therefore imperative that 
scientists are made aware of this linkage disequilibrium, which results in retention 
of large regions of donor genetic material and its potential to lead to false positive 
results.  Although the linkage of differentially regulated genes to Pik3cd was quite 
apparent in our data, we recognise that this was only by virtue of the limited 
number of genes affected by p110, and to a lesser extent by the fact that these 
genes were not affected by IC87114.  Hypothetically, if twelve out of 200 genes 
identified had been found located on chromosome four, we might not have taken 
this to be indicative of anything untoward.  Assessment of the location of genes 
identified in a microarray study is not considered essential and we suspect that, 
more often than not, only the distribution across chromosomes rather than the 
specific location on the chromosomes is checked.     
This of course is of concern as, we might have published the list of genes including 
the twelve linked to Pik3cd, as genes differentially regulated by p110δ activity in 
macrophages.  As a result, either the Centre for Cell Signalling or another 
laboratory could then have spent valuable resources and research time 
investigating a gene with absolutely no relationship to p110δ activity.  We propose 
that all analyses of the effects of a mutation generated in the described manner at 
the genome-wide expression level should include an assessment of the exact 
location of each of the genes identified, with a particular focus on whether any lie 
within the regions flanking the targeted locus.  This is a trivial task thanks to the 
development of free online software that rapidly identifies significant enrichment 
of identified mapped probe sets across the entire genome or in a single locus with 
minimal user input [176]. 
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Of course, we must also consider the implications this has for the results obtained 
in the genome-wide analysis of p110 KI macrophages compared to WT 
macrophages.  First, based on the data and literature regarding genetics discussed 
above we conclude that it is highly likely that the genetic material flanking Pik3cd 
in the p110 KI mice is of 129 strain origin.  Therefore based on this conclusion, we 
must assume that these twelve genes are not regulated by p110 activity.  This 
suggests that, in fact, p110 inactivation has even less impact on transcription that 
our results initially suggested.   This is consistent with the very limited effects that 
pharmacological inactivation of p110δ has upon primary macrophage gene 
expression, although the genes identified differ.  This conclusion does still need to 
be confirmed and we reason that comparing the expression of these linked 
differentially regulated genes in WT 129-derived macrophages and in WT C57BL/6 
mice would resolve this. 
Furthermore, the fact that this presumed retention of genetic material seems to 
result in differential regulation of twelve genes may have implications for data that 
has been obtained by studying the p110 KI mice.  We should perhaps particularly 
scrutinise data regarding any phenotype(s) that are found to vary between mice 
strains, as this could be indicative of an independence from the actual mutation.  In 
the case of the p110 KI mice, the only variable phenotype of which we are aware 
is the inflammatory colitis and the associated rectal prolapse.  Inflammatory colitis 
is observed in p110KI mice maintained in the C57BL/6 genetic background and 
results in rectal prolapsed in female mice [123].   In BALB/c strain p110 KI mice 
the inflammatory colitis occurs at a later age and rectal prolapse is not observed 
[Unpublished data W. Pearce, Centre for Cell Signalling].  In this instance, the 
phenotype does occur but is observed at a later stage and, therefore, this may not 
be as a result of genes in the differential chromosomal segment.  Instead, this may 
represent the effect of different alleles of modifier genes that affect the expression 
of the phenotype in C57BL/6 mice compared to in BALB/c mice as reviewed by 
Crusio in 2004 [188]. 
Characterisation of a PI3K mutant usually begins with observing in vivo 
phenotypes and subsequently the mechanism behind any dysfunction is 
investigated and delineated ex vivo using cells extracted from the mutant mice.  
This ex vivo analysis is usually carried out in conjunction with analysis of the 
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effects of isoform-selective inhibitors on WT cells, as was the case in this project.  
As a result, any effect on cell biology that is independent of the inactivation 
mutation would be highlighted by its absence in the drug treated WT cells.  As 
such, in publications where the same effect is seen in response to treatment with a 
p110-selective drug, one can be more confident that the effects are genuinely 
related to loss of p110 activity.  To our knowledge this is the first instance in 
which genetic and pharmacological inactivation of a Class IA PI3K isoform have 
had dissimilar effects.  There will, of course, be targets that are undruggable or 
targets for which drugs have not yet been developed, including the Class II PI3K 
isoforms for which comparisons to the effects of a selective inhibitor are not 
currently possible.   
 
 
 
 
 
 
 
7.4.2.3. PGE of differentially regulated genes in p110δ KI Tregs 
Based on our data and assuming that our explanation is correct, we predicted that 
there would also be an enrichment of genes flanking Pik3cd in the list of genes 
found to be differentially regulated by Patton et al. in p110δ KI Tregs [50].  We did 
indeed find an enrichment of genes in this region.  Although it consisted of only 
four genes, Vamp-3, Kif1b, Ubiad1 and Slc25a33, their proximity within a small area 
of chromosome four was found to be highly significant (p = 3.1 x10-6).  This finding 
certainly supports our theory that the region flanking Pik3cd may have been 
retained in the 129 form in the p110 KI mice.  It is interesting that different genes 
were identified as differentially regulated in the p110 KI macrophages compared 
to in the p110 KI Tregs.  We hypothesize that this may represent the different 
expression of genes in macrophages and Tregs, and suggest that in another cell 
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type the list of genes within this region that are differentially regulated might also 
be different.   
 
7.4.2.4. Are linked genes in fact genuinely regulated by p110δ activity? 
Of course, until the above theory is proved we cannot exclude the seemingly 
unlikely possibility that these genes linked to Pik3cd are genuinely regulated 
downstream of p110δ activity.  To our knowledge, there are no examples of a 
protein regulating the expression of genes located proximal to its encoding gene.  
Nevertheless, it is not entirely inconceivable that some of these genes could be 
genuine targets and situated close to Pik3cd by chance. 
 
7.5. Locus independent differential effects of genetic and 
pharmacological inactivation 
We did not find that any of the genes differentially regulated in p110δ KI 
macrophages were also differentially regulated in WT- IC87114 macrophages, 
including those that were independent of the Pik3cd locus.  We confirmed this 
Affymetrix result by TaqMan®, by checking that the expression of the seven of the 
genes found to be differentially regulated in the p110δ KI macrophages were not 
significantly deregulated in WT-IC87114 macrophages.  Importantly, we have 
confirmed by TaqMan and by western blot that the expression of Rab6b, a gene 
independent of Pik3cd, is not differentially expressed in WT-IC87114 
macrophages.  Hence, we conclude that there may well be multiple factors 
contributing to the different effects of pharmacological and genetic inactivation of 
p110δ.  At this stage, we cannot explain why the genes affected by IC87114 are not 
affected in p110 KI macrophages.  It is possible that they are differentially 
expressed as a result of off-target effects of IC87114.  To test this, it would be 
pertinent to differentiate p110 KI macrophages in the presence of IC87114 and, 
also to differentiate WT macrophages in the presence of other p110δ selective 
inhibitors. 
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7.5.1. Why are unlinked genes also not affected by differentiation in 
IC87114? 
We could conceive of a number of reasons why genes such as Rab6b are not 
differentially regulated macrophages differentiated in IC87114.  We address the 
first possibility, which also relates to the generation of the original mutation in ES 
cells derived from 129 mice. 
7.5.1.1. Are unlinked differentially regulated genes passenger loci in the p110δ 
KI mouse line? 
As well as retaining a large area flanking the targeted gene, congenic strains may 
also carry what are referred to as passenger loci, which are tiny sections of donor 
(129) genetic material at random positions dispersed throughout the genome.  It is 
therefore possible that the allele of Rab6b that is carried within the p110KI 
mutant mice is 129 in origin, whilst the allele in the WT control mice will of course 
be of C57BL/6 origin.  This could be tested by comparing the expression of Rab6b 
in WT macrophages derived from 129 strain mice to expression in macrophages 
derived from C57BL/6 strain mice.  Alternatively, if we took p110 KI mice and 
backcrossed them to the C57BL/6 inbred strain we should be able to obtain mice 
WT for p110 but with reduced expression of Rab6b, i.e. the expression of Rab6b 
would segregate independently of the Pik3cd mutant allele. 
 
We set aside the first possibility to contemplate why else Rab6b expression might 
be differentially regulated in p110δ KI macrophages but not in macrophages 
differentiated in IC87114.  We noted that the main differences were the mode of 
inactivation and also the stage at which the inactivation of p110δ occurred. This 
led us to generate two alternative hypotheses. 
 
1. The regulation of the genes requires a minimal level of p110 activity which 
is absent in the p110 KI macrophages but is present in macrophages 
differentiated in IC87114  
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2. The regulation of Rab6b expression is pre-determined early in development 
prior to the bone marrow precursor stage at which we start IC87114 
treatment 
 
 
7.5.1.2. Is Rab6b is developmentally regulated? 
The activity of p110δ may regulate the expression of Rab6b at an earlier stage in 
development within the bone marrow, prior to the formation of bone marrow 
precursor cells that we extract.  If this is the case, then bone marrow precursor 
cells extracted from p110δ KI macrophages will express lower levels of Rab6b than 
their WT counterparts.  Potentially this regulation of Rab6b by p110δ may not be 
cell-intrinsic; the activity of p110δ in another cell type such as a stromal cell may 
be required to regulate its expression.  In either instance, treatment of extracted 
bone marrow precursor cells with IC87114 would be ineffective.  It would be 
interesting to observe whether bone marrow precursor cells or macrophages 
differentiated from them would have reduced expression of Rab6b if the mouse 
they were derived from was treated with IC87114 in vivo.  It might be necessary to 
set up breeding pairs fed regularly with IC87114 and to continue to dose the 
mother with IC87114 throughout gestation and weaning.  
 
 
7.5.1.3. Is Rab6b expression only affected by complete ablation of p110δ 
activity? 
Alternatively, we wonder if the key difference between the IC87114-treated 
macrophages and the p110δ KI macrophages is simply the degree of residual 
p110δ activity.  Whilst genetic inactivation completely abrogates p110δ activity, 
chronic treatment with IC87114 may well cause less than complete repression of 
p110δ activity.  It is plausible that the regulation of Rab6b requires only a minimal 
level of p110δ activity.  In which case, this could explain why IC87114 treatment 
does not suppress Rab6b expression.  We reasoned that there was a logical way to 
begin investigating this hypothesis, by comparing the expression of Rab6b in 
macrophages derived from mice heterozygous for the D910A mutation.  We 
reasoned that we could eliminate this possibility if these macrophages had reduced 
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levels of Rab6b, as they have only a fifty percent decrease in p110δ activity.  In fact, 
our preliminary data indicated that Rab6b expression is normal in heterozygous 
p110δ KI macrophages.  This is consistent with the possibility that complete 
ablation of p110δ activity is necessary to repress Rab6b expression.  In addition, 
this result is of relevance to our hypothesis that Rab6b expression may be 
developmentally regulated.  Thus, the normal expression of Rab6b in heterozygous 
p110δ KI macrophages supports the possibility that the transcription of Rab6b is 
only affected by more complete ablation of p110δ activity, and is evidence against 
the developmental regulation of Rab6b but alone is insufficient to rule out this 
option.  We also tested whether differentiation of macrophages in the presence of a 
higher dose of IC87114 (5 μM instead of 1 μM) would result in repression of Rab6b 
expression in WT macrophages.  Our results at the protein level indicate that the 
expression of Rab6b was unaffected by differentiation in the presence of either 1 
µM or 5 µM of IC87114.  In order to fully investigate and eliminate this dose-
dependent effect of p110δ inactivation, several additional experiments would need 
to be performed.  For example, we are interested to know whether Rab6b 
expression is reduced in p110δ null macrophages or whether small interfering 
RNA (siRNA) targeting p110δ would result in the repression of Rab6b expression.  
The latter would be challenging as primary macrophages are not readily 
permissive to siRNA techniques and the former is difficult as we do not have access 
to a p110δ null mouse line at present. 
7.6. Concluding remarks 
The results of our investigation into the role of p110δ in transcriptional regulation 
have been somewhat surprising.  As a result of comparing the effects of genetic and 
pharmacological inactivation of p110δ on the macrophage transcriptome, we have 
revealed that, at this level, these two modes of inactivation have entirely distinct 
effects.  Furthermore, we have identified an enrichment of differentially regulated 
genes in p110δ KI macrophages in the region flanking the Pik3cd gene.  We 
currently support the hypothesis that the observed differences in the expression of 
these genes are representative of mouse strain-specific variation, caused by the 
retention of 129 mouse strain-derived genetic material.  To the best of our 
knowledge, there are no publications revealing the impact of the retention of 
donor-mouse strain genetic material surrounding a mutation on genome-wide 
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expression analysis.  We propose that our data highlights the need for mandatory 
assessment of the precise chromosomal location of genes found to be differentially 
regulated in mutant mice.  This should ensure that differential regulation resulting 
from the retention of genetic material surrounding a mutation is not incorrectly 
associated with the direct effects of the mutation.  The recent development of 
C57BL/6 ES cell lines that can be used to generate germline transmissible 
mutations, should also allow more mutations to be generated in ES cells of the 
same genetic background as the recipient mice.  The mutant mice lines generated 
in this way will have homogenous genetic backgrounds and thus this problem 
should be circumvented.  
We have found that Rab6b is differentially regulated in p110δ KI macrophages, but 
is not differentially regulated in WT-IC87114 macrophages.  Whilst another 
laboratory found that Rab6b was also reduced in p110δ KI Tregs [50], we found 
that its expression was normal in p110δ KI brain tissue.  This suggests that the 
regulation of Rab6b expression by p110δ might be restricted to leukocytes.  We 
have confirmed that this differential regulation does result in a reduced expression 
of rab6b protein.  We propose that this reduction of rab6b could contribute to the 
migratory defects in p110δ KI macrophages.  The mechanism by which genetic but 
not pharmacological inactivation affects Rab6b expression is currently unclear.  As 
such, we are left with the uneasy question of whether the differential regulation of 
Rab6b in p110δ KI macrophages is in fact genuinely related to inactivation of 
p110δ.   
Based on our data, we conclude that p110 inactivation by either genetic or 
pharmacological inactivation has a minimal effect on transcriptional regulation in 
growing macrophages and that very few (less than twelve genes) may be affected.  
This conclusion is based on the observation that less than twenty known genes are 
differentially regulated in either p110 KI macrophages or WT macrophages 
differentiated in the presence of IC87114.   As a result of these unexpected 
findings, it has been difficult to identify a biomarker of p110δ inactivation.  Those 
genes differentially regulated in WT-IC87114 macrophages could, if validated, 
prove useful in this respect.   
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